The Effect of Cardiac Resynchronisation Therapy on Left Ventricular Remodelling, Plasma Apelin and Cytokine Levels in Patients with Heart Failure with Systolic Dysfunction. by Chandrasekaran, Badrinathan
 i 
 
The Effect of Cardiac Resynchronisation 
Therapy on Left Ventricular Remodelling, 
Plasma Apelin and Cytokine Levels in 
Patients with Heart Failure with Systolic 
Dysfunction. 
 
 
Badrinathan Chandrasekaran BSc MBBS MRCP 
 
NHLI and Royal Brompton Hospital 
 
 
 
 
 
Submitted for as a MD (Res) thesis to Imperial College London 
 
 
 ii 
 
Acknowledgements 
 
I would like to thank NHLI and Imperial College for granting me the Luff Fellowship so that I 
could undertake this research project.  I would like to acknowledge the help I received from 
Cardiology department at the Royal Brompton Hospital for helping me to complete this research.  
This project involved the cooperation of a large number of people and departments working 
together and I learned a great deal from all of them.  I am eternally grateful to the patients who 
consented to take part and without whom any clinical research would not be possible.  I also 
would like to thank my supervisor for her guidance and patience throughout this whole venture.  
Finally my heart felt gratitude for the invaluable support and encouragement from my family 
who had to put up with me while I completed this thesis. 
 
 
Declaration of Originality 
 
The work contained in this thesis is my own and all other material is appropriately referenced 
 iii 
 
 Abstract 
 
Aims:  To investigate the human production of the vasodilating, inotropic peptide apelin in heart 
failure (HF) and the effect of cardiac resynchronisation therapy (CRT) on left ventricular 
remodelling (LVR), venous apelin, serum cytokines and their soluble receptors in humans.  
Methods:  Plasma apelin and B-type natriuretic peptide (BNP) were measured in coronary sinus 
(CS), Aorta (Ao) and renal vein (RV) of patients with HF and healthy controls.  In a population 
of patients who were eligible for CRT clinical parameters apelin, soluble ST2 (sST2), and an 
array of cytokines: Interferon (IFN)-γ, Interleukin (IL) -1b, IL-1ra, IL-6, Tumour necrosis factor 
(TNF)-α, soluble TNF receptor (sTNFR)1, sTNFR2, IL-4 and IL-10 were measured at baseline, 
6 and 12 months.  LVR was assessed by radionuclide ventriculography.  Results:  Apelin was 
higher in CS compared to Ao in controls and this was not maintained in patients with HF.  After 
12 months of CRT clinical parameters and left ventricular ejection fraction (LVEF) improved.  
Apelin was unchanged in the whole group, but was decreased in those that failed to remodel at 6 
months and LVEF was increased significantly more in individuals whose apelin rose early.  sST2 
was unchanged at 12 months, but changes correlated with change in BNP and negatively with 
changes in LVEF.  In individuals where sST2 decreased, LVEF was significantly increased.  
IFN-γ, IL-10 and IL-6 were reduced following 12 months of CRT.  In those that remodelled 
favourably IL-10 was reduced whereas in those who failed to remodel IFN-γ was reduced.  
Conclusions:  Apelin is produced in the heart and myocardial apelin is reduced in HF.  Early 
changes in apelin are associated with LVR post CRT.  A reduction in sST2 post CRT is 
associated with favourable LVR and a fall in BNP.  Following CRT there is a relative shift away 
from a TH2 towards a TH1 pattern of cytokines.  
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Chapter 1: Introduction 
Background 
Heart failure 
Heart failure (HF) is a clinical syndrome characterised by breathlessness, fatigue and fluid 
retention.  It can arise from any structural or functional cardiac disorder that impairs the ability 
of the heart to maintain a physiological circulation.  The diagnosis of HF remains clinical; there 
is no single diagnostic intervention that can be considered as a gold standard.  The accepted 
criteria for the diagnosis of HF require the presence of symptoms and signs of HF (at rest or on 
exercise) with objective evidence of cardiac dysfunction.  Where there is doubt the response to 
HF treatment is required 
1
.   
Epidemiology of Heart failure 
Prevalence 
The majority of HF is secondary to left ventricular systolic dysfunction (LVSD), which is most 
commonly assessed by transthoracic echocardiography (TTE).   The overall prevalence of HF is 
2% increasing to 15% in those aged over 85 years and is more common in men than women of 
all ages (male: female 1.8:1) 
2
.  Recent cross-sectional surveys in Europe using TTE have shown 
3-4% of the adult population and have LVSD rising to 5-6% in the elderly 
3
.  In this cohort just 
over half with LVSD are symptomatic therefore would be labelled as HF.   
 2 
 
Incidence 
In the US and Europe studies show similar findings with an increasing incidence of HF with age.  
The Framingham Heart Study, a large cohort study, conducted in the US reported an annual 
incidence of 0.2-0.3% of cardiac failure in those aged 50-59 years which increased tenfold in 
those over 80-89 years 
4
.  The Hillingdon HF study showed an annual incidence of 0.12% in 
those aged 55-64 years rising to 1.2% in those aged over 85 years 
2
.  Extrapolating these results 
to the UK population means that an estimated 63 000 new cases of HF per annum.  The mean 
age of diagnosis is 76 years old; higher in men at all ages with an overall male female ratio 1.8:1.   
Prognosis 
 
Heart failure with LVSD is associated with a high mortality and morbidity.  The 5-year survival 
is estimated at 50%, which is worse than many common malignancies 
5
.  Although recent 
advances in treatment have made some inroads into this figure the mortality from HF remains 
unacceptable high.  Annually 0.2% of the UK population is admitted to hospital with cardiac 
failure.  This accounts for 4-5% of all acute medical admissions and the average inpatient stay is 
11 days 
6
.  Cardiac failure is also associated with a high readmission of rate of 30% within 12 
months of discharge.  The high cost of treating HF is mainly due to the cost of hospitalisation 
and in Europe and North America accounts for 2% of healthcare expenditure.  The number of 
admissions for HF has been increasing rapidly in the developed world however it reached a 
plateau in the 1990s, which may reflect the wider uptake of disease modifying therapies and 
multidisciplinary management strategies. 
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Pathophysiology 
 
The most common underlying cardiac abnormality in cardiac failure is left ventricular systolic 
dysfunction and regardless of the aetiology leads to a reduction in pump function and cardiac 
output.  In the chronic state the neurohormonal response to cardiac dysfunction maintains cardiac 
output at rest.  However this leads to a progressive deterioration in pump function and results in a 
vicious cycle of episodes of decompensation in between periods of relative stability.  The 
understanding of the mechanisms by which the complex interplay of autonomic nervous system, 
neurohormones and the mediators of the immune system interact in the pathophysiology of 
cardiac failure has improved in the last few decades (Figure 1).  Pharmacological agents targeted 
at neurohormonal blockade form the basis of modern medical management of cardiac failure.  
Large multicentre trials have shown clear benefits in symptoms and mortality reduction with the 
use of angiotensin converting enzyme inhibitors 
7
, beta-blockers 
8-10
 and aldosterone antagonists 
11, 12
  in patients with symptomatic left ventricular systolic dysfunction.   
Adverse ventricular remodelling 
 
The change in size shape and function of the heart is known as cardiac remodelling 
13
.  
Regardless of the original insult there are progressive molecular, cellular and interstitial changes 
in cardiomyocyte architecture.  Eventually these microscopic changes manifest macroscopically 
as cardiac chamber hypertrophy and dilatation, which is known as adverse remodelling 
14
.   
 
Adverse remodelling may be triggered by an abnormal genetic program as in the cases of certain 
cardiomyopathies or by cardiac injury such myocardial infarction.  In either case there is a 
change in genomic expression, which results in cardiomyocyte death and changes to the  
 
 4 
 
Figure 1 Pathophysiology of Heart Failure 
 
RAS=Renin-angiotensin system.  HR =heart rate 
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extracellular matrix.  These changes are influenced by pressure and loading conditions over a 
period of time.   
 
The mechanisms underlying adverse left ventricular remodelling are not fully understood.  The 
original hypothesis was that cardiomyocyte hypertrophy is initially an adaptive response to 
increased wall stress 
15.  Using Lapace’s law the compensatory increase in wall thickness results 
in a reduction in wall stress induced by pressure overload e.g. aortic stenosis.  In the longer term 
this leads to progressive cardiac failure and dilatation.  In the volume overloaded ventricle e.g. 
mitral regurgitation there is myocyte elongation and eccentric hypertrophy leading to increase in 
internal ventricular dimensions 
15
.  In myocardial infarction there is the combined effect of 
infracted tissue (scar) and the effects of pressure and volume on non-infarcted areas 
14
.  The 
studies of a number of biological pathways have expanded upon initial theories and propose that 
molecular signalling pathways are involved in directing myocytes to survive and experience 
beneficial hypertrophy or undergo apoptosis (programmed cell death), which leads to ventricular 
dilatation and failure (Figure 2).  These pathways are likely to be activated simultaneously in 
response to cardiac injury, sustain pressure or volume overload.  The equilibrium between 
adaptive (beneficial growth) and maladaptive (cell death and fibrosis) is influenced at a local and 
systemic level.  At a local level an array of cytokines is involved in orchestrating the interaction 
between cardiomyocytes, immune cells and the extracellular matrix.  The neurohormonal 
response acts at a local level and systemically to alter preload and afterload.   
Adaptive and maladaptive growth of cardiac myocytes 
Increased wall stress results in the release of myocardial angiotensin II 
16
 that binds to its 
transmembrane receptor (AT1) which eventually leads to activation of a number of mitogen  
 6 
 
Figure 2 Schematic illustrating adaptive and maladaptive pathways of left ventricular remodelling 
 
 
 
MAP =Mitogen activated protein, TNF-α=Tumour necrosis factor alpha, IGF-1=Insulin like growth factor-1, 
TGF-β=Transforming growth factor beta, eNOS=endothelium derived nitric oxide synthase, ROS=reactive 
oxygen species. 
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activated protein kinases (MAPK) via a G-protein -Protein kinase C (PKC) signalling pathway.  
Mitogen activated protein kinases acting at mRNA level can either promote cell survival or 
apoptosis.  The interaction of MAP kinases with the extracellular matrix and other pathways that 
influence cell fibrosis eventually results in an adaptive or maladaptive growth of myocytes 
(Figure 2) 
14
.  Stress related cytokines, which are released early after myocardial injury such as 
interleukins –1, (IL-1), tumour necrosis factor (TNF)-α and the interleukins-6 (IL-6) family 
(which includes cardiotrophin-1) initially exert a protective effect favouring adaptive growth 
17
.  
However, prolonged exposure to these cytokines or supra-physiological concentrations, promote 
cell death and tips the balance towards a maladaptive response 
17
.  The early effects of these 
cytokines may partly balance the effect of the fibrosis and cell death caused by aldosterone 
18
, 
angiotensin II, and transforming growth Factor-β 19.  Insulin like growth factor (IGF-1) also has a 
potent adaptive response by signalling through protein kinase B (PKB or AKT) which act via 
many downstream regulators to promote growth and inhibit apoptosis 
20
.  In human survivors 
with idiopathic dilated cardiomyopathy serum IGF-1 concentrations are increased compared to 
non-survivors and healthy controls 
21
.  Another protective pathway, stimulated by a response to 
natriuretic peptides, is the formation of cyclic guanosine monophosphate (GMP) which reduces 
hypertrophy 
22, 22, 23
. 
 
Sustained pressure or volume overload leads to diastolic dysfunction, then ventricular dilatation 
and eventually systolic dysfunction.  In myocardial infarction there is also the contribution of 
myocardial scar to the derangement in ventricular architecture.  A number of biological pathways 
are thought to be involved in the transition from a predominantly adaptive response to a 
maladaptive response.   
 8 
 
Metalloproteinases and their inhibitors 
 
The extracellular matrix is synthesised by cardiac fibroblasts and maintains myocardial 
architecture.  Increase in collagen synthesis, which can be induced by, aldosterone 
24
, angiotensin 
II and transforming growth factor (TGF)-β 25, leads to fibrosis.  Matrix metalloproteinases 
(MMPs) are enzymes, which break down collagen and tissue inhibitors of matrix 
metalloproteinases (TIMPs) counteract them.  Conditions, which favour the metalloproteinase 
activity or reduce TIMPs activity, result in collagen breakdown and ventricular dilatation 
26
.  In 
humans the most studied isoforms are matrix metalloproteinase 9 and TIMP 1 and 2 
27, 28
.   
Oxidative stress and nitric oxide synthase 
 
Mechanical strain, angiotensin II and TGF-β can also promote formation of reactive oxygen 
species (ROS) 
29
.  These have an adaptive hypertrophic response at low levels of ROS 
production and at higher levels cause cell death and breakdown in collagen 
30
.  Endothelial nitric 
oxide synthase (eNOS) also stimulates ROS production and eNOS knockout mice are protected 
from ventricular dilatation in the presence of chronic pressure overload 
31
.  Plasma and 
pericardial markers of oxidative stress are increased in patients with chronic cardiac failure and 
relate to the clinical severity of the cardiac failure 
32, 33
.   
Neurohormonal actions  
 
A reduction in cardiac output and ventricular dilatation stimulate the adrenergic and renin-
angiotensin-aldosterone systems.  Prolonged adrenergic action of the SNS causes:  1) 
Exaggeration of the effect of MMPs which promotes fibrosis 
34
.  2) Beta-receptor down 
regulation and hyperphosphorylation with inhibition of calcium release from the sarcoplasmic 
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reticulum thereby reducing contractile function 
35
.  3) Cellular calcium overload and increased 
chance of cardiomyocyte apoptosis 
36
.   
Increase in myocardial angiotensin II leads to increased ROS formation and increased cytosolic 
calcium which both augment apoptosis 
36
.  Furthermore angiotensin II promotes fibrosis 
mediated by the cytokine TGF-β 37.  An increase in angiotensin II leads to water and sodium 
retention increasing preload leading to further dilatation of the ventricle.  Fibrosis and sodium 
retention is further augmented by angiotensin II mediated release of aldosterone.   
Dyssynchrony 
 
In patients with systolic HF there is a progressive deterioration of left ventricular (LV) function 
with time known as adverse LV remodelling.  A certain proportion of these patients will also 
develop an uncoordinated regional contraction-relaxation pattern known as dyssynchrony.  
Dyssynchrony can be predominantly mechanical or electrical, but more often it is a combination 
of both, and manifest by progressive changes on the surface ECG which include:  a prolongation 
in QRS width (>120 ms) in 25-50%, LBBB in 15-27% or first degree AV block (PR interval 
>200ms) in 35% 
38
.  Dyssynchrony can be between atria and ventricles (atrio-ventricular), 
between right and left ventricles (inter-ventricular), between different walls of the left ventricle 
(intra-ventricular) or any combination of the three.  The efficiency of the cardiac cycle is 
dependent on the synchronous timing of atrio-ventricular contraction to achieve maximal filling 
and ejection.  The consequences of dyssynchronous cardiac contraction are regional variations 
with myocardial segments contracting early or late. There is also a redistribution of myocardial 
blood flow and regional changes at a molecular level in the expression of stress kinase proteins 
and proteins involved in calcium handling 
39, 40
.  This leads to a reduction in LV filling and 
contraction of parts of the left ventricle after closure of the aortic valve, known as post systolic 
 10 
 
contraction and an increase in functional mitral regurgitation.  Atrio-ventricular dyssynchrony 
exacerbates this process further and leads to a further reduction in LV filling and pre-systolic 
mitral regurgitation (MR).  Persistent dyssynchrony leads to further adverse remodelling 
accelerating symptomatic decline in advanced HF patients.   
Cardiac resynchronisation therapy  
Despite optimal pharmacological therapy HF secondary to LVSD is still associated with a very 
high morbidity and mortality.  A prolongation of the QRS width (>120ms) is a marker for 
cardiac dyssynchrony and is associated with a poorer prognosis in patients with HF 
41
. Cardiac 
resynchronisation therapy (CRT) also known as biventricular pacing has emerged in the last 20 
years as a treatment for HF patients with cardiac dyssynchrony.  By re-timing the cardiac 
contraction sequence, CRT has been shown in large randomised controlled trials to improve 
symptoms, prevent hospitalisation for HF and reduce mortality in symptomatic patients with left 
ventricular systolic dysfunction with broad QRS refractory to optimal medical therapy 
42-45
.  
CRT improves electromechanical dyssynchrony and maximises the efficiency of the cardiac 
contraction sequence, leading to an acute haemodynamic benefit and, over time, a reduction in 
LV volumes and an improvement in left ventricular ejection fraction (LVEF).  A prolonged QRS 
width (>120ms) is a marker for cardiac dyssynchrony, with approximately 70% of these patients 
demonstrating symptomatic improvement following CRT.  Cardiac resynchronisation therapy 
can be delivered on its own as a pacemaker (CRT-P) or in addition to an internal cardiac 
defibrillator, where it is referred to as CRT-D.   
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Biventricular pacemaker insertion 
 
The most common method of delivering CRT is transvenously.  Standard endocardial leads are 
placed in the right atrial appendage and right ventricular (RV) apex using the subclavian and / or 
cephalic vein for vascular access.  The epicardial surface of the left ventricle (LV) is paced using 
a posterior-lateral tributary vein of the coronary sinus.  This allows atrially sensed biventricular 
pacing to be achieved (Figure 3).   
 
Left ventricular lead placement is limited by the heterogeneous nature of the coronary sinus 
tributaries.  Haemodynamic studies have shown that pacing the area of most delayed contraction 
results in the best acute haemodynamic response based on a rise in LV dP/dT 
46
.  Pacing the 
lateral wall of the LV using posterior-lateral or lateral veins is recommended largely as a result 
of this data.  However the actual site is variable between individuals as shown by Van Campen et 
al and in 26% an anterior position was haemodynamically superior 
47
.  A retrospective analysis 
of the COMPANION study showed that the location of the LV lead did not predict survival or 
hospitalisations 
48
.  As most implants in clinical practice are not performed with acute 
haemodynamic monitoring it is difficult to make firm conclusion with this data, however it is 
difficult to believe that there is not some role in optimising LV lead position at the time of 
implant.  A small study in Japan has shown that an acute rise in arterial blood pressure at the 
time of implant predicted event free survival, clinical and echocardiographic response 
49
.   
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Figure 3 Fluoroscopy of coronary venous anatomy and biventricular pacemaker defibrillator leads 
 
 
 
Panel A: AP projection of coronary sinus venogram using balloon occlusion catheter (arrow) demonstrating a 
lateral vein.  Panel B: Final positions of right atrial (RA) lead, right ventricular (RV) dual coil defibrillator 
lead and left ventricular (LV) lead 
 
The optimal positioning of the RV lead is still controversial.  The DAVID study showed that 
chronic RV apical pacing in patients with LVSD was detrimental 
50
.  Haemodynamic studies also 
suggest that a high septal RV pacing is preferable to the RV apical pacing 
51
.  However a recent 
study by Haghjoo et al showed no difference in acute haemodynamic parameters between RV 
septal or apical pacing in patients undergoing biventricular pacing 
52
.  In this same study an RV 
septal position was better when the LV lead was placed in a posterior lateral vein compared with 
an anterior lateral position, suggesting that optimal positioning of RV and LV leads in CRT can 
differ between patients and may be related to achieving a maximal separation between both 
leads.   There are currently no randomised controlled trials looking at optimal RV lead position 
in CRT.    
 13 
 
Evidence base for Cardiac Resynchronisation Therapy. 
 
There are 13 randomised controlled trials of CRT with a total of > 6000 patients (Table 1) 
42-45, 
53-62
.  The initial studies required surgical placement of the LV lead 
54, 55
.  However subsequent 
developments of catheter techniques to implant the LV Lead transvenously via the coronary 
sinus have replaced this as method of choice for delivering CRT 
63
.  The trials of CRT include a 
mixture of patients with CRT-P and CRT-D and the early studies demonstrated an improvement 
in symptoms, exercise capacity and quality of life measures comparable and in some cases better 
than those obtained in pharmacological studies 
42, 43, 54-56
.  The magnitude of these benefits were 
a 0.5-0.8 point reduction in NYHA class, a 20% increase in 6 minute walk distance with a 10-
15% increase in VO2 max capacity.  Quality of life assessed predominantly by Minnesota living 
with HF questionnaire also improved.  These early studies were disadvantaged by short follow 
up times of 3-6 months and they were not powered to assess HF morbidity and mortality.  The 
much larger COMPANION study compared CRT-D and CRT-P with medical therapy over a 12 
month period.  It showed that CRT with or without a defibrillator reduced hospital free survival 
(CRT-P 19%, CRT-D 20% ) and hospitalisation for HF (CRT-P 34% , CRT-D 40%) 
significantly compared with medical therapy alone 
45
.  The secondary endpoint of all-cause 
mortality was only significantly reduced by CRT-D (36% p<0.003), however it was not suitably 
powered to assess the effect of CRT-P alone which itself showed a strong trend towards reducing 
mortality (24%, p=0.059).  The CARE-HF study was the largest study comparing CRT-P with 
medical therapy over a follow up of 29.4 months 
44
.  Both groups were extremely well treated for 
a HF study with 72 % on beta-blockers and 95% on Angiotensin converting enzyme inhibitors 
(ACE-I) or angiotensin receptor blockers (ARBs).  However on top of optimal medical therapy 
 14 
 
there was a 37% reduction in the primary endpoint of mortality and hospitalization for a major 
cardiovascular event (p<0.001) with CRT-P.  All-cause mortality was also reduced by 36% 
(p<0.002) and hospitalisation for unplanned HF was reduced by 52% (Figure 4).  There was also 
a significant reduction in sudden arrhythmic death with CRT alone in the extended follow up of 
the CARE-HF study 
59
, which taken together with results of the COMPANION study suggest 
that there may be only a marginal additional survival benefit of CRT-D compared to CRT in 
patients with advanced HF.  The number needed to treat with CRT to save a life over 2 years is 
10, which is comparable with medical therapy.  
 
Legend for Table 1:  MUSTIC=MUltisite Stimulation In Cardiomyopathies, SR=Sinus Rhythm, AF=Atrial 
fibrillation, MIRACLE=Multicentre InSync Randomised CLinical Evaluation,  PATH-CHF=PAcing 
THerapies in Congestive Heart Failure, ICD=Internal Cardiac Defibrillator, COMPANION=Comparison of  
Medical Therapy Pacing and Defibrillation Therapy in Heart  Failure, CARE-HF=Cardiac resynchronisation 
-Heart Failure, HOPIPACE=Homburg Biventricular Pacing Evaluation, REVERSE = REsynchronization 
reVErses Remodeling in Systolic left vEntricular dysfunction.  MADIT-CRT=Multicenter Automated 
Defibrillator Implantation Trial with Cardiac Resynchronisation Therapy.  NYHA=New York Heart 
Association, * Inclusion criteria included indication for right ventricular (RV) pacing therefore comparison 
of RV pacing vs  BiV pacing, † Included patients with epicardial left ventricular lead placement, LVEF= Left 
ventricular ejection fraction, LVEDD= Left ventricular end diastolic dimension,  6MWT= 6 minute walk test, 
QoL =Quality of life,  HF =Heart failure, ** median,  N/A =not available 
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Table 1: A summary of the randomised controlled trials of cardiac resynchronisation therapy 
 
RCT 
 
Authors, country 
 
N 
 
Age 
(years) 
 
NHYA 
class 
 
QRS (ms) 
Entry 
criteria 
 
 
Mean QRS 
(ms) 
 
 
LVEF 
(%) 
 
LVEDD 
(mm) 
 
Follow up 
(months) 
 
Primary end point 
 
Main result 
MUSTIC –SR 
(42)
 Cazeau et al Europe 
2001 
58 63 III >150 176  <35 >60 3 6MWT Positive effect of CRT 
MUSTIC-AF* 
(53) Leclerq et al Europe 
2002 
43 63 III >200 209  <35 >60 3 6MWT No significant effect 
MIRACLE 
(43)
 Abraham et al USA 
2002  
453 64 III. IV >130 167  <35 >55 6 6MWT, QoL, NYHA Class Positive effect of CRT 
PATH-CHF 
(55)
 Auricchio et al 
Germany 2002 
41 60 III, IV >130 175  <35 NA 6 6MWT, Peak VO2 Positive effect of CRT 
PATH-CHF II 
(54)
 Auricchio et al 
Germany 2003 
86 60 ≥ II >120 155  <35 NA 3 6MWT, Peak VO2 No difference in primary 
endpoint 
MIRACLE-ICD 
(56)
 Young et al USA 
2003 
369 63 III-IV >130 165  <35 >55 6 6MWT, QoL, NYHA Class Positive effect of CRT 
CONTAK-CD 
(57)
 Higgins et al USA 
2003 
445 66 II-IV >120 160  <35 NA 6 HF progression No significant effect of CRT 
COMPANION 
(45)
 Bristow et al USA 
2004 
1520 67 III, IV >120 160 ** <35 NA 12 All cause mortality and 
hospitalisation 
12 % reduction in primary 
endpoint 
MIRACLE-ICD II 
(58)
  Abraham et al USA 
2004 
186 60 II >130 164  <35 >55 6 Peak VO2 No significant effect of CRT 
CARE-HF 
(44)
 Cleland et al Europe 
2005 
814 67 III, IV >120 160 ** <35 >30/ height 29.4 All cause mortality and 
hospitalisation 
37% reduction in primary 
endpoint 
CARE-HF extension 
(59)
 Cleland et al Europe 
2006 
813 67 III, IV >120 160 ** <35 >30/ height 36.4 All cause mortality and 
hospitalisation 
55 % reduction in primary 
endpoint 
HOBIPACE * 
(60)
 
 
Kindermann et al 
Germany 2006 
30 70 NA NA 174  <35 >60 3  LVEF, LVESV, Peak VO2 Positive effect of CRT 
REVERSE 
(61)
 Linde et al Europe 
and North America 
2008 
610 62 I-II >120 154 <40 >55 12 HF clinical composite 
response (% worsened) 
No difference with CRT 
MADIT-CRT 
(64)
 
 
Moss et al Europe 
and USA 2009 
1820 65 I-II >130 N/A <30 N/A 28.8 All cause mortality or non-
fatal HF event 
44 % reduction in primary 
endpoint 
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Figure 4:  The CARE-HF study 
 
 
 
 
Kaplan-Meier estimates of time to primary endpoint (Panel A) and the principle secondary outcome (Panel 
B):  The primary outcome was death from any cause or unplanned hospitalization for a major cardiovascular 
event.  The principle secondary outcome was death from any cause 
44
 
 
CRT and acute haemodynamic response  
Biventricular pacing has been shown to increase peak dP/dT, pulse pressure and cardiac output 
while reducing capillary wedge pressure in patients in patients with severe systolic LV 
dysfunction and LBBB 
65, 66
.  The effects are instantaneous and persist at least over 6 months 
67
.  
Although this is thought to contribute to observed long-term clinical benefits of CRT 
55, 67
 there 
have been no randomised studies that have shown that haemodynamic improvement at the time 
of implant relates to clinical or surrogate endpoints.   Mechanical rather than electrical 
dyssynchrony has been shown to predict acute haemodynamic response in humans and in animal 
models 
68, 69
.   However contact mapping studies suggest that patients with a > 20% area of late 
endocardial activation show an improved acute haemodynamic response to CRT 
70
.  Reduced LV 
contractility measured non-invasively correlates with indices of LV dyssynchrony better than 
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with other indices of LV systolic function such as EF 
71
 and an increase in dP/dT calculated 
using TTE post implant predicted clinical events over a 12-month follow up 
72
.   
Measuring dyssynchrony 
There have been a variety of non-invasive methods to quantify dyssynchrony in order to 
accurately define populations of patients who would most benefit from CRT.   However the non-
invasive assessment of dyssynchrony is hampered a lack of a gold standard. The predominant 
method of assessment for dyssynchrony is TTE; however other imaging modalities, including 
radionuclide ventriculography (RNV) and cardiac magnetic resonance (CMR) have also been 
used.   
Transthoracic echocardiography (TTE) 
 
Echocardiographic definitions of dyssynchrony are based on a number of single centre 
observational studies, using different methods for measurement and criteria for a positive 
response to CRT (Table 2).  The presence of dyssynchrony by the various TTE criteria listed in 
table 2 has been shown in a number of small series to predict a favourable response to CRT.  It is 
estimated that 30% of patients with severe LVSD have LBBB.  However although dyssynchrony 
is more common in the presence of a prolonged QRS, it is not always present.  Dyssynchrony 
may also be present with a normal QRS width leading to suggestions that patients with normal 
QRS width who have TTE evidence of dyssynchrony may benefit from CRT.  The only 
randomised study to use echo parameters in 10% of patients with a QRS width of 120-149ms 
was CARE-HF 
44
.  In the CARE-HF study, interventricular delay did not predict survival, 
clinical response or favourable left ventricular remodelling.  However those patients with an 
interventricular  delay >49ms  (Normal<40ms) or low systolic blood pressure at baseline showed 
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a greater clinical response in both the CRT and medically treated patients 
73
.  Despite the entry 
criteria for most CRT trials of >120 ms the average QRS width of the patients recruited was a lot 
higher at 167ms in MIRACLE 
43
 and 165ms in COMPANION and CARE-HF 
44, 45
.  It is also 
apparent that the greatest benefit from CRT is in patients with a QRS width of >150 ms 
45, 64
.  
Therefore current NICE guidelines do not include echo assessment of dyssynchrony to select 
patients for CRT if they have a QRS width of > 150ms 
74
.  There are a number of problems that 
preclude the use of TTE for dyssynchrony assessment.  The agreement between the different 
TTE techniques is poor 
75, 76
.  Often single centre experience is not borne out by other centres 
and certain techniques are hampered by the fact that the parameter cannot be measured in a large 
number of patients 
77
. 
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Table2: The transthoracic echocardiographic methods for assessing dyssynchrony and response to CRT 
Method Parameter measured Type of Dyssynchrony Definition of response Authors and ref. 
PW Doppler Difference between APET and 
pulmonary pre-ejection time (PPET) 
>40ms 
Interventricular N/A St John Sutton et 
al 78 
PW Doppler Total isovolumic time (T-IVT) Global Increase in CO >15% Duncan et al 79 
M-Mode Septum to posterior wall motion delay 
(SPWMD) >130ms 
Intraventricular Improvement in LVEF Pitzalis et al 80 
TDI pulse wave Septum to lateral wall delay (>65ms) Intraventricular Improvement in NHYA class 
> 1 and improvement in 
6MWT >25% 
Bax et al 81 
TDI pulse wave Sum asynchrony  (>102ms) Intraventricular + 
interventricular 
Increase of 25% in LVEF 
from baseline and clinical 
events 
Penicka et al 82
, 83 
TDI pulse wave SD of time to peak systolic velocity 
12 segments (Ts-SD) > 35ms 
Intraventricular Reduction in LVESV >15% Yu et al 84 
TDI pulse-wave Peak velocity difference between 6 
basal segments (PVD) > 110ms 
Intraventricular Reduction in LVESV >15% Notabartolo et al 
85 
TDI longitudinal 
strain 
Time exceeding aortic valve closure 
of 12 segments oExT  >760ms 
Intraventricular Reduction in LVESV >15% Porciani et al 86 
Radial wall 
motion 
Difference in phase between septum 
and lateral wall {ΦLS >25
ο) 
Intraventricular Increase in Dp/DT acutely Breithardt et al 87 
TDI radial strain Difference between septum and 
posterior wall peak radial strain 
(>130ms) 
Intraventricular Increase in stroke volume 
acutely > 15% 
Dohi et al 88 
TDI radial strain 
speckle tracking 
Difference in septum-lateral wall peak 
radial strain  (>130ms) 
Intraventricular Increase in stroke volume 
acutely > 15% 
Suffoletto et al 89 
3-D Echo Systolic dyssynchrony index (SDI) 
>14.7% 
Intraventricular Sustained symptomatic 
improvement  
Kapetanakis et al 
90 
3-D Tissue 
doppler 
Percentage of base with delayed 
longitudinal contraction (DLC) 
Intraventricular Reduction in LV volumes and 
improvement in LV systolic 
performance 
Sogaard et al 91 
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The result of the multicentre PROSPECT study has shown that a variety of echo derived 
parameters of dyssynchrony were not reproducible or able to predict response a clinical or 
echocardiographic response to CRT 
92
.  However there are newer echo modalities such as 
speckle tracking which may well improve upon the disappointing results of the PROSPECT 
study. 
Radionuclide ventriculography (RNV) 
 
RNV is an accurate and reproducible method of quantifying left ventricular function using 
radiolabelled blood pool analysis 
93
.  It has been used in the follow up of heart transplant 
recipients to quantify LVEF.  Using RNV phase analysis it is possible to quantify 
interventricular dyssynchrony (the difference between mean RV and LV phase) and 
intraventricular dyssynchrony (the standard deviation in LV phase) 
94
 and the method is 
reproducible 
95
.  In patients with dilated cardiomyopathy, 25% of whom had LBBB, 
intraventricular dyssynchrony but not interventricular dyssynchrony predicts adverse cardiac 
events over a mean follow up of 27 +/- 23months 
96
.  A small study into the effects of 
biventricular pacing using RNV, showed that LVEF and RVEF increased significantly with CRT 
97
.  The degrees of left ventricular inter and intraventricular dyssynchrony negatively correlated 
with baseline LVEF and there was a significant reduction in both after CRT 
97
.  A reduction in 
dyssynchrony correlated strongly with the overall improvement in LVEF acutely and further 
improvement over a mean follow up of 20 +/- 7 month.  The majority of these studies using 
RNV are with standard planar acquisition using 2-dimensional imaging.  The use of gated 
tomographic acquisition allows for the calculation of 3 dimensional wall motions to assess 
dyssynchrony and may have a role to play in the future 
98
.  Also the use of gated tomographic 
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acquisition has the potential to calculate ventricular volume with a greater degree of accuracy.  
The disadvantages of using RNV for the assessment of dyssynchrony are that the patients require 
a significant radiation dose and that the temporal resolution of (32 frames per cycle) 
99
 is less 
than the majority of echocardiographic techniques, which have frame rates of 100Hz with TDI 
100
 and between 200-1000Hz with M-mode 
101
.  The advantages of RNV are that there is 
consensus on the parameters to assess dyssynchrony and the serial assessment of LVEF is more 
reproducible, being subject to less inter and intra observer variation than TTE.   
Cardiac magnetic resonance scanning (CMR) 
 
CMR is the gold standard for the assessment of cardiac structure, volumes and function.  CMR 
can also be used to calculate an index of dyssynchrony and the use of intravenous gadolinium 
and delayed hyper enhancement can quantify myocardial scar.  The use of CMR is currently 
hampered by the fact that it is currently contraindicated in patients with devices in situ and 
therefore only baseline studies may be undertaken.  However with the development of CMR 
compatible pacemakers this is likely to change in the future.  Small studies have demonstrated 
that longitudinal function can be assessed by CMR phase velocity mapping and is comparable to 
assessing intraventricular delay between the septum and lateral wall by TTE TDI imaging 
102, 103
.  
The potential of CMR to provide a three-dimensional representation of myocardial motion means 
that CMR may be a very useful and more accurate tool for assessing dyssynchrony in the future.  
With the use of tagging, CMR can be used to evaluate circumferential myocardial strain in up to 
80 segments from base to apex.  This was used to calculate the strain variance at the time of 
maximal shorten dyssynchrony index, which was significantly higher in patients with DCM and 
correlated with acute haemodynamic improvement following CRT 
68
.  The amount of post 
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systolic shortening may also be calculated by CMR although this has not been investigated in 
patients undergoing CRT 
104
.  The main limitation of CMR is the temporal resolution.  Even with 
rapid acquisition used for CMR tagging the temporal resolution is 14ms which is still less than 
TTE TDI.     
Selection for CRT 
 
The current selection criteria for CRT are based on the results of the randomised control trials 
which had similar inclusion criteria; recruiting patients with severe LVSD and symptoms 
refractory to maximally tolerated medical therapy with a prolonged QRS width.  The European 
Society of Cardiology guidelines for CRT are summarised in table 3 
105
.   
Table 3. ESC guidelines for cardiac resynchronisation therapy (CRT)  
 
Recommendations for the use of cardiac resynchronisation therapy with a biventricular 
pacemaker (CRT-P) 
 NYHA class III-IV despite optimal medical therapy 
 LVEF < 35% 
 LV dilatation * 
 Sinus rhythm 
 QRS ≥ 120ms 
A biventricular pacemaker combined with a defibrillator (CRT-D) can be considered in 
patients who have an expected survival of at least 1 year with a good functional class. 
* LV dilatation is defined as LVEDD of >55mm, LVEDD >30mm/m
2
 or LVEDD 
>30mm/m (height). 
 23 
 
CRT in mild heart failure 
 
CRT has been predominantly studied in Class III/IV HF as noted above and the ESC guidelines 
recommend this therapy only in these patients.  MIRACLE-ICD II studied patients in NYHA 
class II and an indication for an ICD 
58
.  Patients receiving CRT had a mean QRS duration of 165 
ms, yet showed no significant improvement in peak VO2, 6 minute walk time or quality of life.  
Patients did however show evidence of LV remodelling with CRT.  Given the fairly high 
procedural complication rate it was hard to justify CRT in Class II HF on the basis of these 
results. However, it is always hard to clinically distinguish a class II patient from a class III 
patient.  Whilst CARE-HF was a study of Class III/IV HF, when patients were asked to self 
assess their NYHA class, 21.5% classed themselves as either Class I or II at baseline.  There was 
no statistical interaction between the severity of symptoms and the benefits of CRT on morbidity 
and mortality in this study 
106
. 
 
Two further studies of CRT in milder heart failure have recently been published. REVERSE 
studied 610 patients with NYHA class I/II HF with a QRS ≥120ms and LVEF ≤40%.  All 
patients received CRT-devices (predominantly CRT-D) and were then randomly assigned to 
CRT-ON or OFF for 12 months.  Patients receiving CRT showed improved LV end-systolic 
volume index and had delayed time to first HF hospitalisation 
61
.  REVERSE was a European/ 
North American Study.  The European Cohort of 262 patients was followed for 2 years 
according to their randomisation 
107
.  European patients were less likely to have IHD, a history of 
hypertension or peripheral vascular disease; they had longer 6 minute walk times, smaller BMI 
and were less likely to receive CRT-D.  In this population CRT improved clinical outcomes and 
led to reverse remodelling.  The time to first HF hospitalisation or death was delayed by CRT.  
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MADIT-CRT was the largest study to date to assess the effect of CRT in mild heart failure 
64
.  
1820 patients with an ICD indication were randomised to CRT-D or ICD alone in a 3:2 ratio.  
The primary end-point was death from any cause or a non-fatal HF event.  There was a 34% 
reduction in the primary endpoint with CRT over a mean follow up of 2.4 years.  The superiority 
of CRT was however driven by a 41% reduction in heart failure events with no difference in 
mortality.  Importantly the improved outcome with CRT was found in the sub-group of patients 
with QRS duration of ≥150ms or more; a finding which was also evident in REVERSE. 
 
Taken together these findings support the use of CRT in mildly symptomatic patients when the 
QRS is ≥150ms, especially if there has been a prior episode of decompensated heart failure. 
Whilst a mortality benefit has not been shown in this patient population, it does seem clear that 
the progression of heart failure has been reversed in these patients with CRT and in longer term 
follow up one would not unreasonably expect to see a mortality benefit. 
Heart failure with an indication for permanent pacing. 
 
The DAVID study clearly demonstrated that chronic RV apical pacing is associated with an 
increase in the incidence of HF in patients with LVSD and invasive studies have shown that RV 
apical pacing has a detrimental effect on haemodynamic parameters 
50, 108
.  Therefore every 
effort must be made to reduce the need for RV apical pacing in patients with HF.  Newer pacing 
algorithms allow patients with sinus node disease to be programmed to atrial pacing, with the 
back up of dual chamber pacing should it become necessary.  In patients with LVSD and high 
degree AV block biventricular pacing has been shown to improve left ventricular function, 
quality of life and exercise capacity compared to RV apical pacing alone 
60
.  In patients with pre-
existing chronic RV pacing who have LVSD and symptomatic HF, upgrading to a biventricular 
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device has been shown to improve acute haemodynamic parameters which are maintained in the 
medium term and result in an improvement in symptoms and reduction in admissions for HF 
109
.  
Over a longer follow up patients with upgrades of RV pacing to CRT had similar benefits in 
terms of mortality and morbidity at as those with native conduction delay with comparable LV 
reverse remodelling 
110
.   
 
Atrial fibrillation 
 
The majority of the patients included in the large trials were in sinus rhythm at the time of 
implant and there is only one small randomised study of CRT in patients with AF demonstrating 
a marginal improvement of exercise capacity following CRT 
53
.  However there is evidence from 
a metanalysis that similar improvements in symptoms, exercise capacity and LV function result 
from CRT in patients with AF provided there is adequate rate control with either 
pharmacological treatment or AV nodal ablation, in order to achieve > 85% biventricular pacing 
111
.  In one prospective series 25% had cardioverted to sinus rhythm at one year following CRT 
and the morality in the patients with AF was also similar to those in sinus rhythm 
112
.   
Elderly 
 
Similar to most randomized controlled trials the average age of trial patients recruited for CRT 
was 64 years.  However there are a number of observational studies which confirm that the 
benefits of CRT are the same with respects to improvements in LV performance, HF morbidity 
and mortality 
113, 114
. 
 
 26 
 
Reverse left ventricular remodelling following CRT 
 
The detrimental prognostic implications of adverse LV remodelling are well established 
therefore improvement in LV dimensions and increase in ejection fraction as a result of medical 
intervention are desirable.  Observational studies have demonstrated that a decrease in LV end 
systolic volumes of >10 % following CRT is associated with a lower mortality 
115
 .  A number of 
randomised studies have demonstrated that CRT leads to a reduction in LV internal dimensions, 
volumes and an increase in ejection fraction compared to medical therapy alone and is similar to 
the effect of beta-blocker on LV function 
116
.  The majority of the remodelling occurs between 
three to nine months and there is on-going remodelling up to 18 months 
117
.  Remodelling is less 
in those with IHD and to a lesser extent in those with no mechanical dyssynchrony or RV 
dysfunction at baseline 
117
.  At a molecular level there is a reduction in interstitial fibrosis, the 
pro-inflammatory cytokine TNF-α and cellular apoptosis 118.  An improvement in LV function 
following CRT is also associated with favourable changes in genes that regulate contractile 
apparatus and pathological hypertrophy 
119
.  However it is important to note that LV remodelling 
only occurs in 50%-66% of individuals following CRT and clinical improvement is not only 
confined to those that exhibit favourable remodelling 
120
.  There is also on-going haemodynamic 
benefit provided by biventricular pacing in individuals whose LV function does not improve or 
worsens following CRT 
121
.    
Natriuretic peptides 
 
Cardiac resynchronisation therapy results in a greater decrease in B-type natriuretic peptide 
(BNP) than medical therapy alone at three months with further reductions at 18 months, 
correlating with the improvement in LV function 
122
.  A high BNP at one month following CRT 
is associated with a worse prognosis and reduction of BNP at three months is a strong predictor 
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of an improvement in exercise capacity, LVEF and mitral regurgitation 
123, 124
.  Atrial natriuretic 
peptide (ANP) fell in a sub-group of patients with renal impairment taking part in the MIRACLE 
study (GFR 30-60mL/min per 1.73m
2
).  In this same group glomerular filtratration rate increased 
following CRT.  However, norepinephrine, plasma renin activity, aldosterone and Big endothelin 
were unchanged with CRT 
125
. 
Response to cardiac resynchronisation therapy 
 
Implantation of CRT based on current selection criteria is associated with a 70% clinical 
response.  However there are a number of methods of assessing response including an 
improvement in symptoms, exercise capacity, LV dimensions, LVEF and survival.  The reasons 
for a poor response to CRT are also multifactorial and can include a lack of dyssynchrony at 
baseline, a failure to correct dyssynchrony or pacing non-viable myocardium.  The lack of a gold 
standard for assessing dyssynchrony mean selection guidelines currently do not advocate CRT 
implantation solely on the basis of a non-invasive testing.  Prior knowledge of coronary sinus 
anatomy and identification of areas with non-viable myocardium may help plan LV lead 
placement 
126
.  Factors which predicted a poor response to CRT in the CARE-HF trial were an 
ischaemic aetiology, high BNP and severity of mitral regurgitation 
73
.    
Optimization of cardiac resynchronisation therapy 
 
Alterations in pacemaker programming allow changes in timing between atria and ventricle (AV 
delay) and between right and left ventricle (VV delay).  Invasive haemodynamic testing has 
shown that optimizing the AV and VV delay at implantation results in an acute improvement in 
LV systolic performance 
66, 127
.  In clinical practice optimization of CRT is carried out using a 
variety of TTE Doppler methods.  In all the major trials of CRT AV optimization was carried out 
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following implantation to maximise LV filling using pulse wave Doppler at the tips of the mitral 
valve.  The AV interval which was able to achieve the maximal E and A wave separation, 
without premature truncation of the A wave is considered optimal.  Small studies have shown 
that TTE optimised sequential biventricular pacing can improve LV function, dyssynchrony and 
LV filling compared to simultaneous pacing 
100
.  However there remain doubts about the clinical 
benefit from what is often a labour intensive exercise due to a lack of large studies showing a 
clear benefit.  The two randomised studies to date did not show any benefit from CRT 
optimisation compared to empirical settings 
128, 129
.  Optimization is carried out at rest; however 
the haemodynamic benefits of CRT may be more marked during exercise, suggesting 
optimization should also be carried out at higher heart rates 
130
.  Most of the CRT pacemakers are 
also able to programme a rate adaptive AV delay to mimic the physiological shortening of AV 
delay that occurs with exercise however the clinical utility of this feature has not been fully 
evaluated in CRT where an increase in AV delay may be required 
131
. 
Despite the paucity of clinical data; AV optimisation which was performed in the landmark 
clinical studies should be carried out on all patients.  There is also some evidence that a 
systematic protocol driven approach which includes device programming changes and 
optimization of medical therapy can be beneficial in patients who respond poorly to CRT 
132
. 
Apelin 
 
Apelin is an endogenous peptide that is a ligand for the angiotensin receptor-like 1 (APJ) 
receptor 
133, 134
.  The apelin-APJ genes are ubiquitously expressed throughout a number of tissues 
and shows similarities with the angiotensin II (Ang II) – angiotensin-II type 1 (AT1) receptor 
distribution 
135
.  Initial experiments in animal models indicate that the apelin-APJ system has a 
role to play in cardiovascular homeostasis.  Apelin is a powerful inotrope, peripheral vasodilator 
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and maybe involved in fluid homeostasis making it an attractive target for HF therapy.  The 
proposed effects of the Apelin-APJ system are opposite to the effects of the Ang II-AT1 
pathway, which makes it an interesting area for research into the mechanisms of HF as well as 
opening up new targets for the treatment.    
Background  
 
History  
 
In 1993 a gene for a receptor with marked similarities to the AT1 receptor was identified.  At 
that time there was no known ligand and it was named the APJ receptor (also known as 
Angiotensin-like 1 receptor) 
133
.  The APJ receptor is a 377 amino –acid, 7 transmembrane 
domain, G-coupled receptor whose gene is located on the long arm of chromosome 11 
133
.  
Angiotensin II (Ang II) is unable to activate the APJ receptor despite its similarities to the AT1 
receptor and in the absence of a ligand it was known as an “orphan” receptor until 1998 when 
apelin was isolated from bovine stomach extracts 
134
.  Apelin is secreted as a 77 amino acid pre-
proprotein which is cleaved to form several active peptides denoted by their length as apelin –13, 
-16, -17, -19 and –36 134, 136, 137.  It has been shown that apelin-13 and apelin-17 exhibit much 
stronger activity than apelin –36 134.  These isoforms are comprised of C-terminal fragments, 
which may be responsible for the receptor binding and biological activity of apelin 
138
.  There is 
no evidence to date that apelin-APJ pathway involves more than one receptor.   
Distribution of Apelin –APJ system 
 
Apelin and APJ messenger RNA (mRNA) is expressed extensively in body tissue.  There are 
particularly high concentrations in the cerebellum, vascular endothelium, heart, lung and kidney 
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134-137, 139-143
.  It is currently thought that the apelin-APJ pathway is capable of juxtacrine, 
paracrine and autocrine signalling.   There are high concentrations of APJ receptors in the heart 
and it is expressed on a number of cells types including endothelium, smooth muscle and the 
myocyte 
144
.   APJ receptors are expressed in the heart at a similar density to the ATI receptor 
and using radioligand-binding assays human heart tissue demonstrated a high binding affinity for 
apelin 
135
.  Apelin immunoreactivity is found in endothelial cells of human cardiac and vascular 
tissue but not in other tissue suggesting that the physiological effects of apelin may be mediated 
by its actions on the endothelium 
145
.    
The role of the apelin in the cardiovascular system 
 
Physiological actions 
 
The role of the apelin-APJ system in cardiovascular physiology and its interaction with other 
neuroendocrine pathways has not been fully elucidated.  However the few studies, predominantly 
in animals, indicate that apelin signalling may be involved in the regulation of vascular tone, 
cardiac contractile function and fluid balance. 
Vascular tone  
 
Physiological experiments in anaesthetised and conscious animal models have yielded 
conflicting results concerning the role of apelin in regulating vascular tone.  In anaesthetised rats 
intravenous apelin resulted in a transient drop in systolic and diastolic blood pressure with no 
change in heart rate 
135, 143
.  The magnitude of blood pressure reduction was dose dependent, 
inversely correlated with molecular size and abrogated with pre-treatment of rats with a nitric 
oxide synthase inhibitor 
143
.  In conscious rodents apelin is a venous and arterial dilator in vivo 
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and also causes a mild tachycardia that is abolished by ganglionic blockade 
146
.  These initial 
experiments suggest that apelin is a peripheral vasodilator whose effects may be mediated by a 
nitric-oxide (NO) dependent mechanism and that the changes in heart rate are secondary to a 
baroreceptor reflex as opposed to a direct chronotropic effect.  However experiments in 
conscious sheep and both anaesthetised and conscious rats have shown the opposite results with 
an increase in mean arterial blood pressure and heart rate 
147-149
.  In the large animal model 
intravenous apelin-13 caused a biphasic response in mean arterial blood pressure and cardiac 
output with an initial fall followed by a subsequent rise returning to baseline over 15 minutes.  
The right atrial pressure was increased and there was parallel increase in natriuretic peptides 
147
.  
These results are difficult to interpret because of the different doses and methods of apelin 
administered.    
 
In vitro experiments have highlighted mechanisms by which apelin can act as a vasodilator or 
vasoconstrictor.  In isolated rat aortas apelin the mechanism of arterial vasodilatation was shown 
to involve the L-arginine/nitric oxide synthase (NOS)/nitric oxide pathways 
150
.  APJ is 
expressed in vascular smooth muscle of rats where apelin induces phosphorylation of the myosin 
light chains 
151
 and in human saphenous veins causes vasoconstriction in the absence of a 
functional endothelium 
152
.  This suggests that the predominant actions of apelin on peripheral 
vascular tissue are mediated by NO production from endothelium. 
The effects of apelin on vascular tone in vivo may be dependent on a dynamic interaction 
between the apelin-APJ system and Ang II-ATI.  In spontaneously hypertensive rats all trans 
retinoic acid (atRA), which up regulates g-protein receptor signalling, reduced blood pressure, 
increased APJ and apelin expression in the aorta 
153
.  This was accompanied by an increase in 
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NO and reduction in AT1 expression.  Apelin did not directly affect the tone in rat portal veins, 
however regardless of the presence of endothelium apelin abrogated the vasoconstrictor response 
to Ang II by a NO dependent mechanism 
154
.  In APJ knockout mice baseline blood pressure was 
no different compared to the wild type, however the mice showed an increase vasopressor 
response to Ang II 
155
.  In disease states an alteration in the normal interaction between apelin 
and Ang-II may contribute to vascular disease.  In the aortas of diabetic mice there is reduced 
expression of APJ, an enhanced contractile response to Ang II and a reduced relaxation with 
acetylcholine.  This abnormal vascular response was modified by pre-treatment apelin 
156
.   
The difficulties with unravelling the role of apelin in the modulation of vascular tone are 
compounded by its possible effects on the central regulation of blood pressure; an effect which 
may be greater than its peripheral effects 
148, 149
.  The actions of apelin may also be dependent on 
fragment size and the type and location of vascular bed upon which it is acting.    
Contractile actions.   
 
Apelin has a powerful dose dependent inotropic effect on isolated animal preparations and in 
intact animals 
157-159
.  An infusion of apelin in isolated perfused rat hearts paced at a constant rate 
and contracting volumetrically showed a positive inotropic response and increased the peak rate 
of left ventricular pressure rise (peak dP/dT) 
159
.  Pressure volume measurements in rats and mice 
demonstrated similar findings in vivo 
157, 158, 160
.  In vivo chronic apelin increased the velocity of 
circumferential shortening and cardiac output in conscious normal mice as demonstrated by 
echocardiography without causing ventricular hypertrophy 
157
.  In the failing heart after 
experimental infarction apelin infusion also results in an improvement in cardiac contractility 
making its role in the therapy of HF an interesting possibility 
158
.  The inotropic effects of apelin 
are not affected by inhibition of nitric oxide synthase, antagonism of adrenergic signalling or 
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blocking endothelin receptors.  They are also not dependent on cardiac innervation 
159
.  Apelin is 
thought to exert its inotropic action by increasing the availability of intracellular calcium rather 
than enhancing the calcium sensitivity of the myofilaments 
159, 161
.  This increase in contractility 
may be even more potent in the failing myocardium 
161
.  It is not known how calcium availability 
is increased although phospholipase C (PLC), protein kinase C (PKC), sarcolemmal -H 
+
 and Na 
+ 
-Ca 
2+ 
exchangers
 
have been shown
 
to be involved 
159
 (Figure 5).  
 
The pleiotropy of actions of 
the APJ receptor signalling mean further studies are still needed to clarify the exact mechanisms 
of how apelin increases contractility.   
Figure 5: Cellular mechanisms for the inotropic actions of apelin  
 
 
Calcium enters the cell via L-type calcium channels (L-Ca
2+
) and initiates calcium release from the 
sarcoplasmic reticulum (SR) by activating the ryanodine receptor (RyR).  This massive Ca
2+  
release is 
required to trigger the contractile process.  
 
Calcium reuptake is mediated by the energy requiring 
sarcoendoplasmic reticulum Ca
2+ 
- adenosine triphosphatase (SERCA2A) and Phospholamban (P) which in 
turn allows relaxation.  Apelin activates protein kinase C (PKC) and phospholipase C (PLC) that acts on the 
sarcolemmal, Na
+
-H
+
 exchanger (NHE) to increase intracellular Na
+
 resulting in an increase in intracellular 
Ca
2+ 
by action of the reverse mode Na
+
 -Ca
2+
 exchanger (NCX).  This leads to an increase in available 
cytosolic calcium for the cardiac contractile apparatus 
162
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Role in fluid balance.   
 
The role of apelin in fluid homeostasis is unclear.  There is conflicting data from animal work 
concerning the actions of apelin on antidiuretic hormone (ADH).  Apelin and APJ are expressed 
in the supraoptic and paraventricular areas of the hypothalamus areas, which play a vital role in 
fluid balance via production of ADH 
141, 163
.  Apelin is also found in neurons that also express 
ADH mRNA suggesting that it may have an antidiuretic action by inhibiting ADH release 
164-166
.  
However functional studies on animals have yielded different results with intracerebral infusions 
of apelin in rats initially showing decreases in circulating ADH with a reduction in dehydration 
induced water intake 
167, 168
 that were contradicted by further studies involving both peritoneal 
and intracerebral infusions of apelin 
169, 170
.   Furthermore in APJ and apelin knockout mice, 
water intake and urinary electrolyte concentrations were no different to wild type mice exposed 
to the same conditions 
155, 171
.  
Although these studies raise interesting questions about the role of the apelin-APJ system in 
cardiovascular homeostasis and fluid balance, further studies are needed to clarify the overall 
effect of apelin on cardiovascular physiology at a local and central level. 
The apelin-APJ system in cardiovascular disease   
 
The proposed cardiovascular effects of the apelin-APJ system are the opposite to the effects of 
the renin-angiotensin system (RAS) that is known to play a vital role in the pathogenesis of HF 
172
.  Therefore apelin-APJ axis may act as a compensatory mechanism initially ameliorating the 
harmful effects of ATI activation becoming down regulated in end stage HF.  The 
carboxypeptidase angiotensin converting enzyme (ACE) II which breaks down Ang-II into Ang 
(1-7) also acts on apelin 36 and apelin 13 suggesting that there is a dynamic interaction between 
 35 
 
the apelin and Ang II pathways 
173
.  There have been a number of clinical studies in animals and 
humans that go some way towards supporting this hypothesis.   
Animal models of heart failure 
 
Apelin mRNA was markedly down regulated in cultured rat myocytes subjected to mechanical 
stretch and two different rat models of chronic ventricular pressure overload 
159
.  In an ischaemic 
HF model apelin infusion increased stroke volume and cardiac contractility in rats and controls 
158, 160
.  In isoproterenol induced myocardial injury in rats apelin and APJ genes were down 
regulated and apelin infusion ameliorated the effects of cardiac injury 
174
.  However a more 
recent study has suggested that the direct inotropic effects of apelin may only be transitory in the 
absence of mechanical loading 
175
.  In compensated ventricular hypertrophy myocardial apelin 
and APJ mRNA is initially preserved and only down regulated when the Dahl sat sensitive rats 
undergo transition to ventricular failure 
176
.  Interestingly only treatment with an Ang II receptor 
blocker restored apelin-APJ concentrations and infusion of Ang II resulted in decreases in apelin 
and APJ within 24 hours.  However the other treatment arms also restored cardiac function 
without up regulating apelin and APJ levels.  Exercise training in spontaneously hypertensive 
rats reversed the pathological consequences of sustained hypertension by an up regulation of 
apelin and APJ in the myocardial and vascular tissue with an increase in plasma apelin 
177
.  This 
suggests that the benefits of RAS inhibition may in part be mediated by an up regulation in the 
apelin-APJ system.  Apelin deficient mice developed contractile dysfunction with age and with 
pressure overload 
171
 meaning apelin may maintain cardiac contractility in the presence of 
sustained pressure overload.  However the findings in apelin knockout mice are different to the 
APJ deficient mice in which the only abnormality was an increased blood pressure response to 
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angiotensin II infusion under conditions of ACE inhibition or mutant AT1 receptor background 
155
.  
Apelin in myocardial ischaemia 
 
In acute ischaemic myocardial injury apelin may have a protective role.  In vitro and vivo studies 
have demonstrated that like adrenomedullin, apelin and APJ gene expression is up regulated in 
response to hypoxia in peripheral and cardiac tissue 
178, 179
.  Following experimental myocardial 
infarction in rats an increase in apelin and APJ expression was observed 
160
.  Subsequent 
exogenous apelin infusion improved cardiac contractility, suggesting that the endogenous apelin 
production was insufficient to activate all the APJ receptors.  Therefore the apelin-APJ system 
may be induced in ischaemia to limit myocardial injury.  A more recent study provides insight 
into a possible mechanism whereby the apelin-APJ system may protect the myocardium form 
ischaemia reperfusion injury by its actions on the reperfusion injury salvage kinase (RISK) 
pathway 
180, 181
.  
Apelin in human ventricular dysfunction 
 
 In humans apelin like immunoreactivity was reduced in patients with left ventricular 
dysfunction secondary to ischaemic heart disease 
182
.  However ventricular apelin mRNA was 
significantly increased in patients with dilated cardiomyopathy and HF secondary to ischaemic 
heart disease.  In this study APJ receptor mRNA was also reduced in patients with dilated 
cardiomyopathy suggesting that abnormalities in the apelin APJ pathway may play some part in 
the pathogenesis of HF in humans. 
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Plasma concentrations of apelin in patients with chronic HF are reduced compared to normal 
controls 
183
.  Although smaller studies suggested that initially apelin is raised in mildly 
symptomatic HF and reduced in more symptomatic patients this was not confirmed in a larger 
case series, which showed no significant differences between functional classes or relationship 
with ejection fraction 
183, 184
.  In patients with dilated cardiomyopathy APJ polymorphisms were 
not found in a greater frequency compared with normal healthy controls.  However those 
individuals with the at least one copy of the APJ 212A allele were less likely to have progression 
of HF over a 37 month follow up 
185
.  This study suggests that it is unlikely that defects in the 
APJ receptor gene cause dilated cardiomyopathy however they may affect the rate of progression 
to symptomatic heart failure. 
Apelin in human left ventricular remodelling 
In end stage HF patients who had left ventricular assist devices and successful left ventricular 
reverse remodelling, tissue concentrations of apelin were increased and the APJ gene was up 
regulated 
184
.  There is only one study which has looked at the effect of CRT on plasma apelin in 
humans.   In a small prospective observational series Francia et al showed that plasma apelin was 
increased in 14 patients undergoing CRT after a mean follow up of 9 months 
186
.  All the patients 
experienced clinical improvement following CRT and all but one had significant reverse 
remodelling as defined by a decrease of internal LV dimensions and an increase in the LVEF 
measured using TTE.  The majority of patients had ischaemic heart disease (8/14) and all 
patients were on ACE-I with 13/14 on a beta-blocker at baseline. The medications were not 
changed during the study period.  Plasma apelin concentration was lower than in normal controls 
at baseline and following CRT apelin increased to values found in patients without HF.  Even in 
the one patient who did not successfully remodel following CRT, the apelin concentration was 
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still increased.  In a subgroup of 6 patients with dilated cardiomyopathy Mullen’s et al obtained 
endomyocardial biopsies at baseline and at 6 months following CRT 
187
. They showed that apelin 
gene expression was increased following chronic CRT in addition to other genes responsible for 
cardiac contractile apparatus including SERCA, PLN, NCX and β1adrenoreceptor.  These results 
were consistent with the improvement of force frequency observed using non-invasive and 
invasive measures of cardiac contractility 
187
.   
Although there are some conflicting studies and the exact role of apelin-APJ system in the 
pathogenesis of human HF, these early studies suggest that apelin-APJ axis is down regulated in 
HF and up regulated with favourable left ventricular remodelling (Figure 6).  Whether the 
primary source of this apelin is from cardiac tissue or peripheral tissue is not known.  The 
interactions of the apelin-APJ system with other neurohormonal systems involved in the 
pathogenesis of HF are not known and the effect of disease modifying therapy such as ACE-I 
and beta-blockers on apelin concentrations has not been investigated. 
Figure 6 The role of apelin in Heart Failure 
 
 
 
Ang II =Angiotensin II AT1 = angiotensin-II type one receptor.  NO= nitric oxide 
162
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The use of apelin as a biomarker in human heart failure 
 
There have only been three studies that have compared the use of apelin and other biomarkers to 
aid in the diagnosis of HF.  Apelin-36 was reduced in patients with chronic pulmonary disease 
and normal cardiac function while BNP remained unaffected 
188
.  This is in contrast to patients 
with severe left ventricular dysfunction or idiopathic pulmonary hypertension where apelin was 
still decreased whereas BNP was raised suggesting that apelin may be a marker for chronic 
pulmonary disease.  In patients with presenting to an emergency room with dyspnoea apelin did 
not reliably predict acute HF and was not a prognostic marker in those with confirmed HF 
189
.  In 
patients with chronic HF secondary to idiopathic dilated cardiomyopathy plasma apelin was no 
different to normal controls unlike the other biomarkers which included NT-proBNP, IL-6, TNF-
α and norepinephrine 190.  Unlike the biomarker BNP which can be used as a diagnostic 
screening test and prognostic marker for HF, current data does not suggest a similar application 
for apelin.   
Apelin in atherosclerosis 
 
There is a small amount of evidence that the apelin-APJ system may be involved in modulating 
endothelial oxidative stress and the formation of coronary atherosclerotic plaques.  In APJ and 
ApoE double knockout mice fed a high cholesterol diet, atherosclerotic plaque burden was 
considerably reduced compared with single ApoE knockout mice without any difference in 
cholesterol concentrations 
191
.  There was also a reduction in markers of oxidative stress and 
vascular smooth muscle cells in the double knockout mice.  However in humans with 
hypercholesterolemia, plasma apelin was decreased compared to matched controls 
192
 and there 
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was no increase in the expression of APJ receptors in atherosclerotic vessels compared to normal 
controls 
193
 
 
Apelin following myocardial infarction (MI) 
There have been two studies which have looked at plasma apelin concentration following MI in 
humans.  Weir et al prospectively studied 100 patients with acute MI who had a LVEF <40% on 
TTE at 46 hours post admission and at 24 weeks 
194
.  Apelin-12, Plasma N-terminal proBNP 
(NT-proBNP), norepinephirine (NE) and arginine vasopressin (AVP) were measured and all 
patients had a CMR prior to discharge which was repeated at 24 weeks.  Compared with 38 
normal controls with no cardiac disease, plasma apelin was reduced (0.54+/-0.25ng/ml vs 3.22+/-
3.01ng/ml, p<0.0001) early post MI and increased significantly at 24 weeks (0.62+/-0.25ng/ml, 
p=0.03) despite remaining lower than controls 
194
.  There was no relationship between plasma 
apelin concentration and any parameter of LV function, but apelin correlated with NE (r=0.26, 
p<0.0008).  A smaller study measured Apelin-36 on admission and on day 5 post acute MI.  
There was a significant reduction of apelin concentration on day 5 in all patients regardless of 
LVEF measured by TTE or composite clinical outcomes after a 1 year of follow up 
195
.   
Apelin and cardiac conduction 
Apelin may well have an important role to play in cardiac electrophysiology.  A recent study has 
shown that high concentrations of apelin are found around the intercalating discs that are vital to 
cellular electrical coupling 
175
.  In this study apelin increases the frequency of spontaneous 
activation, conduction velocity and reduces the field potential duration in monolayers of cultured 
neonatal rat cardiomyocytes.  In the large animal model there was evidence of high grade AV 
block in 50 %, which was not observed in smaller animals raising concerns about the use of 
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supraphysiolgical doses of apelin for therapy 
147
.  Apelin levels are raised in patients without 
structural heart disease and in sinus rhythm that have had a history of lone atrial fibrillation 
196
.  
However the true significance of this finding and the relationship between medication usage and 
timing of previous cardioversion require further investigation therefore the role of apelin in 
human arrhythmogenesis is unknown.   
Apelin and the cardiorenal axis. 
Heart failure and renal failure are inextricably intertwined giving rise to the term cardiorenal 
syndrome.  The actions of RAS system directly affect the kidney and therefore a link between 
renal disease and the apelin-APJ system seem entirely plausible.  In haemodyalised patients 
without HF symptoms the concentration of apelin-36 were lower in patients with coexisting 
coronary artery disease and correlated with diastolic LV dimensions 
197
.  In a further study by a 
different group apelin was lower in dialysed uraemic patients, most of whom had systolic 
dysfunction, compared to patients with dilated cardiomyopathy (DCM) with normal renal 
function 
198
.  This observation was independent of cardiac function despite the DCM having 
lower ejection fractions.  Apelin has also been shown to regulate arterial tone in diabetic mice by 
modulating the vascular responsiveness to Ang II and by increasing generation of NO by 
endothelial NOS 
199
.  It is well documented that death from cardiovascular disease is a major 
cause of mortality and morbidity in patients with end-stage renal disease.  Although further work 
is needed there may well be a link between apelin-APJ system and the pathogenesis of 
cardiovascular disease in chronic renal disease opening up the possibility of apelin as a 
therapeutic agent in these patients.   
Cardiovascular development and angiogenesis 
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There is growing evidence that apelin and APJ may play an important role in cardiac 
development and angiogenesis.  In zebrafish apelin and its receptor have been shown to control 
heart field formation during gastrulation and regulate the migration of early myocardial 
progenitors 
200
.  An under or over expression of apelin-APJ signalling results in reduction in 
cardiomyocyte numbers and abnormal cardiac morphology 
201
.  Similar findings have been 
shown in the frog embryo as well 
202
.  Apelin and APJ are also expressed in developing 
vasculature in addition to other endothelial structures in the zebrafish and the frog 
203, 204
.   In 
retinal cell lines apelin induces angiogenesis 
205
.  However it is not known whether apelin has a 
similar role to play in vivo.   
Despite these findings APJ and apelin deficient mice did not show any abnormalities in 
cardiovascular morphological development 
155, 171
.  The reasons for the differences between the 
findings in APJ deficient mice and the zebrafish and frog models is not known, but may be due 
to the presence of different signalling mechanisms involved in cardiac differentiation in mice.   
Other physiological actions of apelin 
 
The extensive distribution of apelin means that it is likely it has a wide range of effects on a 
variety of different organs.  Most of these are beyond the scope of this review but are mentioned 
here briefly.   
Apelin is one of a number of adipokinins (adiponectin, leptin, resistin), abundantly expressed in 
adipose tissue and up regulated by insulin and steroids 
206
.  The high concentration of apelin and 
its receptor in the anterior pituitary also point towards a role in the adrenal neurohormonal axis 
207, 208
.  Apelin may also be involved in immune signalling and has been shown to influence T-
cell cholinergic activity in human cell lines and cytokine production in mice 
209, 210
.  Apelin also 
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inhibits HIV-1 viral entry into CD4+ cells by preventing the virus binding to APJ, which acts as 
a co receptor for HIV1 
211, 212
.   
 
The discovery of the apelin-APJ axis is an exciting development in cardiovascular research.  
Although the exact mechanisms of how this molecular pathway interacts with the Ang II-AT1 
pathway are still to be fully elucidated, there is growing evidence that apelin may be involved in 
the transition from compensated hypertrophy to clinically significant HF.  The use of apelin as a 
diagnostic or prognostic marker in human HF seems unlikely on the basis of current evidence.  
The vasodilator and inotropic actions of apelin in addition to its up regulation after favourable 
left ventricular remodelling, opens up the possibility of its use as a therapeutic agent in HF.  
Apelin is abundantly present in endothelial tissue in a number of organs and it is still not known 
whether the increases in plasma concentrations following favourable left ventricular remodelling 
are as a result of increased myocardial apelin production or enhanced peripheral production 
following improvement in central haemodynamics.  The relative importance of the central and 
peripheral actions of apelin on normal cardiovascular physiology and cardiovascular disease are 
also undetermined.  Apelin may also be involved in cardiac electrophysiology although its exact 
role in vivo is not known therefore any therapeutic application requires caution because of the 
risk of malignant ventricular arrhythmias or heart block.  The discrepancies between initial 
experiments on embryos and the more recent knockout mice models make it difficult to make 
firm conclusions about the role of the apelin-APJ system in cardiac development.   
There are number of unanswered questions about apelin and its receptor APJ providing the need 
for further research into the role of the apelin-APJ axis in normal cardiovascular physiology and 
in disease states.   
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Immune activation in Heart Failure 
 
Inflammation is a normal response to any tissue injury and is governed by a complex interaction 
between a variety of organ specific cells, the extra cellular matrix and the innate and cellular 
immune system.  Cytokines are proteins, which are secreted by a number of cells, play a vital 
role in orchestrating this immune response in removing any offending pathogen or damaged 
tissue and ultimately lead to healing.  As previously indicated cardiomyocytes are known to 
secrete cytokines which are thought to be involved in the process of left ventricular remodelling.  
There are 3 proposed mechanisms activation of the immune system in heart disease: 1) Direct 
antigenic stimulation caused by a viral pathogen, as in the case of viral cardiomyopathy.  2) 
Indirect exposed to myocardial proteins secondary to myocardial damage i.e myocardial 
infarction or shear stress from pressure or volume overload.  3) Immune activation to endotoxin 
exposure from the bowel 
213, 214
.  Cytokines can act at local level or systemically and there is 
increasing data that there is an imbalance between proinflammatory cytokines (TH1 response) 
and regulation of a healing (TH2) response in patients with HF.  Measurement of cytokines, their 
soluble receptors, or receptor antagonists can help determine prognosis in patients with HF and 
targeting cytokines or their membrane bound receptors may offer new therapeutic avenues in the 
treatment of HF.  However the disappointing results of trials of immunomodulation therapy in 
HF have led to the realisation that the subject of immune activation in HF is more complex than 
previously envisaged and targeting specific cytokines may be a fruitless strategy as there is 
considerable redundancy in the actions of the immune system 
215
.  It may also be the case that the 
immune activation in HF is a bystander phenomenon.  
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Tumour necrosis factor alpha (TNF-α) 
 
Normal myocardial cells do not express TNF-α, but do express its receptors, the high affinity 
receptor 1 (TNFR1) and the lower affinity receptor 2 (TNFR2).  The biological effects of TNF-α 
can be attenuated by soluble receptors.  Serum concentrations of TNF-α are raised in patients 
with chronic HF and increase with NYHA class whereas TNFR1 and TNFR2 expression is down 
regulated in left ventricular dysfunction 
216, 217
.  The actions of TNF-α are dependent on its 
concentration and at low levels it acts in an autocrine fashion on leukocytes and endothelium to 
regulate a local inflammatory response.  At higher concentrations it is released into the 
circulation and can have a variety of effects akin to a systemic inflammatory response such as 
wasting, coagulation, hypotension and fever 
218
.   
 
There is evidence that TNF-α can be a stimulus for an adaptive or maladaptive response to 
cardiac injury.  Adult myocytes showed hypertrophy when exposed to exogenous TNF-α 219.  
Transgenic mice with overexpression of TNF-α develop a HF clinical phenotype ,with  
progressive chamber dilatation and reduced ventricular systolic function compared to wild type 
mice 
220
.  However high TNF-α concentration does not invariably result in ventricular 
dysfunction and clinical scenarios in which systolic function is preserved despite high circulating 
TNF-α concentration are aortic stenosis and mitral regurgitation 221.  Tissue concentrations of 
TNF-α is elevated in hypertrophic cardiomyopathy (HOCM) and reduced with regression of 
pressure overload following alcohol septal ablation 
222
.  Along with Interleukin -1 (IL-1), TNF-α 
can lead to a down regulation of the response of the myocardium to adrenergic stimulae 
223
.  
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Soluble TNF-α receptors 
 
In chronic heart failure soluble TNF-α (sTNFR) 1 and 2 were elevated in preterminal patients 
with severe HF compared to normal individuals and those with mild HF symptoms 
224
.  In this 
small study of 37 patients sTNFR2 independently predicted short term prognosis in 37 patients  
224
.  A larger study of 152 HF patients by Rauchhaus et al showed that inflammatory cytokines 
TNF-α, Il-6 and soluble CD14 (a marker for endotoxin) were raised significantly along with 
sTNFR1 and 2 and in HF patients and predicted survival in univariate analyses over 24 months 
225
.  However even compared to other clinical variables known to be associated with prognosis in 
HF, sTNFR1 was the strongest multivariate predictor of survival in this patient population 
225
.  
Soluble TNF-α receptors are also increased with NHYA class 226, in oedematous patients 227 and 
with cardiac cachexia 
228
.  However they are more stable in the short term 
229
 and are already 
detectable in stable patients with mild HF even in the absence of cachexia 
228
.  The authors 
hypothesised that this was the reason sTNFR1 may be a superior marker of the long term 
immune activation than TNF-α 225.   
Interleukin- 6 (IL-6) 
 
Interleukin-6 is a pleiotropic cytokine which affects both cellular and humoral immunity.  It is 
involved in the acute phase response by stimulating hepatocyte C-reactive protein (CRP) 
secretion 
230
.  The release of IL-6 is stimulated by IL-1, TNF-α, and Interferon-γ (IFN-γ) and it 
has a relatively short half-life of 6 hours.  Tsuatamota et al measured IL-6 in femoral artery and 
femoral vein of 80 patients with HF and 13 controls 
231
.  They showed an increase in IL-6 in the 
venous plasma in both groups suggesting spill over of IL-6 into the systemic circulation.  The 
spill over of IL-6 increased with severity of HF and correlated with activation of the sympathetic 
nervous system.  The same group went on to show that in 100 patients with HF, the 
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concentration of plasma Il-6 was increased and able to predict prognosis independent of LVEF 
231
.  Other studies have also shown increasing concentrations of IL-6 correlate with HF severity, 
disease progression and mortality, suggesting a role for IL-6 in the pathophysiology of HF 
216, 
232
.   
Interleulin-1 (IL-1) 
 
Interleukin-1 was the prototype inflammatory cytokine originally identified in rabbit sera and 
shown to be pyrogen in animals and humans 
233
.  It has two isoforms, IL-1α and IL-1β which 
exert the same biological effects and act upon the same receptors IL-1 receptor (IL-1R)1 and 2 
234
.  Both isoforms of IL-1 are secreted as larger proproteins. Pro-IL-1α is biologically active and 
cleaved by calpain to form IL-1α which remains intracellular.  Pro-IL-1β is not biologically 
active and requires cleavage by IL-1β-converting enzyme (ICE capase 1) to become the 
biologically active IL-1β which is secreted into the circulation.  Binding of both isoforms to IL-
1R1 induce signal transduction responsible for the biological effects of IL-1.  However binding 
to IL-1R2 does not result in signal transduction and so is an innate method of mopping up excess 
IL-1 (Figure 7) 
234
. 
 
All cells are also able to secrete a 3
rd
 member of this family of proteins known as IL-1 receptor 
antagonist (IL-1Ra).  This protein competitively binds to IL-1R1, but does not result in a signal 
transduction also acting as an internal balancing mechanism for the actions of IL-1.  It has three 
membrane bound isoforms and a soluble isoform which is released into the circulation (sIL-1Ra) 
235
. 
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Subsequent to the initial characterisation of IL-1 and similar proteins there has been an 
expansion of new members of this protein family primarily from research using molecular 
sequence homology, three dimensional structure and receptor binding sites.  This has led to a  
Figure 7. Interleukin-1 binding and signalling through its receptors. 
 
 
 
IL-1 signalling is mediated through the type I IL-1 receptor (IL-1RI). After IL-1 (either IL-1αor IL-1β) 
binding to IL-1RI, the IL-1R accessory protein (IL-1RAcP) forms a complex with IL-1/IL-1RI. This results in 
signal transduction. In contrast, IL-1 binding to the type II receptor (IL-1RII) does not transduce a signal; 
this receptor serves as a “decoy” trapping IL-1 molecules and regulating activity of the cytokine. IL-1 
signalling is also regulated by IL-1 Receptor antagonist (IL-1Ra). Binding of IL-1Ra to IL-1RI fails to recruit 
IL-1RAcP, does not initiate signal transduction, and prevents IL-1 signalling, competitively inhibiting IL-1- 
mediated responses 
234
. 
 
change in nomenclature where IL-1α, IL-1β, IL-1Ra are referred to as IL-1 Family member (IL-
1F) 1-3 and the newer members are denoted as IL-1RF 4-11 
236
. For instance a recent addition to 
the IL-1 family is Interleukin -33 (IL-33) or IL-1F11 which is the ligand for the orphan ST2 
receptor 
237
.  
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Biological effects of IL-1 
 
Interleukin-1 is ubiquitously expressed and released in response to tissue injury. Both isoforms 
exert a variety of effects on an array of cell types.  Signalling via IL-1R1, IL-1 induces 
phosphorylation of a number of kinases known as the mitogen activated protein kinase (MAPK) 
pathway, leading to up regulation of nuclear factor- κβ (NF- κβ) and activator protein 1 (AP-1) 
238
.  These proteins are translocated to the nucleus and facilitate transcription of a number of 
inflammatory genes including: chemokines, other proinflammatory cytokines, adhesion 
molecules, colony stimulating factors, mesenchymal growth factor genes, phospholipase A2, 
Nitric oxide synthase (NOS) and type -2 cyclooxygenase (COX-2) 
238
.  Different genes are 
stimulated depending on the cell subtype and this allows IL-1 to initiate an immune response 
allowing infiltrates of leukocytes to remove damaged tissue and eventually to repair (Figure 8).  
The healing process and scar formation is also influenced by IL-1 expression by acting on 
fibroblasts and smooth muscle cells to alter the balance between MMPs and TIMPS allowing 
deposition of the collagen matrix.  The method of intracellular signalling allows post receptor 
amplification and this explains how IL-1 is a potent inflammatory mediator despite the relatively 
low membrane receptor density of IL-R1 
238
.  There is also evidence that IL-1Ra is highly 
expressed and its antagonism forms a dynamic equilibrium with IL-1α and IL-1β to regulate the 
actions of IL-R1 activation.  Knockout mice that are deficient in IL-1Ra develop a premature 
inflammatory aortitis and arthropathy 
239, 240
.   
Proinflammatory cytokines in Left ventricular remodelling 
Interleukin-1 has been shown in animal and humans to be involved in cardiac hypertrophy.  
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In a murine model of pressure overload myocardial IL-1β and TNF-α were increased early and 
associated with cardiac hypertrophy 
241
.  In genetically altered mice with cardiac specific 
overexpression IL-1α, there was significant left ventricular hypertrophy without systolic 
impairment, suggesting that IL-1 stimulation alone can lead to cardiac hypertrophy 
242
.  In failing 
rat hearts IL-1β is increased further with the onset of systolic dysfunction and adverse left  
Figure 8: The actions of Interleukin-1 (IL-1). 
 
 
 
IL-1 signalling modulates phenotype and function of all cell types involved in infarct healing.IL-1 suppresses 
cardiac function and induces cardiomyocyte hypertrophy and apoptosis.  Beside its effects on 
cardiacmyocytes, IL-1 signalling exerts pro-inflammatory actions activating leukocytes, inducing expression 
of cytokines, chemokines and adhesion molecules in endothelial cells, and promoting infiltration of the 
infarcted myocardium with inflammatory cells. In addition, IL-1 modulates fibroblast function by enhancing 
MMP expression. These actions are critically involved in cardiac injury, repair and remodelling following 
myocardial infarction 
234
. 
 
ventricular remodelling 
243
.  The expression of IL-1β at this stage is mainly in the endothelium 
and interstitial macrophages suggesting that the initial hypertrophic response to local IL-1 later 
develops into a regenerative response to IL-1 secreted primarily from leukocytes.  In human with 
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aortic stenosis there is an increase in IL-1β, Il-6 and TNF-α expression in myocardial tissue 244.  
In patients with compensated DCM, IL-1β is still highly expressed, but TNF-α and IL-6 are 
reduced 
244
.  In patients with decompensated DCM, TNF-α is reduced further.  The serum 
concentrations of these cytokines are inversely correlated to their expression in tissue.  This data 
suggests that cytokine networks are involved in an early adaptive response to cardiac stress and 
changes in the ratio or persistence of high concentrations of proinflammatory cytokines may be 
involved in adverse left ventricular remodelling.   
The role of T-cell subsets on the immune response 
 
After the initiation of the initial inflammatory process following tissue injury the cellular 
immune system is brought into play.  Phagocytic cells in the form of neutrophils and then 
macrophages are recruited to the site of injury via the circulation.  These cells are summoned by 
a number of specific and non-specific chemoattractant factors.  They are initially involved in the 
processing of antigens which leads to the stimulation of the adaptive immune system in the form 
of CD4+ T helper cells.  T-cell subsets then play a central role in determining the type of 
immune response i.e. a cellular or humoral response.  CD4+ T-cells are found in two distinct 
subtypes known as TH1 and TH2, which are differentiated by the types of cytokines that they 
secrete. TH1 cells secrete IFN-γ, TNF-α, IL-12 and IL-18 and TH2 cells secrete IL-4, IL-5, IL-9, 
IL-10, IL-13 and TGF-β 245.  The TH1 cells shift the immune response towards cellular mediated 
response which is required to eradicate intracellular pathogens.  The TH2 cells promote a 
humoral or antibody mediated response which is required to deal with blood borne infective 
agents and parasites.  The TH2 array of cytokines also promotes healing and collagen deposition 
particularly acting on fibroblasts.  An abnormal expression of TH1 cells has been implicated in 
autoimmune diseases such as multiple sclerosis and rheumatoid arthritis 
245
.  There is evidence 
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that in HF there is a shift towards a TH1 pattern of response and treatments that are known to 
improve prognosis in HF modulate this type of immune activation 
246-248
.  In animal models both 
TH1 and TH2 subsets are responsible for cardiac fibrosis and left ventricular remodelling 
249
.  
TH1 cells are thought to be responsible for early fibrosis and TH2 cells at a later stage.  In 
patients with chronic HF the percentage of TH1 cells assessed by flow cytometry was higher in 
peripheral blood and the percentage of CD4+ cells staining for IGN-γ, correlated with the 
severity of symptoms and reduced with treatment after 2 weeks 
250
.  The same authors found that 
TH1 cells were higher in patients with HF secondary to IHD as opposed to idiopathic DCM 
251
.  
Therefore modulating these T-cell interactions may provide a treatment avenue in HF and 
prevent adverse left ventricular remodelling.   
 
However the TH1/TH2 dichotomy has recently been modified with the discovery of further T-
cell subsets.  This simple dual hypothesis is much more complicated and there are also TH17, 
TH9, follicular T-cells and T-regulatory (Tregs) cells to add to the milieu of T-cell subsets.  
There is also emerging evidence that the differentiation of the T-cells into their subsets is 
governed by a complex interaction with a variety of cytokines and other cells.  Previously it was 
thought that there was no plasticity between T-cell subsets, but recent data suggests that this is 
untrue and dependent on the cytokines present, T-cells can change between subsets and which 
cytokines they secrete 
245
.   
Interferon gamma (INF-γ) 
 
Interferon–gamma is a proinflammatory cytokine and is mainly secreted by TH1 cells and in 
some cases by natural killer cells (NKC).  It has a wide range of actions including: stimulation of 
macrophage phagocytosis, expression of major histocompatibility molecules I and II on antigen 
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presenting cells, enhancing leukocyte –endothelial interactions and influencing cellular 
proliferation and apoptosis.  Interferon-gamma release is stimulated by crosslinking of the T-cell 
receptor complex under the appropriate conditions and also by IL-12 and TNF-α secreted by 
macrophages 
252
.   There are over 200 genes which are stimulated by IFN-γ making it difficult to 
investigate its complex role in the inflammatory process.  It is one of the main players in steering 
the adaptive immune response to a more cellular (TH1) response.  Interferon-gamma also 
inhibits IL-10 which is secreted by TH2 cells whereas the production IFN-γ is down regulated by 
and IL-4 and TGF-β which are also predominantly TH2 secreted cytokines 252.    
Interleukin-4 (IL-4) 
 
Binding of the T cell receptor and IL-4 induces GATA transcription factor which is responsible 
for differentiation into the TH2 cell 
245
.  GATA then stimulates the transcription of IL-4, IL-10 
and TGF-β.   In patients with chronic HF serum IL-4 concentrations were unchanged, but the 
ratio of IFN-γ/IL-4 was increased compared to normal controls 253.  Atorvastatin was shown to 
reduce IFN-γ and IFN-γ/IL-4 ratio in vivo and in vitro in patients with HF 253.  In the peripheral 
blood of patients with chronic HF there was no increasing CD4+ve T cells producing IL-4 
250
.   
Interleukin-10 
 
One of the predominant cytokines secreted by the TH2 type cells is IL-10.   It plays an important 
role in dampening down inflammation by down regulating IL-1, TNF-α and IL-6.  Interleukin-10 
also upregulates sTNFRs which can ameliorate the effects of TNF-α.  Another important action 
of IL-10 is its action on macrophages to inhibit NO production and the formation of free radicals.  
In patients with HF IL-10 was able to supress peripheral blood mononuclear cell production of 
TNF-α in response to stimulation with lipopolysaccharide antigen 254.  In cultured rat myocytes 
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TNF-α exposure resulted in increased cell damage secondary to oxidative stress. This effect was 
abolished by the addition of IL-10, suggesting that the ratio of TNF-α/IL-10 may play a role in 
cardiac remodelling 
255
.  There is also evidence that plasma IL-10 concentrations may be reduced 
in HF patients with DCM compared IHD and correlate with increased intracardiac filling 
pressures 
256
.  With increasing severity of HF symptoms there is a decrease in serum 
concentrations of 1L-10 
257
 and in patients with end stage heart failure requiring mechanical 
support a reduction in tissue concentrations of IL-10 was associated with worsening survival 
258
.  
In patients with depressive symptoms and heart failure IL-10 concentrations in serum were 
reduced and markers of apoptosis and TNF-α were elevated compared to those without emotion 
distress 
259
.  In a larger cohort of heart failure patients with symptoms of depression, raised BNP 
and low IL-10 were independent predictors of event free survival over a 1 year follow up 
260
.  
These data add wait to the hypothesis that a failure to mount a TH2 response may be associated 
with adverse remodelling and worsening outcomes in patients with HF.   
Interleukin-33(IL-33) and ST2  
 
Interleukin-33 has been recently identified as the ligand for the orphan receptor ST2 which is 
also known IL-1RL1 
237
.  It is a member of the IL- family and originally ST2 was described on 
TH2 cells, but not on TH1.  The gene for ST2 encodes for 3 proteins: 1) a membrane bound 
receptor, 2) a functional soluble receptor (sST2) and 3) a variant ST2 
261
.  Initial experiments 
showed that blocking ST2 with a specific antibody or sST2 inhibited TH2 responses.  However 
conventional methods to find a biological ligand for the ST2 receptor were unsuccessful 
requiring computational modelling to eventually identify IL-33.  Since then there has been 
renewed interest in the IL-33–ST2 pathway in human disease.  There is evidence that this 
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pathway is involved in host responses to parasitic infections, allergic reactions, atherosclerosis 
and HF 
261
 .   
 
Interleukin-33 mRNA is expressed in many organs and tissues, however at a protein level it is 
mainly expressed by endothelial cells, epithelial cells and fibroblasts 
262
.  The full length Il-33 
protein is intracellular and bound to the nucleus, similar to IL-1α.  It is only active in its full 
length form and although it can be degraded by proteases and calpain, the products are not 
biologically active.  Therefore release of IL-33 is primarily from tissue damage and as it is 
mainly expressed in tissue linings, IL-33 is thought to form part of the first line of defence 
against pathogens 
261
.  
The actions of IL-33 are predominantly on immune cells such as T-cells, Basophils and 
Eosinophils where the ST2 receptor expressed.  The signalling of IL-33 requires binding to ST2 
and IL-1R accessory protein (IL-1RAP).  This activates the phospholipase D2-sphingosine 
kinase pathway (PLD-SK) and the MAPK pathway (Figure 9) 
261
.  This leads to calcium influx 
and upregulation of NF-κβ which leads to mast cell degranulation and increase in transcription of 
a number of cytokines.  Soluble ST2 acts as a decoy receptor binding directly to IL-33 and 
thereby inhibiting its actions.  However sST2 or soluble human ST2-IgG fusion protein can 
prevent release of inflammatory cytokines (IL-1, TNF-α and IL-6) from monocytes stimulated 
with lipopolysaccharide antigen (LPS) suggesting they have immunomodulatory effects 
independent of IL-33 
263, 264
.  Acting on TH2 cells IL-33 induces the production of IL-5 and IL-
13 independent of IL-4.  Interleukin-33 also acts as a chemokine for TH2 cells and can direct 
naive CD4+ T-cells towards a TH2 response 
265
.  However IL-33 can also stimulate release of 
 56 
 
proinflammatory cytokines IL-1, IL-6, TNF-α and chemokines from human mast cells as well as 
IFN-γ and IL-4 from human NK cells 266.   
Figure 9: Diagram of the actions of IL-33 /ST2 pathway 
 
 
This schematic demonstrates Interleukin-33 (IL-33) binding to the heterodimer receptor comprising of 
Interleukin-1receptor accessory protein (IL-1RAP) and membrane bound ST2. This initiates signalling by the 
myeloid differentiation primary response 88 (MYD88) complex.  Activating the phospholipase D2 (PLD) 
sphingosine phosphokinase (SPK) leads to calcium (CA
2+
) mobilisation and subsequent activation of (nuclear 
factor) NF-κβ.  This results in mast cell degranulation and the release of a number of proinflammatory 
cytokines (Interleukins (IL)-1β, IL-3, 6, Tumour necrosis factor (TNF-α), and chemokines (CCL2,3, CXCL2) 
prostaglandin D2 (PGD2), and leukotriene B4 (LTB4)).  Activation of mitogen activated protein kinases 
(MAPK) can also lead to the transcription of a number of TH2 cytokines (IL-5, 13) and chemokines (CCL-5, 
17 and 24).  The soluble ST2 (sST2) acts as a decoy receptor binding free IL-33.  Adapted from Liew et al 
261
. 
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Interleukin-33/ST2 pathway in cardiovascular disease 
 
Interleukin-33 and sST2 are expressed in endothelial cells of the heart and vasculature of animals 
and humans 
267
.  Animal studies have suggested a pathogenic role for IL-33 mediated action of 
the TH2 subset in atherosclerosis 
267
.  Soluble ST2 mRNA is upregulated in rat myocytes 
subjected to mechanical strain or IL-1 and in human myocardial infarction sST2 is increased in 
serum early and high concentrations are an independent predictor of mortality and HF 
268
 
269
.  
Soluble ST2 is increased in serum of humans with HF and is an independent prognostic marker 
in patients presenting with decompensated HF with preserved and reduced LVEF 
270
.  In acute 
heart failure sST2 correlates with NYHA class, natriuretic peptides, creatinine clearance, CRP 
and with decreasing LVEF 
270
.  In patients with acute decompensated HF a decrease in serial 
sST2 concentrations predicted 90 day mortality independent of natriuretic peptides 
271
. In 
patients presenting with dyspnoea, serum sST2 correlated with echocardiographic abnormalities 
of right and left ventricular dysfunction and, high serum sST2 was an independent predictor of 
mortality in patients with and without HF 
272
.  The serum concentration of sST2 was raised in 
patients with congestive cardiomyopathy and aortic stenosis compared with normal controls and 
correlated with BNP and left ventricular end diastolic pressure 
273
.  However ST2 and IL-33 
mRNA were no different in patients and controls and there was no gradient between coronary 
sinus and aorta for sST2 
273
.  Leukocytes and endothelium expressed IL-33 and there was a 
strong correlation between leukocyte expression of ST2 and IL-33.  Based on this data the 
authors conclude that although the IL-33-ST2 system is activated in HF, serum sST2 production 
is exogenous to the heart 
273
.  Weir et al recently measured sST2 in 100 patients post MI with 
LVSD during admission and at 12 and 24 weeks.  Their LV function was assessed with CMR 
and changes in sST2 correlated favourable LV remodelling and baseline sST2 predicted the 
 58 
 
extent of myocardial scarring and microvascular obstruction 
274
.  In patients with systolic 
dysfunction high sST2 was a marker for sudden cardiac death 
275
 suggesting that sST2 may be a 
marker for abnormal remodelling and scar formation, which is known to predict adverse events 
in HF 
276
. 
 
Overall the data suggest that serum sST2 is a marker for upregulation of the IL-33-ST2 pathway 
and offers a prognostic marker in patients with HF.  However as sST2 inhibits IL-33 activity it is 
not still clear weather sST2 is involved in the pathogenic process or is by-product of pathway 
activation.   
Cytokines and cardiac resynchronisation therapy 
 
There have been a number of studies looking at cytokines following CRT and they have 
produced conflicting results.  In the dogs with induced LBBB, atrial tachy pacing was compared 
with CRT.  Both resulted in LVSD, but there was regional upregulation of tissue TNF-α, stress 
related kinases and markers of myocyte apoptosis in the late contracting lateral wall of the 
atrially paced dogs but not with biventricular pacing 
277
.  In humans D’Ascia et al studied 
endomyocardial biopsies of 10 patients before and 6 months following CRT.  They found that 
myocardial TNF-α, Collagen volume fraction and markers of apoptotic death were reduced 
following CRT 
118
.   
In a group of 8 patients Lappegard et al showed that serum IL-6, monocyte chemoattractant 
factor-1 (MCP-1) and Interleukin-8 (IL-8) were reduced 6 months following CRT.  However 
TNF-α, IL-1-and IL-1β were unchanged 278.  In a 140 patients with optimised medical treatment 
for HF there was a reduction of IL-6 and high resolution CRP concentrations in patients over a 
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median follow up of 9 months following CRT 
279
.  This observation was restricted to the group 
who survived free of hospitalisation for a cardiac event, in which there was significant reverse 
left ventricular remodelling.  In 28 patients with LVSD, serum TNF-α, IL-6 and markers of 
oxidative stress were measured 48 hours after switching to biventricular pacing from one week 
of RV apical pacing 
280
.  There was an improvement in haemodynamic indices measured by TTE 
and a decrease in inflammatory cytokines and oxidative stress with an increase in NO 
production.  These findings were apparent despite no change in CRP and apparent in even in the 
group whose cardiac output did not increase > 10%.  Theodorakis et al showed that in 20 patients 
following 3 months of CRT, IL-6 and the soluble product of the intracellular adhesion molecules 
(sICAM)-1were reduced 
281
.  In the subsequent 3 months with pacing off these molecules 
remained reduced compared to baseline and TNF-α and sTNFR1 and II were also reduced 
significantly compared to baseline suggesting that the immunomodulatory effects of CRT might 
persist for at least 3 months following CRT 
281
.  In a 158 patients who underwent CRT pre-
implant serum growth differentiation factor-15 (GDP-15), a member of the TGF-β family, was 
shown to independently predict hospital free survival and add prognostic value to clinical 
variables including BNP, LVEF, and NYHA class over a median follow up of 950 days 
282
.  
However in three further studies of between 32-120 patients; despite significant favourable LV 
remodelling and improvement in a number of clinical variables, a broad range of 
proinflammatory cytokines were unchanged 12 months following CRT 
283-285
.   Therefore the 
effect of CRT on cytokines networks is still unclear and whether there is a shift in the balance 
between TH1 and TH2 cytokines is unknown.  The effect of CRT on sST2 has not been 
investigated to date.   
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Aims 
 
 
1) To investigate the source of apelin production in humans with heart failure secondary to 
left ventricular systolic dysfunction compared to individuals without left ventricular 
impairment. 
 
2) To prospectively investigate favourable left ventricular remodelling in patients 
undergoing cardiac resynchronisation therapy using radionuclide ventriculography  
 
3) To investigate changes in plasma apelin in patients undergoing cardiac resynchronisation 
therapy and study the relationship between plasma apelin and left ventricular 
remodelling.  
 
4) To investigate changes in serum soluble ST2 (sST2) in patients undergoing cardiac 
resynchronisation therapy and study the relationship between serum sST2 and left 
ventricular remodelling. 
 
5) To investigate the changes in a range of cytokines following cardiac resynchronisation 
and investigate the relationship to left ventricular remodelling. 
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Chapter 2: Materials and methods 
 
Investigating the source of apelin production 
 
Primary Hypothesis 
 
Apelin production is primarily from the myocardium and this is altered in heart failure secondary 
to left ventricular systolic dysfunction 
Methods 
 
The measurement of intracardiac gradients of serum and plasma biomarkers is an established 
method for determining whether production is predominantly from cardiac or peripheral tissue 
286
.  We measured apelin concentrations in the coronary sinus (CS), aorta (Ao) and renal vein 
(RV) of patients with heart failure and systolic ventricular dysfunction (LVSD) undergoing 
elective right and left heart catheterization or elective biventricular pacemaker (BVP) insertion.  
A comparison was made with subjects without structural heart disease who were admitted for 
elective electrophysiological investigation.  B-type natriuretic peptide (BNP), which is known to 
be produced in the myocardium,
287
 was also measured from the same samples as an internal 
control.   This study complied with the Declaration of Helsinki.  Ethical approval was granted for 
this study by the local ethics committee and informed consent was obtained from all individuals 
participating in the study.   
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Study population 
 
Patients with chronic heart failure 
 
Twelve patients with proven heart failure and significant left ventricular systolic dysfunction 
attended for left & right catheterization and 9 patients for elective BVP insertion (2 upgrades of 
permanent right apical pacing systems).  The diagnosis of heart failure was made based on 
clinical symptoms and appropriate investigations (chest radiograph, CMR or transthoracic echo).  
Patients were receiving conventional treatment for heart failure which included angiotensin 
converting enzyme inhibitors (ACE-I) / angiotensin receptor antagonists (ARBs) (19), beta-
blockers (9), aldosterone antagonists (7) and loop diuretics (16).  The aetiology of heart failure 
was ischaemic heart disease (IHD) in 9 (43%) patients and idiopathic dilated cardiomyopathy 
(DCM) in 11 (52%).    
Subjects with paroxysmal supraventricular arrhythmias and normal left ventricular 
function (control group) 
 
Ten subjects were recruited.  Of these five had paroxysmal atrial fibrillation, one of whom had 
an AV nodal ablation with dual chamber pacemaker implantation. The other subjects had 
paroxysmal atrial tachycardias.  All individuals had normal left ventricular function as assessed 
by transthoracic echo (TTE).  One patient had a small patent foramen ovale with normal right 
heart size and pressures and one individual had previous angioplasty to his right coronary artery 
but was free of angina at the time of study with a normal exercise test.  Two individuals were in 
atrial fibrillation at the time of assessment.  One patient was in a narrow complex tachycardia at 
the time of sampling and therefore was excluded from any further analysis leaving 9 controls.   
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Blood sampling  
 
All patients were fasted for at least four hours and were supine at rest for at least 15 minutes.  
The CS and RV were intubated with standard catheters and satisfactory catheter position beyond 
the CS ostium, and RV were confirmed by fluoroscopy before blood was collected into chilled 
E.D.T.A tubes.  The samples were centrifuged immediately at 3000 r.p.m for 15 minutes and the 
supernatant plasma was stored in aliquots at -80
0
C until analysis.  It was not possible to 
cannulate the CS in one patient and there was insufficient sample for analysis from the CS for 
analysis in a further patient.  The RV sampling was possible in 9 HF patients who had left & 
right heart catheterization and 8 of the control subjects.  Renal vein sampling was not attempted 
in the patients undergoing biventricular pacing.   
Apelin assay 
 
Plasma apelin-12 was measured using a commercially available enzyme immunoassay without 
extraction (Phoenix Pharmaceuticals, Belmont, CA, USA) according to the manufactures 
instructions; inter-assay and intra-assay co-efficient of variation (CV) at 500 pg/ml was 12.5% 
and <5.0% respectively.  The antibody used in this assay is an immunoaffinity purified rabbit 
antibody specific for apelin 1-12 with a 100% cross-reactivity to apelin 1-12, 1-13 and 1-36 but 
no cross-reactivity to ADM-52, BNP-32, CNP-22, ANP (25-56), ghrelin, ET-1 or bradykinin.   
BNP assay 
 
Plasma BNP was measured on the Beckman Access 2 immunoassay analyser using Triage BNP 
Access reagents (Biosite Ltd, Belfast UK).  The apelin and BNP assays were performed by 
individuals blinded to the patients’ characteristics.   
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Statistical analysis 
 
Normally distributed values are displayed as means with standard errors.  Variables which were 
not normally distributed are displayed as a median with interquartile range.  Comparison of 
concentrations of apelin and BNP between CS, Ao and RV as well as between patients with heart 
failure and controls were carried out using Wilcoxon Signed Ranked test and Mann-Whitney U 
test respectively.  For repeated measures Friedman test was used.  A p-value of <0.05 was 
determined to be statistically significant.  For comparison of categorical variables 2 or Fisher’s 
exact test was used.  A univariate regression analysis was performed on log apelin concentrations 
in the CS, Ao and RV using clinical variables and p-value of < 0.1 was deemed to be significant.  
The data were analysed with MS SPSS 13.0 (Microsoft Office 2000, Redmond WA, USA).  
Investigating Apelin, Cytokines and sST2 in patients undergoing 
Cardiac resynchronisation therapy 
 
Primary hypothesis 
 
Patients who undergo cardiac resynchronisation therapy undergo favourable left ventricular 
remodelling  
Secondary hypotheses 
 
In patients who undergo favourable remodelling we would expect the following: 
 
1) A reduction plasma BNP concentration 
 
2) An increase in plasma apelin concentration 
 
3) A reduction in sST2 concentration 
 
4) A reduction in Proinflammatory cytokines and an increase in anti-inflammatory cytokines 
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Multidisciplinary heart failure pacing clinic 
 
In order to optimize the selection of patients for device therapy a multidisciplinary clinic was set 
up to select, optimize and follow up patients who underwent CRT.  This allowed the integration 
of the heart failure service and the pacing service so that assessment and investigations could be 
undertaken as a one stop service.  The patients for this research study were selected and followed 
up in this clinic.  All patients underwent a comprehensive clinical assessment by a cardiologist 
specializing in HF and baseline investigations included: 12 lead ECG, echocardiography, full 
blood count, renal profile, urate, thyroid function, liver function, haematinics, BNP, 6 minute 
walk test and quality of life questionnaires.  Patients were then followed up at one month 
following implantation for echo guided optimization of device settings and subsequently at 6 
months and 12 months (table 4).  At baseline, 6 months and 12 months blood samples were taken 
for storage of serum and plasma.  This study complied with the Declaration of Helsinki.  Ethical 
approval was granted for this study by the local ethics committee and informed consent was 
obtained from all individuals participating in the study.   
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Table 4: Project protocol 
 
Time point Investigations 
Baseline Blood tests, ECG, 6MWT, QoL, TTE, RNV 
Plasma and serum for storage 
Implant  
1 month Device optimization 
Blood tests, ECG, TTE, 
6 months Blood tests, ECG, 6MWT, QoL, TTE, RNV 
Plasma and serum for storage 
12 months Blood tests, ECG, 6MWT, QoL, TTE, RNV 
Plasma and serum for storage 
6MWT =6 minute walk test, QoL=Quality of life questionnaires, TTE=Transthoracic echocardiogram, 
RNV=Radionuclide ventriculography. 
. 
Patient selection 
 
The inclusion criteria for the study were based on the CARE-HF study and are detailed below: 
Inclusion criteria 
 
1. Age >18 years of either sex 
2. The patient is willing and capable of complying with the requirements of this protocol 
3. The patient has provided written informed consent 
4. The patient has been selected by his routine care physician to receive a biventricular 
pacing device 
5. The patient has clinical evidence of chronic heart failure: 
 67 
 
a) Reduced ejection fraction (<=35% by radionuclide ventriculography) 
b) Stable clinical condition and medication for at least 1 month prior to the study 
(New York Heart Association class III-IV). 
c) QRS width >150ms or between 120ms and 149ms with evidence of dyssynchrony 
on TTE 
d) The patient is receiving appropriate conventional medical therapy for heart failure 
(ACE inhibitor or angiotensin II blocker, diuretics, beta-blocker as indicated and 
tolerated). 
Exclusion criteria 
 
1. Uncorrected congenital heart disease 
2. Any life threatening disease, other than heart failure 
3. Active malignancy of any type, or history of a malignancy within previous 5 years. 
Patients with a history of other malignancies that have been surgically removed and who 
have no evidence of recurrence for at least five years prior to study enrolment are 
acceptable. 
4. Previous heart transplant 
5. Severe neuro-muscular disease 
6. History of unstable angina, myocardial infarction or stroke within 3 months prior to the 
study 
7. Pregnancy 
8. Treatment with immunosuppressive therapy e.g. steroids for rheumatoid arthritis or 
obstructive lung disease 
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9. Significant renal dysfunction (serum creatinine >250mmol/l), severe liver disease (liver 
function tests > 3 times normal) 
10. Unable to understand and comply with protocol or to give informed consent 
11. Clinical diagnosis of depression requiring medical treatment 
 
Suitable patients were selected using TTE and then they underwent a further assessment of left 
ventricular function by radionuclide ventriculography (RNV) prior to device implantation.  
Blood sampling 
 
All patients were fasted for greater than four hours and were supine at rest for greater than 15 
minutes.  Twenty millilitres of blood was collected into chilled E.D.T.A tubes and serum 
separator tubes.  The samples were centrifuged immediately at 3000 r.p.m for 15 minutes and the 
supernatant plasma and serum was stored in aliquots at -80
0
C until analysis.   
Apelin and BNP assays 
 
The apelin and BNP assays were performed by individuals blinded to the patients’ characteristics 
and RNV results and the methods are as described previously 
Cytokine assays 
 
The panel of cytokines was measured using a commercially available enzyme linked 
Multiplex
TM
 MAP panel immunoassay (Millipore Corporation, Billercia, M.A, U.S.A) and read 
using a Luminex 100 reader (Luminex Corp, Austin, Texas, U.S.A).  This assay is a validated 
research tool, used to measure any combination of 42 human cytokines simultaneously.  The 
intra assay and inter assay coefficients of variation are typically <7.2% and <10.7 % 
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respectively.  We chose to look at IFN-γ, IL-1b, IL-1ra, IL-6, TNF-α, TNFR1, TNFR2, IL-4 and 
IL-10.  The individual coefficients of variation and normal values are quoted in the appendix 2.   
The measurement of the serum cytokines was performed by individuals blinded to the clinical 
characteristics of the patients and the RNV results.   
C-reactive protein (CRP) 
 
High resolution CRP was measured using a Beckman Coulter assay and Beckman DxC600 
analyser (Beckman Coulter Inc., Brea, CA, U.S.A).  This is a turbidimetric assay, where goat and 
mouse anti-CRP antibody is used to bind CRP in the human serum resulting in the formation of 
insoluble aggregates which increase the turbidity of the sample.  The change in absorbance at a 
600 nanometres is proportional to the concentration of CRP.  The range of detection was 1mg/L-
250mg/l and the intra and inter assay CVs were 5% and 7.5% respectively 
Soluble ST2 assay 
 
Soluble sST2 was measured using a commercially available enzyme linked immunosorbent 
assay (ELISA).  The Critical Diagnostics Presage™ ST2 Assay (Critical Diagnostics, 3030 
Bunker Hill, Suite 115A, San Diego, USA) is a quantitative sandwich monoclonal ELISA in a 96 
well plate format for measurement of ST2 in serum or plasma.  Diluted plasma was used 
according to the manufacturer’s instructions.  Precision evaluation of the assay was performed 
according to the Clinical and Laboratory Standards Institute (CLSI) guideline EP5-A.  Four 
pooled patient plasma samples were aliquoted into twenty 1.5 mL plastic tubes for each 
concentration level and frozen at -80°C.  These samples were analysed in duplicate in one run 
per day for 20 days.  Intra-assay and inter-assay CV was calculated with the CLSI single-run 
precision evaluation test. The assay had a within-run CV of 6.5% and a total CV of 9.1% at a 
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mean concentration of 16.9 ng/mL (low), a within-run CV of 3.4% and a total CV of 5.5% at a 
mean concentration of 33.1 ng/mL (medium-1), a within-run CV of 3.8% and a total CV of 6.3% 
at a mean concentration of 68.7ng/mL (medium-2) and ), a within-run CV of 2.4% and a total 
CV of 4.8% at a mean concentration of 159.1 ng/mL (high).  The normal ranges across the 
general population in U.S.A have been documented recently and the 95th percentile reference 
interval in normal, healthy males is 8.5-49.3 ng/mL (median 23.6 ng/mL), in females is 7.1-33.5 
ng/mL (median 16.2 ng/mL) and in the entire group is 1.75-34.3 (median 18.8 ng/mL) 
288
.  The 
measurement of sST2 was undertaken by individuals blinded to the patient characteristic and 
clinical data.   
 
Radionuclide ventriculography (RNV) 
 
Left ventricular function was evaluated by RNV performed by operators blinded to the clinical 
characteristics of the patients.  Planar acquisition was performed with best septal separation view 
(32 frames, 20% window for R-R interval).   SPECT was performed from right anterior oblique 
(RAO) 45
0 
to left posterior oblique (LPO) 45
0 
(16 frames, 20% window).  The planar data was 
processed with Hermes (FUGA) and SPECT was processed with Cedars Sinai QBS software.  
Favourable reverse left ventricular remodelling was pre-specified as an increase of > 5 
percentage points in LVEF from baseline.  Inter user variability was assessed using two 
operators who were fully trained in the techniques and reported the scans independently of each 
other.  Intra observer variability was assessed by one of the operators who re-reported the scans 
at a later time without access to their previous measurements (Figure 10).  The coefficients of 
variability for inter and intra observer measurements of planar RNV LVEF were 6.8% and 5.2 % 
 71 
 
respectively.  The coefficients of variability for inter and intra observer measurements of planar 
RNV RVEF were 15.7% and 7.8 % respectively.   
 
Figure 10: Bland-Altman plots for radionuclide ventriculography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Bland-Altman plots.  Panels A and B show inter and intra observer variability for planar 
radionuclide ventriculography (RNV) measurements of left ventricular ejection fraction (LVEF) while panels 
C and D are for the measurement of right ventricular ejection fraction (RVEF).  The middle line represents 
the mean difference and the outer lines the 95% confidence intervals.   
 
 
 
 
 
A B 
C D 
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Transthoracic Echocardiography (TTE) 
 
Transthoracic echocardiography was performed using a Phillips Sonos 5500 echocardiograph 
and a multifrequency transducer (Andover, MA, USA).  Standard two-dimensional parasternal 
long and short-axis views and apical four-, five-, and two-chamber views were performed.  
Cross-sectional two-dimensional guided M-mode recordings of the LV minor axis were 
obtained.  Left ventricular ejection fraction (LVEF) and end systolic volume (ESV) were 
calculated by Simpson’s method.  Mitral regurgitation (MR) was recorded using colour-flow 
Doppler Mitral regurgitation (MR) was recorded using colour-flow Doppler and continuous-
wave Doppler in the apical four- and two-chamber views, and its duration, expressed as 
percentage of the RR interval, was calculated.  
 
Subaortic flow velocity was obtained by pulsed-wave Doppler from the apical five-chamber 
view, with the sample volume placed in the LV outflow tract (LVOT), 1 cm below the aortic 
cusps. Stroke distance was calculated as the time integral of aortic velocity, stroke volume as the 
product of stroke distance and subaortic area, and cardiac output as stroke volume multiplied by 
heart rate.  
 
Transmitral flow velocities were recorded from the apical four chamber view using pulsed-wave 
Doppler.  Peak E (early diastolic) was obtained in all patients and A (atrial) velocities were 
obtained in all patients who were in sinus rhythm.   
 
Aortic pre-ejection time (APET) and pulmonary pre-ejection time (PPET) were measured from 
the onset of the QRS complex to the onsets of aortic and pulmonary flow, respectively.  With 
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CRT, the pacing artefact was taken as the onset of ventricular activation.  The inter -ventricular 
delay (IVD) was calculated as APET minus PPET. 
Echo optimisation of pacemaker settings 
 
At one month following implant all patients underwent TTE guided optimisation according to 
the following protocol (appendix 2).  The heart rate was set at 70 bpm and transmitral pulse wave 
Doppler was at the mitral valve tips was obtained at a series of AV delays.  The AV delay with 
the maximal E/A separation was selected.  Subsequently the VV delay was altered in 20 ms 
increments.  The velocity time integral (VTI) from the LVOT (5 chamber view) 1 cm below the 
aortic valve leaflets was measured as a surrogate of cardiac output.  The setting with the maximal 
VTI was selected.  Indices of dyssynchrony and MR were measured as detailed previously at 
baseline and after optimisation.   
Six minute walk testing (6MWT) 
 
Patients were asked to walk between two markers which were 10 meters apart along a level 
corridor in the cardiology department of our institution.  They were asked to walk at the pace 
they felt comfortable for 6 minutes.  During the test they were not encouraged and allowed to 
rest if they felt so inclined.  Their heart rate blood pressure and oxygen saturation by pulse 
oximetry was measured before and after the test.  The total distance covered in 6 minutes was 
recorded.   
Quality of life questionnaires 
 
Quality of life was assessed by the Minnesota Living with Heart failure questionnaire (MLWHF) 
(University of Minnesota, Minneapolis, U.S.A) which has been validated as a tool to measure 
quality of life in heart failure patients.  The patients were asked to fill in the questionnaire 
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independently without help.  The test comprises a set of 21 questions about how HF impacts on 
daily activities and patients are asked to mark a numeric score between 0-5 for each question.  
The scores were tallied to obtain a total out of 105, with the higher scores indicating a poorer 
quality of life attributable to HF.   
Implantation of biventricular pacemakers 
 
All implants were left sided.  Endocardial right atrial and RV leads were implanted using 
standard techniques and access was using left subclavian vein.  Those patients that fulfilled the 
criteria for ICD received a dual coil defibrillator lead delivered to the RV apex.  The coronary 
sinus (CS) was intubated using standard catheters.  A balloon occlusion venogram was 
performed to delineate coronary sinus anatomy before delivering an LV lead to a suitable target 
vein.  The position of the lead and choice manufacture for the device used was left to the 
operator’s discretion and not pre-specified in the protocol.  The device was programmed to a 
nominal AV delay of 120 ms with simultaneous ventricular pacing until device optimisation at 
one month.   
Statistical analysis and power calculation 
 
Primary Endpoint 
 
The primary outcome of the study was to be an increase in RNV LVEF of 5 percentage points. 
 
Calculating the expected sample size was performed with the help of a statistician using data 
from previous cohort studies of HF patients undergoing CRT.  Using SPECT data the baseline 
EF was calculated as 23.1 % with a standard deviation of 8 % 
289
.  Therefore to detect a 
statistically significant increase of 5 % in EF (p value of 0.05) with a statistical power of 0.9 the 
calculated sample size is 23.  Using the baseline characteristics of the MUSTIC and MIRACLE 
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trials the baseline EF was 24.4 % and 25 % respectively with standard deviations of 6.6% and 
7% respectively using TTE.  Therefore to detect a statistically significant increase of 5 % in 
LVEF (p value of 0.05) with a statistical power of 0.9 the calculated sample size is between 16 
and 18. 
Adjustment of sample size for calculation for neurohormones and cytokines 
 
The group was dichotomised into responders and non-responders.  As the concentrations of 
neurohormones were not normally distributed median apelin concentrations at the end of study 
was compared in the two groups by a Mann Whitney U test or log transformed data and 
compared using student t tests.  The same univariate statistical methods were used to compare 
the response to CRT with the other neurohormones, cytokines and clinical parameters which are 
not normally distributed.  Normally distributed variables and their effect on predicting response 
will be evaluated by a Student's t-test.  The baseline concentrations of the neurohormones were 
examined as to their accuracy at predicting a positive response to CRT.  This was by receiver 
operator curve (ROC) analysis.  The clinical variables measured: arterial blood pressure at 
implant, dyssynchrony by TTE, age, co−morbidities, baseline concentrations of neurohormones 
and cytokines were entered into a multivariate logistical regression analysis to determine the 
independent predictors of a favourable response to CRT. 
It was estimated that 10% of eligible patients may fail to have a successful LV lead and in order 
to adjust for this fact and to enable analysis of secondary endpoints with sufficient power, we 
planned to recruit a sample of 100 patients.   
 
 76 
 
The analysis of changes in clinical parameters 6 months and 12 months was performed using 
ANOVA analysis of variance for normally distributed variables, with Bonferroni corrections.  
For variables which are not normally distributed Friedman test was used.   
Patient recruitment 
 
Twenty four patients were recruited for the study.  The baseline characteristics of the group are 
detailed in table 5.  Two patients were excluded; one patient declined CRT prior to admission 
and another patient had a new diagnosis of renal cell carcinoma discovered in the course of his 
preliminary investigations.  Twenty two patients had attempted insertion of a CRT device.  In 
three patients it was not possible site an LV lead, either due to unsuitable suitable coronary sinus 
anatomy or inadequate pacing parameters.  In two of these patients the operators elected to place 
an extra lead in the RV outflow tract, to maximise separation to the existing RV apical lead and 
allow for multisite pacing.  The other patient had an existing RV lead placed in the mid septum, 
and further attempts at coronary sinus pacing were abandoned.  This resulted in 21 patients with 
multisite pacing who included in the cohort.  One patient died between 6 months and 12 months 
and so 20 patients were available for 12 month follow up (Figure 11). 
 
 
Demographics  
 
N=23
* 
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Table 5: Demographics of the patients recruited from the heart failure-pacing clinic 
 
Age (years) median, (interquartile range) 
 
74 (56-79) 
Male, n (%) 21 (88%) 
 
BMI mean, (SE) 28 (1.3) 
 
Heart rate (bpm) mean, (SE) 70 (2.5) 
 
Systolic BP (mmHg) mean, (SE) 117 (5.2) 
 
Diastolic BP (mmHg) mean, (SE) 68 (3.0) 
 
Mean BP (mmHg) mean, (SE) 88 (3.5) 
 
Diabetes, n (%) 4 (17%) 
 
Atrial Fibrillation, n (%) 8 (33%) 
 
Chronic right ventricular pacing, n (%) 11 (46%) 
 
QRS width (ms), mean (SE) 182 (4.3) 
 
6 minute walk distance (m), mean (SE) 
 
245 (69) 
MLWHF score, mean (SE) 
 
48 (15) 
Aetiology of heart failure n, (%)  
 
Ischaemic heart disease 10 (42%) 
 
Dilated cardiomyopathy  11 (46%) 
 
Valvular heart disease 3 (12%) 
 
Non-ischaemic dilated cardiomyopathy (NIDCM)  14 (58%) 
 
Ventricular function calculated by radionuclide ventriculography  
 
Left ventricular ejection fraction (%), mean (SE) 23 (1.7) 
 
Right ventricular ejection fraction (%), mean (SE) 33 (3.5) 
 
Left ventricular end diastolic volume (ml), mean (SE) 279 (27) 
 
Left ventricular end systolic volume (ml), mean (SE) 208 (24) 
 
Standard deviation left ventricular phase (
0
), mean (SE) 
 
82 (5.2) 
Aortic pre-ejection time (ms), mean (SE) (TTE) 171 (7.0) 
 
Intra-ventricular mechanical delay (ms), mean (SE) (TTE) 53 (6.1) 
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SE=standard error, MLWHF=Minnesota living with heart failure, *the results of the patient who 
declined CRT are not available 
Medications  
 
ACE-I / ARB n, (%) 23 (100%) 
 
Beta-blockers n, (%) 17 (74%) 
 
Aldosterone antagonists n, (%) 17 (71%) 
 
Loop diuretics n, (%) 17 (71%) 
 
Digoxin n, (%) 6 (25%) 
 
Laboratory investigations  
 
Haemoglobin (g/dl) mean (SE) 13.4 (0.4) 
 
Sodium (mmol/l) mean (SE) 137(0.7) 
 
Potassium (mmol/l) mean, (SE) 4.3 (0.1) 
 
Urea (mmol/l) mean (SE) 10.1 (0.8) 
 
Creatinine (umol/l) mean, (SE) 127(6.0) 
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Figure 11: Flow diagram of patients in the study. 
 
 
 
CRT=Cardiac resynchronisation therapy, LV=Left ventricular, RVOT=Right ventricular outflow tract,  
24 patients 
recruited 
1 declined CRT 
1 diagnosed with 
renal ca 
22 patients for 
implantation 
1 failed LV lead 19 LV leads 
10 CRT-D, 11 CRT-
P, Upgrades of RV 
pacing 
21 patients with 
successful 
CRT/Multisite 
pacing  
21 patients 
available for 6 
month follow up 
20 patients 
available for 
12month follow up 
1 death 
2 RVOT leads 
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Chapter 3: Myocardial Apelin Production is Reduced in 
Humans with Left Ventricular Systolic Dysfunction 
 
Abstract 
 
Aims: Apelin is a novel endogenous peptide with inotropic and vasodilatory properties that is the 
ligand for the APJ receptor.  Apelin and APJ are widely distributed in the vasculature of a 
number of organs and peripheral venous apelin is reduced in heart failure (HF).  The location of 
apelin production in humans with and without HF was investigated. 
Methods:  Plasma apelin and B-type natriuretic peptide (BNP) concentrations in coronary sinus 
(CS), aorta (Ao) and renal vein (RV) of individuals with HF (n=9) were compared to subjects 
with normal structural hearts (n=8).   
Results: In HF the concentration of CS apelin was reduced compared to controls (310 pg/ml 
(interquartile range 290-390) vs. 470pg/ml (340-570), p<0.04) but Ao apelin (330 pg/ml (275-
375) vs. 340 pg/ml (230-455), p=0.76) and RV apelin (290 pg/ml (280-360) vs. 370 pg/ml (273-
410, p=0.60) were unchanged.  Plasma BNP was increased at all sampling sites in patients with 
HF as compared to controls. A step down from CS to Ao to RV in all subjects was observed.  
The step down in apelin from CS to Ao (470 pg/ml (310-595) vs. 320 pg/ml (225-482), p<0.04) 
in control subjects was not apparent in patients with HF.   
Conclusions: These novel data show that apelin is produced in the human heart and that 
production is reduced in individuals with HF.  In contrast to BNP, apelin production is not 
exclusive to the heart. 
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Introduction 
 
Apelin is a novel peptide which has recently been established as the only known ligand for the 
APJ receptor.
133, 134
  Apelin is a powerful inotrope,
158
 vasodilator 
135
 and may help regulate 
central fluid homeostasis 
141
.  The APJ receptor shares a similar homology to the angiotensin II 
type 1 receptor (AT1) and acts through a G-Protein pathway 
133
.   Both apelin and APJ are 
widely distributed in the endothelium of a number of organs including the heart 
136, 137
.  Apelin 
causes peripheral vasodilatation by an endothelial nitric oxide (NO) dependent pathway 
143, 290
.  
The effects mediated by apelin appear to be opposite to those seen with angiotensin II interacting 
with AT1.  Data from animal models suggests that the apelin-APJ axis may modulate the 
detrimental effects of angiotensin II-AT1 interaction 
176, 177
. 
 
Therefore there is much interest in the role of apelin in the pathogenesis of heart failure.  In 
humans with heart failure peripheral plasma apelin is reduced compared to patients without 
structural heart disease 
183
.  Patients with advanced heart failure who exhibit favourable left 
ventricular remodelling following left ventricular assist device insertion demonstrate an 
associated increase in myocardial apelin mRNA 
184
.  The wide distribution of apelin throughout 
the body suggests that it has both autocrine and paracrine actions. It is unclear whether apelin is 
produced primarily in the heart and what is the influence of ventricular dysfunction.  The aim of 
this study was to determine whether apelin is produced in the heart in humans and whether this is 
different in individuals with heart failure compared to those without structural heart disease.   
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Methods: 
 
We measured apelin concentrations in the coronary sinus (CS), aorta (Ao) and renal vein (RV) of 
patients with heart failure and systolic ventricular dysfunction (LVSD) undergoing elective right 
and left heart catheterization or elective biventricular pacemaker (BVP) insertion.  A comparison 
was made with subjects without structural heart disease who were admitted for elective 
electrophysiological investigation.  B-type natriuretic peptide (BNP), which is known to be 
produced in the myocardium,
287
 was also measured from the same samples as an internal control.   
This study complies with the Declaration of Helsinki.  Ethical approval was granted for this 
study by the local ethics committee and informed consent was obtained from all individuals 
participating in the study.   
Study population 
 
Patients with chronic heart failure 
 
Twelve patients with proven heart failure and significant left ventricular systolic dysfunction 
attended for left & right catheterization and 9 patients for elective BVP insertion (2 upgrades of 
permanent right apical pacing systems).  The diagnosis of heart failure was made based on 
clinical symptoms and appropriate investigations (chest radiograph, CMR or TTE).  Patients 
were receiving conventional treatment for heart failure which included angiotensin converting 
enzyme inhibitors (ACE-I) / angiotensin receptor antagonists (ARBs) (19), beta-blockers (9), 
aldosterone antagonists (7) and loop diuretics (16).  The aetiology of heart failure was ischemic 
heart disease (IHD) in 9 (43%) patients and idiopathic dilated cardiomyopathy (DCM) in 11 
(52%).    
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Subjects with paroxysmal supraventricular arrhythmias and normal left ventricular 
function (control group) 
 
Ten subjects were recruited.  Of these five had paroxysmal atrial fibrillation, one of whom had 
an AV nodal ablation with dual chamber pacemaker implantation.  The other subjects had 
paroxysmal atrial tachycardias.  All individuals had normal left ventricular function as assessed 
by transthoracic echo (TTE).  One patient had a small patent foramen ovale with normal right 
heart size and pressures and one individual had previous angioplasty to his right coronary artery 
but was free of angina at the time of study with a normal exercise test.  Two individuals were in 
atrial fibrillation at the time of assessment.  One patient was in a narrow complex tachycardia at 
the time of sampling and therefore was excluded from any further analysis leaving 9 controls.   
 
The baseline demographics of the study population are detailed in table 6.  Both groups were 
predominantly male.  The control group was younger and the individuals were receiving 
significantly fewer vasoactive medications and diuretics.  The plasma haemoglobin and serum 
sodium concentrations were lower in the patients with heart failure as compared with the control 
group.  Whilst no subject exhibited significant renal dysfunction, urea was significantly higher in 
those subjects with heart failure and a trend towards a higher creatinine was seen.  Three patients 
in the heart failure group were in atrial fibrillation.     
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Table 6: Baseline demographics of patients with heart failure and controls 
 Heart failure (n=21) 
 
Controls (n=9) P-value 
Age (years) mean, (SE) 
 
63 (1.8) 52 (3.3) <0.006 
Male, n (%) 20 (95%) 
 
9 (100%) ns 
BMI median, (IQR) 24.9 (22.2-30.3) 
 
26.2 (23.7-28.0) ns 
Heart rate (bpm) median, (IQR) 80 (68-86) 
 
65 (55-75) ns 
Systolic BP (mmHg) median (IQR) 119 (95-132) 
 
108 (101-120) ns 
Diastolic BP (mmHg) median, (IQR) 67 (60-74) 
 
67 (53-77.) ns 
Mean BP (mmHg) median, (IQR) 84 (72-91) 
 
83 (70-87) ns 
Etiology of heart failure n, (%)  
 
  
Ischaemic heart disease 9 (43%) 
 
  
Dilated cardiomyopathy 11 (52%) 
 
  
Valvular 1 (5%) 
 
  
Symptomatic class of heart failure  
 
  
NYHA class 1-2 10 (48%) 
 
  
NYHA class 2-4 11 (52%) 
 
  
Medications  
 
  
ACE-I / ARB n, (%) 19 (91%) 
 
0 <0.001 
Beta-blockers n, (%) 9 (43%) 
 
1 (10%) ns 
Aldosterone antagonists n, (%) 7 (33%) 
 
0 0.07 
Loop diuretics n, (%) 16 (76%) 
 
0 <0.001 
Digoxin n, (%) 3 (14%) 
 
0 ns 
Laboratory investigations  
 
  
Hemoglobin (g/dl) mean (SE) 13.1 (0.31) 
 
15.3 (0.27) <0.001 
Sodium (mmol/l) mean (SE) 136(0.80) 
 
139 (0.66) <0.04 
Potassium (mmol/l) mean, (SE) 4.3 (0.11) 
 
4.4 (0.12) ns 
Urea (mmol/l) median (IQR) 6.85 (5.83-10.70) 
 
5.10 (4.85-5.25) <0.004 
Creatinine (umol/l) median (IQR) 103 (87-126) 
 
91 (81-95) ns 
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Legend for Table 6:The patients with heart failure had documented left systolic ventricular dysfunction and 
the control group had normal structural hearts.  SE = standard error.  IQR= interquartile range.  
NHYA=New York heart association BMI=body mass index.  BPM=beats per minute.  ACE-I=Angiotensin 
converting enzyme-II inhibitor.  ARB=Angiotensin-II receptor blocker.  
Blood sampling  
 
All patients were fasted for at least four hours and were supine at rest for at least 15 minutes.  
The CS and RV were intubated with standard catheters and satisfactory catheter position beyond 
the CS ostium, and RV were confirmed by fluoroscopy before blood was collected into chilled 
E.D.T.A tubes.  The samples were centrifuged immediately at 3000 r.p.m for 15 minutes and the 
supernatant plasma was stored in aliquots at -80
0
C until analysis.  It was not possible to 
cannulate the CS in one patient and there was insufficient sample for analysis from the CS for 
analysis in a further patient.  The RV sampling was possible in 9 HF patients who had left & 
right heart catheterization and 8 of the control subjects.  Renal vein sampling was not attempted 
in the patients undergoing biventricular pacing.   
Apelin and BNP assays 
 
Plasma apelin-12 was measured using a commercially available enzyme immunoassay without 
extraction (Phoenix Pharmaceuticals, Belmont, CA, USA) according to the manufactures 
instructions; inter-assay and intra-assay co-efficient of variation at 500 pg/ml was 12.5% and 
<5.0% respectively.  The antibody used in this assay is an immunoaffinity purified rabbit 
antibody specific for apelin 1-12 with a 100% cross-reactivity to apelin 1-12, 1-13 and 1-36 but 
no cross-reactivity to ADM-52, BNP-32, CNP-22, ANP (25-56), ghrelin, ET-1 or bradykinin.  
Plasma BNP was measured on the Beckman Access 2 immunoassay analyser using Triage BNP 
Access reagents (Biosite Ltd, Belfast UK).  The apelin and BNP assays were performed by 
individuals blinded to the patients’ characteristics.   
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Statistical analysis 
 
Normally distributed values are displayed as means with standard errors.  Variables which were 
not normally distributed are displayed as a median with interquartile range.  Comparison of 
concentrations of apelin and BNP between CS, Ao and RV as well as between patients with heart 
failure and controls were carried out using Wilcoxon Signed Ranked test and Mann-Whitney U 
test respectively.  For repeated measures Friedman test was used.  A p-value of <0.05 was 
determined to be statistically significant.  For comparison of categorical variables 2 or Fisher’s 
exact test was used.  A univariate regression analysis was performed on log apelin concentrations 
in the CS, Ao and RV using clinical variables and p-value of < 0.1 was deemed to be significant.  
The data were analysed with MS SPSS 13.0 (Microsoft Office 2000, Redmond WA, USA).  
Results 
 
In total there were 28 paired samples for CS and Ao, 18 paired samples for CS and RV and 20 
paired samples for Ao and RV.  In one patient there was insufficient CS plasma remaining from 
the aliquot to measure BNP as well as apelin.  In the 17 subjects with paired samples from CS, 
Ao and RV; BNP concentrations were reduced significantly between CS, Ao and RV (413 pg/ml 
(105-644) vs 173 pg/ml (55-388) vs 107 (35-325), p<0.0003). 
 
In the patients with heart failure the BNP concentration was significantly increased compared to 
controls in the CS, Ao and RV.  In patients with heart failure CS apelin was significantly reduced 
compared to controls. In contrast no difference was seen between the subject groups (i.e. heart 
failure and controls) in apelin concentrations in either the Ao and RV (Table 7).  
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Table 7: Apelin and BNP concentrations in individuals with heart failure compared with controls 
 
  
 
Heart Failure 
 
 
 
Control 
 
 
P-value 
N Median (IQR) 
 
N Median (IQR) 
 
 
Apelin 
(pg/ml) 
Coronary sinus 19 310 (290-390) 
 
9 470 (340-570) <0.035 
Aorta 21 330 (275-375) 
 
9 340 (230-455) 0.874 
Renal vein 11 290 (280-360) 
 
8 370 (273-410) 0.604 
 
 
BNP 
(pg/ml) 
Coronary sinus 19 581 (377-903) 
 
9 66 (38-116) <0.0001 
Aorta 21 324 (137-561) 
 
9 52 (19-81) <0.0001 
Renal vein 11 273 (128-519) 
 
8 35 (18-62) <0.0001 
 
IQR =interquartile range, BNP=B type natriuretic peptide 
 
Paired samples were available for CS, Ao and RV in 9 patients with heart failure and 8 control 
subjects.  As expected there was a significant step down of BNP between CS, Ao and RV in both 
heart failure (585 pg/ml (379-777) vs 412 pg/ml (123-766) vs 325 pg/ml (140-654) p<0.04) and 
controls (76 pg/ml (41-120) vs 54 pg/ml (19-94) vs 35 pg/ml (18-63), p< 0.006) (Figure 12).  
When considering apelin no significant trend was seen across the sites in patients with heart 
failure.  Control subjects did show a significant reduction in apelin concentration between CS 
and Ao (470 pg/ml (310-595) vs. 320 pg/ml (225-482), p<0.04) which was not seen in patients 
with heart failure (300 pg/ml (265-380) vs. 310 pg/ml (265-350), p=0.483) (Figure 13).  This 
difference was still significant when changes between CS Ao and RV were compared using all 
samples available.  This data is shown contrasted to expected changes in BNP in Figures 14 and 
15.  In the controls the median decrease in apelin concentration between CS and Aorta was 60 
pg/ml (25-175) or a mean decrease of 21% (8.1%).  This compares to a median decrease in BNP 
of 35 pg/ml (2.5-213) from CS to Ao in controls and 212 pg/ml (77-435) in HF; mean decreases 
 88 
 
Figure 12: Concentration gradients for B-Type natriuretic peptide in heart failure vs controls 
 
 
 
A significant step down in BNP from coronary sinus to aorta to renal vein in the heart failure and control 
groups.   
Figure 13: Concentration gradients for Apelin in heart failure vs controls 
 
 
 
A different pattern of secretion is seen for apelin compared to BNP.  Apelin is not exclusively produced in the 
heart; however a significant step down in apelin from coronary sinus to aorta is seen in the control group, 
which is diminished or absent in patients with heart failure.   
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Figure 14: Apelin concentrations in individuals with heart failure and normal controls 
 
 
 
 
 
The panels above show the plasma apelin concentrations from coronary sinus, aorta and renal vein in patients with heart failure (top row) and normal 
controls (bottom row).  There is a clear step down in apelin concentrations between coronary sinus and aorta in normal controls which is not present in 
patients with heart failure.  There is appears to be a decrease between coronary sinus and renal vein in both sets of patients which is not statistically 
significant. 
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Figure 15: B-type natriuretic peptide in individuals with heart failure and normal controls 
 
 
 
The panels above show the plasma BNP concentrations from coronary sinus, aorta and renal vein in patients with heart failure (top row) and normal 
controls (bottom row).  There is a clear step down in BNP concentrations between coronary sinus and aorta and between aorta to renal vein in patients 
with heart failure and controls.   
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of 33% (9.3%) and 36% (7.4) respectively.  No difference in the concentration gradient for 
apelin between Ao and RV in both HF and control subjects was seen.  In controls and in HF 
there was a trend to a reduction in apelin concentration between CS and RV,(p<0.12 Controls 
and p<0.16 HF).   
 
With logistic regression analysis there was no significant correlation of apelin with age, heart 
rate, body mass index or systolic blood pressure.  A weak negative correlation between CS 
apelin and CS BNP was observed ( -0.315, P=0.097). 
Discussion 
 
For the first time to our knowledge this study has demonstrated that apelin is produced in the 
human heart.  Patients with systolic left ventricular dysfunction exhibit a reduction in myocardial 
apelin production as compared with subjects with normal cardiac structure.  In comparison to the 
internal control BNP, which is known to be secreted by ventricular myocardium and is increased 
in patients with HF, the pattern of secretion of apelin suggests that it is not exclusively produced 
in the heart.  There was no significant difference between CS and RV apelin or RV and Ao 
apelin and this suggests that apelin may also be produced in the kidneys and possibly other 
organs as well.  There was a weak negative correlation between apelin and BNP only in CS 
apelin which compares to previous work that showed similar results using NT-pro BNP in 
peripheral venous blood with a larger population of patients with lone AF but no structural heart 
disease 
196
. 
 
The wide distribution of apelin and APJ throughout the body and its predominant localization in 
vascular mirrors the distribution of angiotensin II-AT1 
145
.  The physiological effects of apelin 
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are opposite to the actions of angiotensin-II.  Therefore apelin acting through the APJ receptor 
may modulate the detrimental effects of the AT1 activation and help to prevent progressive 
LVSD and the onset of heart failure.  It has been hypothesized that apelin secretion slows down 
the process of adverse LV remodelling by maintaining cardiac output and reducing afterload 
162
.  
It may even prevent excessive fluid retention by its actions on central vasopressin release.  
Evidence from animal models of heart failure provides support to this working hypothesis.  
Apelin mRNA is reduced in rat myocytes subjected to mechanical stretch and chronic pressure 
overload 
159
.  In compensated ventricular hypertrophy myocardial apelin and APJ mRNA is 
initially preserved and only down regulated when Dahl salt sensitive rats undergo transition to 
ventricular failure 
176
.  Apelin knockout mice develop left ventricular contractile dysfunction 
with age and pressure overload 
171
. 
 
In humans peripheral venous plasma apelin concentrations are reduced in patients with heart 
failure 
183
.  In patients who have exhibited favourable LV remodelling following left ventricular 
assist device implantation, an increase in ventricular APJ and apelin mRNA and peripheral 
plasma apelin as compared with baseline 
184
.  Following cardiac resynchronisation therapy in a 
small group of patients (n=14), 90% of who had positive LV remodelling on transthoracic echo, 
plasma apelin was increased after a mean follow up of 9 months 
186
.  However plasma apelin was 
also increased in the 1 patient who did not remodel favourably.   
 
To date the primary site of apelin secretion in humans has not been established. Furthermore it is 
also not known how the pattern of secretion changes in HF from LVSD.  This study shows that 
for patients with LVSD apelin concentration is significantly different in the CS.  This 
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observation can be explained by a reduction of myocardial apelin production.   A reduction in 
myocardial apelin production could either be due to the inability of myocytes to produce 
sufficient apelin in LVSD or a response to an increase of apelin production in the pulmonary 
circulation with subsequent peripheral breakdown.  Apelin has been found in the pulmonary 
vascular endothelium 
145
, and a 3.3 fold reduction in peripheral plasma apelin-36 concentrations 
is seen in patients with chronic lung disease and normal LVSD 
188
.  In individuals with LVSD 
and a mean pulmonary artery pressure (mPAP) of  26 (17-50) mmHg a 2.1 fold reduction in 
peripheral apelin-36 is seen, which compares with a 4.0 fold reduction in idiopathic pulmonary 
hypertension (mPAP = 56 (50-99) mmHg) 
188
.  The smaller isoforms of apelin exhibit greater 
biological activity and the role of differing isoforms on a variety of vascular beds has not been 
determined 
134
.  It is plausible that peripheral apelin production may not accurately reflect 
changes in apelin in the pulmonary vasculature.  To determine whether there is an increase in 
apelin production from the pulmonary circulation would require pulmonary venous sampling. In 
the current study we did not have ethical approval to conduct a full right heart study in the 
control group to compare with the right heart haemodynamic data we had in a small number of 
heart failure patients.   
 
Despite neurohormonal blockade heart failure carries a significant risk of morbidity and 
mortality.  The search for additional pathways involved in the pathogenesis of heart failure 
continues in the hope of finding further targets for pharmacological therapies.  The use of 
inotropic agents in heart failure has not shown any mortality benefit and although a temporary 
improvement in haemodynamic parameters may be seen this is at the expense of increased 
myocardial oxygen demand.  Apelin is an endogenous agent which has the opposite effects to 
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angiotensin II and may therefore represent a potential therapeutic agent in acute heart failure.  A 
synthetic analogue has been used safely in humans and results in peripheral vasodilatation in 
healthy volunteers 
290
.  Comprehensive haemodynamic effects in humans are yet to be studied. 
The current finding of a reduction in myocardial apelin production in humans with LVSD adds 
weight to exploring the therapeutic potential of exogenous administration of apelin.   
 
The study has a number of potential limitations.  It is difficult to recruit a homogeneous 
population of healthy control subjects for a catheter laboratory based study.  Exposure to 
ionizing radiation and invasive catheterization is difficult to justify ethically in the absence of a 
clinical mandate to undertake such investigations.  Therefore we sought to identify a population 
of patients with preserved left ventricular function undergoing electrophysiological study. As 
such the control population was younger than the HF patients.  However the mean age of patients 
with heart failure and systolic dysfunction is 76 and so our population was relatively young for a 
heart failure study.  Whilst the patients with heart failure were receiving standard treatment, it is 
possible that the lower than expected use of beta-blockers reflects the early stage at which a 
number of subjects were undergoing invasive cardiac investigations.  Not all the patients had 
cardiac imaging performed at our institution however the heart failure group all had significant 
structural heart disease with left ventricular ejection fraction below 40% documented either on 
TTE or cardiac MRI.  The control group had normal structural heart on TTE with an ejection 
fraction above 50%.  As expected in the heart failure group the BNP was significantly higher and 
the haemoglobin and sodium were lower as compared with the control subjects. 
 
 95 
 
Previous studies have shown peripheral apelin to be lower in patients with lone atrial 
arrhythmias.  It is therefore plausible that circulating apelin might be lower in subjects with 
paroxysmal arrhythmia as compared with completely healthy subjects (in whom it would be 
difficult to ethically justify invasive investigation).  Despite this fact CS apelin was significantly 
lower in the HF failure group compared with the control group.  Regardless of the small sample 
size there were significant differences in the BNP concentrations between the two groups and an 
obvious step down from CS to Ao to RV.  As such it is clear that apelin is not exclusively 
produced in the myocardium, but CS apelin is significantly lower in heart failure with no step 
down to aorta suggesting that myocardial production of apelin is impaired in LVSD. 
Conclusions  
 
This study has demonstrated for the first time that in humans apelin is produced in the heart and 
that in chronic heart failure secondary to LVSD myocardial apelin production is reduced.  The 
secretion pattern of apelin differs to that of BNP which is exclusively produced in the heart and 
suggests that although myocardial apelin production may be important in the pathogenesis of 
heart failure and adverse left ventricular remodelling, apelin production is not exclusive to the 
heart and may involve other organs.  Further work is needed to clarify the role of apelin in the 
development of heart failure and how the apelin-APJ axis interacts with other neuroendocrine 
systems known to be instrumental in the pathogenesis of heart failure.  There may also be a role 
for the use of synthetic apelin in the treatment of patients with heart failure; however the 
physiological effects on apelin administration on cardiac haemodynamics in normal individuals 
and those with heart failure are still to be elucidated.   
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Chapter 4: Plasma apelin is reduced in patients who fail to 
remodel at 6 months following cardiac resynchronisation 
therapy  
 
Abstract 
 
Aims:  Apelin is an endogenous inotropic and vasodilator peptide acting through the APJ 
receptor on vascular endothelium.  The effect of cardiac resynchronisation therapy (CRT) on 
plasma apelin was investigated in patients with advanced heart failure (HF).  Methods:  21 
patients with a left ventricular ejection fraction (LVEF) < 35% on radionuclide ventriculography, 
QRS > 150ms and New York Heart association class III underwent CRT 
implantation.  Evaluation at baseline and after 6 months of CRT included a 6 minute walk test 
(6MWT), Minnesota living with heart failure questionnaires (MLWHF), plasma B-type 
natriuretic peptide (BNP) and plasma apelin. Results:  LVEF increased (22+/-1.6% to 27+/-
2.4%, p<0.003), 6MWT improved (251 +/-14.3m to 325 +/-22.4m, p<0.0001), MLWHF score 
decreased (48+/-3.5 to 28 +/-3.3, p<0.0001) but BNP and apelin were unchanged.  LVEF 
increased of >5 % in 13/21 (62%) patients.  There was no significant change in plasma apelin in 
those that remodelled, but BNP was reduced (290 +/- 73 pg/ml to 140 +/- 28 pg/ml, p<0.05).  In 
6/21 (29%) patients apelin increased and was associated with a greater rise in LVEF (11 % +/- 
1.2% vs 3 % +/- 1.5%, p<0.002).  In 8 patients who did not remodel there was a significant 
decrease in apelin (413 +/- 43 to 296 +/- 21 pg/ml, p<0.002).  Conclusion:  Plasma apelin is 
reduced in individuals who fail to remodel following CRT.  The apelin-APJ pathway is an 
endogenous counter regulatory pathway which may be down regulated in patients with adverse 
LV remodelling making it a potential therapeutic target in HF patients.  
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Introduction. 
 
Apelin is a peptide which has been recently identified as the only known ligand for the APJ 
receptor on vascular endothelium
133, 134
.  Both apelin and APJ are widely distributed in the 
endothelium of a number of organs including the heart 
136, 137
.  Apelin is a powerful inotrope 
158
, 
vasodilator 
135
 and may help regulate central fluid homeostasis 
141
.  The APJ receptor shares a 
similar homology to the angiotensin II type 1 receptor (AT1) and acts through a G-Protein 
pathway 
133
.  Apelin causes peripheral vasodilatation by an endothelial nitric oxide (NO) 
dependent pathway 
143, 290
.  The effects mediated by apelin are opposite to the effects of 
angiotensin II (ang-II) acting on AT1 and there is some evidence from animal models that the 
apelin-APJ axis may modulate the detrimental effects of ang II-AT1 
176, 177
.  Therefore there is 
much interest in the role of apelin in the pathogenesis of heart failure.   
In humans with heart failure peripheral plasma apelin is reduced compared to patients without 
structural heart disease 
183
.  In advanced heart failure patients apelin mRNA increased in the 
myocardium with favourable left ventricular remodelling following left ventricular assist device 
(LVAD) insertion 
184
. The effect of therapy targeted at heart failure on plasma apelin is not 
known. 
The aim of this study was to study the effect of cardiac resynchronisation therapy (CRT) on 
plasma apelin.  Large trials have shown that CRT improves survival and symptoms in patients 
with severe left ventricular systolic dysfunction, left bundle branch block and symptoms 
refractory to optimally tolerated medical therapy.  After successful CRT, up to 50% of patients 
may show favourable left ventricular remodelling.  We hypothesized that patients who 
remodelled favourably following CRT would show an increase in plasma apelin.  A small study 
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showed that apelin is unchanged immediately following CRT but increases after a mean follow 
up of 9 months 
186
. 
Methods 
 
Consecutive patients who were eligible under current guidelines for CRT with or without the 
requirement for an internal cardiac defibrillator (ICD) were recruited.  All patients were referred 
to our heart failure service for consideration of device therapy.  They underwent baseline 
evaluation which included a full clinical history and examination, ECG, transthoracic 
echocardiography (TTE), 6 minute walk test (6MWT) and Minnesota living with heart failure 
questionnaires (MLWHF).  Laboratory investigations included: full blood count, serum 
biochemistry and plasma B-type natriuretic peptide (BNP).  Patients who had New York heart 
classification (NYHA) class III symptoms, left ventricular ejection fraction (LVEF) < 35% and a 
prolonged QRS width (>150ms) were considered eligible for inclusion.  Individuals with QRS 
width 120-140 ms required additional TTE evidence of dyssynchrony as defined in the CARE-
HF study 
44
.  Patients with atrial fibrillation (AF) and chronic right ventricular (RV) pacing were 
also included.   Those who fulfilled the current National institute for clinical excellence (NICE) 
guidance for an ICD received a defibrillator as well.  Exclusion criteria included:  Age < 18 
years, uncorrected congenital heart disease, significant renal dysfunction (creatinine > 300 
μmol/l) and significantly elevated liver enzymes (> 3 x normal range).  All patients gave written 
informed consent and the study was approved by the local ethics committee 05/Q0404/121. 
Assessment of left ventricular function 
 
Left ventricular function was evaluated by radionuclide ventriculography (RNV) performed by 
operators blinded to the clinical characteristics of the patients at baseline and six months 
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following successful CRT.  Planar acquisition was performed with best septal separation view 
(32 frames, 20% window for R-R interval). SPECT was performed from RAO 45
0
 to LPO 45
0 
(16 frames, 20% window). The planar data was processed with Hermes (FUGA) and SPECT was 
processed with Cedars Sinai QBS software.  Favourable reverse left ventricular remodelling was 
pre-specified as an increase of > 5 percentage points in planar LVEF from baseline.  As RNV 
SPECT data was also available for 19 patients results were also analysed using a second 
definition of favourable remodelling of > 10% reduction in left ventricular end systolic volume 
(LVESV). 
Blood sampling 
 
All patients were fasted for greater than four hours and were supine at rest for greater than 15 
minutes.  Twenty millilitres of blood was collected into chilled E.D.T.A tubes.  The samples 
were centrifuged immediately at 3000 r.p.m for 15 minutes and the supernatant plasma was 
stored in aliquots at -80
0
C until analysis.   
Apelin and BNP assays 
 
Plasma apelin-12 was measured using a commercially available enzyme immunoassay without 
extraction (Phoenix Pharmaceuticals, Belmont, CA, USA) according to the manufacturer’s 
instructions; inter-assay and intra-assay coefficient of variations at 500 pg/ml were 12.5% and 
<5.0%, respectively.   The antibody used in this assay is an immunoaffinity purified rabbit 
antibody specific for apelin 1-12 with a 100% cross-reactivity to apelin 1-12, 1-13 and 1-36 but 
no cross-reactivity to ADM-52, BNP-32, CNP-22, ANP (25-56), ghrelin, ET-1 or bradykinin.  
Plasma BNP was measured on the Beckman Access- 2 immunoassay analyser using Triage BNP 
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Access reagents (Biosite Ltd, Belfast UK).   The apelin and BNP assays were performed by 
individuals blinded to the patients’ characteristics and RNV results. 
Details of implantation 
 
All implants were left sided.  Endocardial right atrial and RV leads were implanted using 
standard techniques.  Eleven (52%) patients requiring an ICD received a dual coil active 
defibrillator lead.  The coronary sinus (CS) was intubated using standard catheters allowing 
placement of the left ventricular (LV) lead epicardially.  The choice of lead and device was left 
to the operator’s discretion and not specified in the protocol. 
Follow up 
 
All patients were followed up at one month and their pacemaker settings were optimized using 
transthoracic echocardiography.  With sinus rhythm the optimal atrio-ventricular (AV) interval 
was set to achieve maximal separation of the E and A wave without truncation of the A wave.  
Then the delay between right and left ventricular pacing (VV interval) was altered to achieve 
maximum aortic VTI.  In patients with AF only the VV optimization was carried out.  Patients 
were then reviewed at 6 months following CRT where the full baseline evaluation was repeated.  
Every effort was made to optimize their medical therapy further as tolerated.   
Statistical analysis 
 
Analysis was by intention to treat.  Normally distributed values are displayed as means with 
standard errors and variables which were not normally distributed are displayed as a median with 
interquartile range (IQR).  Categorical variables were compared using 2 or Fisher’s exact test.  
Comparison between baseline and follow up was by paired t-tests.  Plasma BNP and apelin 
concentrations were highly skewed therefore analysis was carried out on log transformed values.  
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A p-value < 0.05 was deemed to be significant.  Correlations between normally distributed 
variables were carried out using Pearson’s test.  The data were collated and stored using MS 
Excel and analysed with SPSS 13.0.   
Results 
 
Twenty four patients were initially recruited.  One patient declined implantation, and one patient 
was found to have a renal cell carcinoma prior to admission and so did not participate in the 
study.  In three patients it was not possible to implant an LV lead due to unsuitable venous 
anatomy.  Two of these patients received a right ventricular outflow track (RVOT) lead in 
addition to an RV apical lead.  One individual was in atrial flutter at the time of implantation and 
underwent flutter ablation.  Therefore 21 patients were implanted and available for 6 month 
follow up.   
Baseline characteristics 
 
The baseline characteristics are detailed in Table 9.   The median age was 74 years (IQR 56-79) 
and they were predominantly male (88%).  A third of them had persistent AF at baseline and 
46% had been chronically RV paced, and were upgraded to biventricular pacing.  The majority 
of the patients (58%) had non ischaemic dilated cardiomyopathy (NIDCM).  At 6 months 13 / 21 
(62%) patients remodelled favourably as defined by planar RNV LVEF and 11/19 (58%) 
remodelled by SPECT criteria.  In this group baseline blood pressure was higher and left 
ventricular volumes were lower.  There was no significant difference in the other baseline 
characteristics.  Both groups were well treated with all of the patients on angiotensin converting 
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Table 9: Demographics of patients undergoing cardiac resynchronisation therapy  
 Full group  
(n=21) 
 
Remodelled 
(n=13) 
No remodelling 
(n=8) 
p-value 
Age (years) median, (IQR) 
 
74 (52-79) 75 (53-79) 72 (45-81) 0.75 
Male, n (%) 18 (86%) 
 
11 (88%) 7 (85%) 0.85 
BMI mean, (SE) 28 (1.3) 
 
29 (1.3) 27 (2.7) 0.35 
Heart rate (bpm) mean, (SE) 72 (2.4) 
 
70 (1.4) 70 (6.2) 0.96 
Systolic BP (mmHg) mean, 
(SE) 
114 (5.2) 
 
123 (6.5) 100 (6.4) <0.04 
Diastolic BP (mmHg) mean, 
(SE) 
66 (2.3) 
 
71 (2.8) 58 (4.6) <0.03 
Mean BP (mmHg) mean, (SE) 82 (3.3) 
 
88 (3.7) 72 (4.5) <0.02 
Diabetes, n (%) 4 (19%) 
 
3 (23%) 1 (13%) 1.0 
Atrial Fibrillation, n (%) 7 (33%) 
 
5 (39%) 2 (25%) 0.66 
Chronic RV pacing, n (%) 10 (48%) 
 
8 (62%) 2 (25%) 0.18 
QRS width (ms), mean (SE) 182 (4.7) 
 
187 (5.9) 173 (7.0) 0.16 
6MWT (m), mean (SE) 
 
253 (13) 238 (15) 278 (23) 0.14 
MLWHF score, mean (SE) 
 
48 (3.5) 51 (4.5) 45 (5.9) 0.42 
Aetiology of heart failure n, (%)  
 
   
Ischaemic heart disease 9 (43%) 
 
5 (38%) 4 (50%) 0.67 
Dilated cardiomyopathy (DCM) 9 (43%) 
 
7 (54%) 2 (25%)  
Valvular 3 (14%) 
 
1 (8%) 2 (25%)  
Non-ischaemic DCM 12 (57%) 
 
8 (62%) 4 (50%) 0.67 
Ventricular function  
 
   
LVEF (%), mean (SE) 22 (1.7) 
 
24 (2.2) 19 (2.4) 0.17 
RVEF (%), mean (SE) 31 (3.5) 
 
34 (5.1) 25 (3.1) 0.13 
LVEDV (ml), mean (SE) 292 (28) 
 
245 (15) 372 (62) <0.03 
LVESV (ml), mean (SE) 219 (25) 
 
172 (13) 299 (54) <0.02 
SD LV Phase (
0
), mean (SE) 
 
85 (5.1) 87 (4.9) 82 (11.3) 0.60 
APET (ms), mean (SE) 171 (7.6) 
 
180 (9.8) 156 (11.0) 0.13 
IVD (ms), mean (SE) 50 (6.5) 56 (8.9) 40 (8.6) 0.25 
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IQR =interquartile range, SE=standard error, bpm=beats per minute, RV=right ventricular, 
MLWHF=Minnesota living with heart failure, LVEF=left ventricular ejection fraction, RVEF=right 
ventricular ejection fraction, LVEDV=left ventricular end diastolic volume, LVESV=left ventricular end 
systolic volume, SD LV =standard deviation of left ventricular, APET=aortic pre-ejection time, 
IVD=interventricular mechanical delay, ACE-I =angiotensin converting enzyme inhibitor, ARB= angiotensin 
receptor blocker, BNP=B-type natriuretic peptide.  
 
Medications  
 
   
ACE-I / ARB n, (%) 21 (100%) 
 
   
Beta-blockers n, (%) 14 (66%) 
 
9 (69%) 5 (63%) 1.0 
Aldosterone antagonists n, (%) 15 (71%) 
 
8 (62%) 7 (88%) 0.33 
Loop diuretics n, (%) 16 (76%) 
 
8 (62%) 8 (100%) 0.11 
Digoxin n, (%) 5 (24%) 
 
2 (15%) 3 (38%) 0.33 
Laboratory investigations  
 
   
Haemoglobin (g/dl) mean (SE) 13.1 (0.4) 
 
12.8 (0.48) 13.5 (0.47) 0.38 
Sodium (mmol/l) mean (SE) 136 (0.8) 
 
137 (0.84) 136 (1.5) 0.40 
Potassium (mmol/l) mean, (SE) 4.2 (0.1) 
 
4.3 (0.1) 4.0 (0.1) 0.11 
Urea (mmol/l) mean (SE) 9.8 (0.9) 
 
9.2 (1.0) 10.8 (1.5) 0.36 
Creatinine (umol/l) mean, (SE) 124 (6.3) 
 
123 (9.8) 126 (5.7) 0.82 
BNP (pg/ml), median (IQR) 308 (135-
447) 
 
221 (68-356) 310 (103-694) 0.33 
Apelin (pg/ml), median (IQR) 328 (268-
402) 
 
324 (237-390) 383 (310-515) 0.12 
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enzyme inhibitors (ACE-I) or angiotensin receptor antagonists (ARB).  The majority of the 
patients were on a beta-blocker (67%) and aldosterone antagonist (71%).   
Changes at 6 months 
 
The changes from baseline and 6 months are detailed in Table 10.  Planar LVEF increased from 
22 % (+/-1.7%) to 27% (+/-2.3%), p<0.002.  Right ventricular ejection fraction also increased 
from 31 % (+/- 3.6%) to 46 % (+/- 3.0%), p<0.002.  SPECT left ventricular diastolic and systolic 
volumes decreased from 292 ml (+/- 28 ml) to 250 ml (+/-29ml) , p< 0.004 and 219 ml (+/-25ml) 
to 181 ml (+/-26ml), p<0.003 respectively.  The standard deviation of left ventricular (SD LV) 
phase, which is a measure of intraventricular dyssynchrony 
94
 fell from 85
0 
(+/-5.1
0
) to 72
0
 (+/- 
6.0
0
), p<0.04 and the change in LVEF correlated inversely with the change in LV SD phase (R=-
0.6, p<0.005).  Exercise capacity increased with 6MWT rising from 251 m (+/-14 m) to 323 m 
(+/-22 m), p<0.0001.  Quality of life improved with MLWHF score decreasing from 48 (+/- 3.5) 
to 28 (+/-3.3), p < 0.0001.  Plasma BNP showed a trend to reduction at 6 month falling from 331 
pg/ml (+/-58 pg/ml) to 258 pg/ml (+/-69 pg/ml), p=0.07.  However apelin remained unchanged at 
6 months following CRT.  There was no correlation between a change in apelin at 6 months with 
changes in ejection fraction, exercise capacity, MLWHF score or BNP.   
 
At 6 months 13 (62%) patients remodelled favourably.  In those patients there was a reduction in 
SD LV phase -24
0
 (+/- 6.3
0
) vs 6.0
0
 (+/-6.9
0
), p<0.006 (Table 11).  The blood pressure was 
higher at baseline in the group that remodelled favourably and the left ventricular dimensions 
were smaller.  However there were no statistically significant differences in other baseline 
characteristics (Table 9).  The change in exercise capacity and MLWHF score did not differ 
significantly between those that remodelled and those that did not (Table 11).  Medical therapy 
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Table 10: Changes at 6 months follow in cardiac resynchronisation therapy 
 
 
LVEF=left ventricular ejection fraction, RVEF=right ventricular ejection fraction, LVEDV=left ventricular 
end diastolic volume, LVESV=left ventricular end systolic volume, SD LV =standard deviation of left 
ventricular, 6MWT=6 minute walk test, MLWHF=Minnesota living with heart failure NYHA =New York 
Heart Association, BNP=B-type natriuretic peptide. 
Parameter N Baseline 
 
6 Months p-value 
LVEF (%) 21 22 (1.7)   
 
27 (2.3) <0.002 
RVEF (%) 20 31 (3.6) 
 
46 (3.0) <0.002 
LVEDV (ml) 19 292 (28) 
 
250 (29) <0.004 
LVESV (ml) 19 219 (25) 
 
181 (26) <0.003 
6MWT (m) 19 251 (14) 
 
323 (22) <0.0001 
SD LV Phase 
 
21 85 (5.1) 72 (6.0) <0.04 
MLWHF score 20 48 (3.5) 
 
28 (3.3) <0.0001 
NYHA class >II 21 21 (100%) 
 
5 (23%)  
BNP (pg/ml) 21 331 (58) 
 
258 (69) 0.07  
Apelin (pg/ml) 21 360 (27) 
 
319 (23) 0.28  
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Table 11: The change at 6 months in patients with favourable  left ventricular remodelling compared with 
those that failed to remodel. 
 
Change at 6 months 
 
N Remodelled 
N=13 
No-remodelling 
N=8 
p-value 
LVEF (%) 
 
21 9.2 (0.8) -2.0 (1.3)  
RVEF (%) 
 
20 13.8 (5.4) 16.4 (5.2) 0.79 
LVEDV (ml) 
 
19 -44 (17) -37 (15) 0.81 
LVEDV (%) 
 
19 -16 (7) -10 (4) 0.54 
LVESV (ml) 
 
19 -43 (13) -30 (18) 0.57 
LVESV (%) 
 
19 -22 (8) -10 (6) 0.26 
SD LV Phase (
0
) 
 
21 -24 (6.3) 6.0 (6.9) <0.006 
6MWT (m) 
 
19 81 (18) 64 (19) 0.52 
MLWHF 
 
20 -22 (5) -18 (7) 0.67 
BNP (pg/ml) 
 
21 -150 (69) 50 (112) 0.09  
Apelin (pg/ml) 
 
21 7 (54) -116 (30) <0.05  
 
LVEF=left ventricular ejection fraction, RVEF=right ventricular ejection fraction, LVEDV=left ventricular 
end diastolic volume, LVESV=left ventricular end systolic volume, SD LV =standard deviation of left 
ventricular, 6MWT=6 minute walk test, MLWHF=Minnesota living with heart failure NYHA =New York 
Heart Association, BNP=B-type natriuretic peptide. 
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was up titrated as tolerated after CRT.  In 7 patients (33%), ACE-I/ARBs were increased.  Beta-
blockers were initiated or increased in 14 (68%) and aldosterone antagonists were added or 
increased in 5 (23%).  Loop diuretic were reduced in 10 (43%) of patients.  There were no 
significant differences in the level of medical optimization between patients that remodelled 
favourably at 6 months and those that did not (Table 12). 
Table 12: Medical up-titration in the study and relationship to left ventricular remodelling. 
 Whole group 
N=21 
 
Remodelled 
N=13 
Non-remodellers 
N=8 
P-value 
Increase in ACE-I/ARB 
 
7 (33%) 4 (31%) 3 (38%) 1.0 
Increase or addition of beta-blocker 
 
14 (68%) 7 (54%) 8 (88%) 0.17 
Increase or addition of AA 
 
5 (23%) 3 (23%) 2 (33%) 1.0 
Decrease in loop diuretic 
 
10 (43%) 5 (38%) 5 (63%) 0.41 
 
ACE-I=Angiotensin-converting enzyme inhibitor, ARB=Angiotensin-Receptor blocker, AA=Aldosterone 
antagonist. 
 
In those that remodelled favourably BNP fell significantly from 290 pg/ml (+/- 73 pg/ml) to 140 
pg/ml (+/- 28 pg/ml), p<0.05.  There was no significant change in BNP in those that did not 
remodel (Figure 16).  Apelin was unchanged in those that remodelled favourably, however in 
those that failed to remodel at 6 months apelin was reduced from 413 pg/ml (+/- 43 pg/ml) to 296 
pg/ml (+/- 21 pg/ml), p<0.002 (Figure 17).  These differences were the same even when the 
volumetric definition of favourable modelling was used (Figure 18 and 19). 
 
Apelin increased in 6 (29%) patients and all those individuals remodelled favourably.  The mean 
increase in those patients was 146 pg/ml (+/- 69 pg/ml).  This was an increase of 62 +/- 32% 
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Figure 16: B-type natriuretic peptide in responders vs non-responders after 6 months of cardiac 
resynchronisation  therapy 
 
 
Plasma B-type natriuretic peptide (BNP) at baseline and 6 months of patients whose left ventricular ejection 
fraction (LVEF), measured by planar radionuclide ventriculography, increased > 5 percentage points 
compared to those that did not.  
Figure 17: Apelin in responders vs non-responders after 6 months of cardiac resynchronisation  therapy 
 
 
Plasma apelin concentrations at baseline and 6 months of patients whose left ventricular ejection fraction 
(LVEF), measured by planar radionuclide ventriculography, increased > 5 percentage points compared to 
those that did not.  
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Figure 18 B-type natriuretic peptide in responders vs non-responders after 6 months of cardiac 
resynchronisation  therapy 
 
 
Plasma B-type natriuretic peptide (BNP) at baseline and 6 months of patients whose left ventricular end 
systolic volume (LVESV), measured by SPECT radionuclide ventriculography, decreased > 10% compared 
to those that did not.  
Figure 19 Apelin in responders vs non-responders after 6 months of cardiac resynchronisation  therapy:  
 
 
Plasma apelin at baseline and 6 months of patients whose left ventricular end systolic volume (LVESV), 
measured by SPECT radionuclide ventriculography, decreased > 10% compared to those that did not.  
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from baseline.  In these individuals baseline apelin was lower 239 pg/ml (208-272 pg/ml) vs 385 
pg/ml (328-469 pg/ml), p<0.002 and 6MWT was lower 214 m (+/-17 m) vs 268 m (+/-17 m), 
p<0.04.  The rest of the baseline characteristics were similar (Table 13).  In those that had an 
increase in apelin at 6 months LVEF increased considerably more compared to those in whom 
apelin remained unchanged or reduced (11 % +/- 1.2% vs 3 % +/- 1.5%, p<0.002).  There was no 
difference in the up titration of medical therapy between the two groups (Table 14).  There was 
also a greater reduction in left ventricular volumes in this group; however changes in quality of 
life and exercise capacity were not significantly different between the two groups (Table 15).  
The mean change in BNP was greater in the group whose apelin increased, but this change was 
not statistically significant however there was a significant decrease in BNP in from baseline to 6 
months in the 6 patients in whom apelin increased (Figure 20).  
 Figure 20 B-type natriuretic peptide changes in individuals where apelin was increased at 6 months 
 
 
In individuals where the plasma concentration of apelin rose there was a decrease in plasma B-type 
natriuretic peptide (BNP) after 6 months of cardiac resynchronisation therapy 
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Table 13:Demographics of patients in whom plasma apelin rose at 6 months compared with the remainder. 
 Full group  
(n=21) 
 
Apelin increased 
(n=6) 
No increase in 
apelin 
(n=15) 
p-value 
Age (years) median, (IQR) 
 
74 (52-79) 77 (42-80) 73 (56-77) 0.80 
Male, n (%) 18 (86%) 
 
2 (33%) 1 (7%) 0.18 
BMI mean, (SE) 28 (1.3) 
 
28 (2.5) 29 (1.6) 0.73 
Heart rate (bpm) mean, (SE) 72 (2.4) 
 
71 (2.1) 70 (3.4) 0.94 
Systolic BP (mmHg) mean, 
(SE) 
114 (5.2) 
 
125 (10.1) 109 (5.9) 0.20 
Diastolic BP (mmHg) mean, 
(SE) 
66 (2.3) 
 
73 (3.8) 63 (3.4) 0.13 
Mean BP (mmHg) mean, (SE) 82 (3.3) 
 
90 (5.5) 79 (3.8) 0.13 
Diabetes, n (%) 4 (19%) 
 
1 (17%) 3 (20%) 1.0 
Atrial Fibrillation, n (%) 7 (33%) 
 
2 (33%) 5 (33%) 1.0 
Chronic RV pacing, n (%) 10 (48%) 
 
4 (66%) 6 (40%) 0.36 
QRS width (ms), mean (SE) 182 (4.7) 
 
 180 (7.3) 183 (6.0) 0.78 
6MWT (m), mean (SE 
 
253 (13) 214 (17) 268 (15) <0.04 
MLWHF score, mean (SE) 
 
48 (3.5) 49 (6)  48 (4) 0.54 
Aetiology of heart failure n, (%)  
 
   
Ischaemic heart disease 9 (43%) 
 
3 (50%) 6 (40%)  
Dilated cardiomyopathy (DCM) 9 (43%) 
 
3 (50%) 6 (40%)  
Valvular 3 (14%) 
 
0 3 (20%)  
Non-ischaemic  DCM 12 (57%) 
 
 3 (33%) 9 (66%) 1.0 
Ventricular function  
 
   
LVEF (%), mean (SE) 22 (1.7) 
 
21 (2.7) 23 (2.1) 0.57 
RVEF (%), mean (SE) 31 (3.5) 
 
24 (4.5) 33 (4.4) 0.24 
LVEDV (ml), mean (SE) 292 (28) 
 
262 (24) 303 (37) 0.53 
LVESV (ml), mean (SE) 219 (25) 
 
192 (18) 229 (34) 0.54 
SD LV Phase (
0
), mean (SE) 
 
85 (5.1) 74 (5.5) 90 (6.6) 0.17 
APET (ms), mean (SE) 171 (7.6) 
 
166 (4.5) 173 (4.4) 0.58 
IVD (ms), mean (SE) 50 (6.5) 
 
37 (10.2) 56 (7.9) 0.20 
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IQR =interquartile range, SE=standard error, bpm=beats per minute, RV=right ventricular, 
MLWHF=Minnesota living with heart failure, LVEF=left ventricular ejection fraction, RVEF=right 
ventricular ejection fraction, LVEDV=left ventricular end diastolic volume, LVESV=left ventricular end 
systolic volume, SD LV =standard deviation of left ventricular, APET=aortic pre-ejection time, 
IVD=interventricular mechanical delay, ACE-I =angiotensin converting enzyme inhibitor, ARB= angiotensin 
receptor blocker, BNP=B-type natriuretic peptide.  
Medications  
 
   
ACE-I / ARB n, (%) 21 (100%) 
 
   
Beta-blockers n, (%) 14 (68%) 
 
3 (50%) 12 (73%) 0.29 
Aldosterone antagonists n, (%) 15 (71%) 
 
3 (50%) 12 (75%) 0.29 
Loop diuretics n, (%) 16 (76%) 
 
8 (66%) 12 (75%) 0.59 
Digoxin n, (%) 5 (24%) 
 
2 (33%) 3 (20%) 0.60 
Laboratory investigations  
 
   
Haemoglobin (g/dl) mean (SE) 13.4 (0.4) 
 
12.7 (0.9) 13.3 (0.3) 0.61 
Sodium (mmol/l) mean (SE) 137(0.7) 
 
137 (1.1) 136 (1.0) 0.89 
Potassium (mmol/l) mean, (SE) 4.3 (0.1) 
 
4.4 (0.2) 4.1 (0.1) 0.14 
Urea (mmol/l) mean (SE) 10.1 (0.8) 
 
7.8 (1.3) 10.6 (1.0) 0.15 
Creatinine (umol/l) mean, (SE) 127(6.0) 
 
113 (10.2)) 120 (7.8) 0.27 
BNP (pg/ml), median (IQR) 308 (135-
447) 
 
332 (178-567) 214 (83-505) 0.52 * 
Apelin (pg/ml), median (IQR) 328 (268-
402) 
 
239 (208-272) 385 (328-469) <0.002 * 
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Table 14: Changes in medical therapy and relationship to apelin  
 Whole group 
N=21 
 
Increase in 
apelin 
N=6 
No increase in 
apelin 
N=15 
P-value 
Increase in ACE-I/ARB 
 
7 (33%) 1 (17%) 6 (40%) 0.61 
Increase or addition of beta-blocker 
 
14 (68%) 5 (83%) 9 (60%) 0.61 
Increase or addition of AA 
 
5 (23%) 1 (17%) 4 (27%) 1.00 
Decrease in loop diuretic 
 
10 (43%) 2 (33%) 8 (53%) 0.63 
 
ACE-I=Angiotensin-converting enzyme inhibitor, ARB=Angiotensin-Receptor blocker, AA=Aldosterone 
antagonist 
Table 15 Changes at 6 months and the relationship to increase in apelin 
 
Change at 6 months 
 
N Increase in apelin 
N=6 
No increase in apelin 
N=15 
p-value 
LVEF (%) 
 
21 11 (1.2) 3 (1.5) <0.002 
RVEF (%) 
 
20 23 (13.0) 11 (18.2) 0.20 
LVEDV (ml) 
 
19 -68 (15) -32 (15) 0.19 
LVEDV (%) 
 
19 -28 (7.8) -9 (12.7) 0.07 
LVESV (ml) 
 
19 -67 (11.9) -28 (12.7) <0.04 
LVESV (%) 
 
19 -37 (8.3) -10 (6.0) <0.03 
6MWT (m) 
 
19 60 (19.7) 79 (16.2) 0.53 
MLWHF 
 
20 -17 (6.4) -21 (5.0) 0.69 
BNP (pg/ml) 
 
21 -209 (109.0) -20 (73.7) 0.38  
Apelin (pg/ml) 
 
21 146 (69.0) -115 (26.2)  
 
LVEF=left ventricular ejection fraction, RVEF=right ventricular ejection fraction, LVEDV=left ventricular 
end diastolic volume, LVESV=left ventricular end systolic volume, SD LV =standard deviation of left 
ventricular, 6MWT=6 minute walk test, MLWHF=Minnesota living with heart failure NYHA =New York 
Heart Association, BNP=B-type natriuretic peptide. 
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Discussion 
 
In a population of advanced heart failure patients CRT increased left ventricular ejection fraction 
and improved exercise capacity and quality of life.  This study population was older than those 
recruited to the large randomized trials and included patients in atrial fibrillation.  In keeping 
with other studies which have used predominantly echocardiography to quantify left ventricular 
function 62% showed significant remodelling at 6 months 
116
.  Those individuals that remodelled 
favourably had higher blood pressures at baseline and smaller left ventricular volumes.  This 
suggests that individuals with more advanced left ventricular dysfunction at baseline may be less 
likely to remodel favourably following CRT.  The increase in LVEF was not significantly 
different between patients with ischaemic heart disease (IHD) compared to NIDCM or in those 
with persistent AF at baseline.  Patients with chronic RV pacing at baseline showed a greater 
increase in LVEF at 6 months (8% +/- 1.5% vs 1.3% +/- 1.6%, p<0.02).  Improvements in 
quality of life and exercise capacity were not different compared to those that did not remodel 
favourably which is consistent with studies that have shown that left ventricular performance and 
exercise capacity may not correlate.  It also suggests that symptomatic improvement can be 
achieved even in the absence of an improvement in LVEF.   
 
Apelin did not change at 6 months throughout the whole group despite a significant change in 
LVEF.  This is different to a previous study in a smaller group of patients in whom there was a 
significant increase in plasma apelin after a mean follow up of 9 months 
186
.  The 13 patients in 
this study were younger (68 y +/- 13y), did not include patients in atrial fibrillation or with 
chronic RV pacing and evaluation of left ventricular function was with echocardiography.  All 
but one of their patients showed an increase in LVEF and apelin was increased even in one 
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individual who did not improve his LVEF.  The baseline apelin in these patients was higher 470 
pg/ml +/- 56 pg/ml compared to 357 pg/ml +/- 25 pg/ml in our study.  There was a marked rise in 
apelin to 990 pg/ml +/- 28 pg/ml, p <0.001 after 9 +/-2 months of CRT, which was the level 
found in normal controls.  Medical therapy was not up titrated further in this study as it was in 
our patients.  The study by Francia et al did not include patients in atrial fibrillation and a 
previous study has shown that plasma apelin is reduced in patients with lone atrial fibrillation 
without structural heart disease 
196
.  As such we would expect lower concentrations of apelin in 
our patients.  In our sample there were no differences in the baseline apelin or the change in 
apelin at 6 months between patients in AF and sinus rhythm or patients who had a paced rhythm 
at baseline.    
 
Previous work has shown that peripheral plasma apelin concentrations are reduced in individuals 
with heart failure compared to normal controls.  In this study there is a weak positive correlation 
of apelin with LVEF and RVEF, however there was no significant difference in apelin between 
NYHA class I-IV 
183
.  In our study, those that did remodel favourably showed no change in 
plasma apelin concentration despite a large increase in LVEF and a significant reduction in BNP.  
However in those individuals who failed to remodel, plasma apelin was significantly reduced at 
6 months.  In the limited number of people that showed a rise in apelin there was a much greater 
increase in LVEF compared to individuals that showed no change or a decrease in apelin 
concentrations. 
 
This suggests that apelin may be involved in the pathogenesis of left ventricular remodelling but 
it is not clear whether it plays an integral role or whether it is an innocent bystander.  In another 
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study looking at myocardial gene expression following CRT, genes that are involved force 
generation are up-regulated following CRT 
187
.  Apelin is widely distributed in the endothelium 
of a number of organs.  It is therefore capable of autocrine, paracrine and endocrine actions.  Our 
previous work suggests apelin is produced in the myocardium in vivo and in LVSD, myocardial 
apelin production is reduced 
291
.  Measuring plasma apelin may therefore be misleading as 
increases in apelin from the myocardium may be result in a negative feedback elsewhere.   
 
The apelin-APJ axis is only one of a possible number of counter-regulatory mechanisms 
involved in the pathogenesis of heart failure.  In the hypertensive animal model, apelin and APJ 
are down regulated only when there is a transition to heart failure.  Following treatment with 
Ang II blockade apelin and APJ mRNA expression was restored.  However other treatment arms 
resulted in an improvement in cardiac function without affecting apelin or APJ expression 
176
.   
 
There are number of differences between this study and the study by Francia et al which could 
explain the different result.  This study had a shorter follow up, and included patients in AF and 
with chronic RV pacing.  There was also up titration of ACE-I and Beta-blockers in our patients, 
which is often possible with successful CRT.  The effects of chronic RV pacing and targeted 
pharmacological heart failure therapy on apelin are yet to be determined so it is not possible to 
determine the relative importance of these factors on the results of our study.   
Conclusion 
 
Patients who fail improve left ventricular function following CRT show a significant reduction in 
plasma apelin whereas individuals who maintain or increase plasma apelin concentrations exhibit 
favourable LV remodelling.  The apelin-APJ pathway is an endogenous counter regulatory 
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pathway which may be down regulated with adverse remodelling making it a potential 
therapeutic target in advanced HF patients.  Targeting the apelin pathway may prevent 
deterioration or even improve left ventricular function in humans with heart failure.  However it 
remains to be seen whether apelin is integral to the pathogenesis of heart failure or just an 
innocent bystander.   
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Chapter 5: Early changes in Plasma Apelin are related to Left 
Ventricular Remodelling in patients following Cardiac 
Resynchronisation Therapy 
Abstract 
 
Aims: To investigate the effect of cardiac resynchronisation therapy (CRT) on plasma apelin.  
Background:  Apelin is an endogenous, inotropic, vasodilator peptide which acts on the APJ 
receptor. Methods: 21 patients with an LV ejection fraction (EF) < 35% on radionuclide 
ventriculography (RNV), QRS > 150ms and NYHA class III on maximally tolerated 
pharmacological therapy underwent CRT implantation. Evaluation at baseline, 6 months and 12 
after CRT included a 6 minute walk distance (6MWD), Minnesota living with heart failure 
questionnaires (MLWHF), RNV, plasma B-type natriuretic peptide (BNP) and plasma apelin. 
Results:  Despite an increase in LVEF from 23 % (+/-1.8) to 28% (+/-2.4) to 30% (+/-2.8), 
p<0.009 and significant improvements in 6MWD and MLWHF scores apelin and BNP were 
unchanged.  In individuals that remodelled favourably at 12 months, BNP was reduced from 335 
pg/ml (+/- 87) to 151 pg/ml/l (+/-34) to 148 pg/ml/l (+/- 35), p<0.01 compared to apelin which 
remained unchanged.  In the 8 patients who failed to remodel at 6 months apelin was reduced 
from 413 pg/ml (+/-43) to 296 pg/ml (+/-21) with a subsequent rise to 357 pg/ml (+/- 35), 
p<0.0005.  The change in LVEF was significantly greater in the 6 patients with an early increase 
in apelin 3% (+/- 1.5) vs 11% (+/-1.2), p<0.008 at 6 months and 5% (+/-2.1) vs 14% (+/-4.4), 
p<0.05 at 12 months. Conclusion: Early changes in plasma apelin following CRT are associated 
with significant changes in LVEF suggesting that apelin-APJ pathway may be involved in the 
pathogenesis of heart failure and LV remodelling.   
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Introduction 
. 
Apelin is a novel peptide which is the only known ligand for the APJ receptor 
133, 134
.  Apelin is a 
powerful inotrope 
158
, vasodilator 
135
 and may help regulate central fluid homeostasis 
141
.  The 
APJ receptor shares a similar homology to the angiotensin II type 1 receptor (AT1) and acts 
through a G-Protein pathway 
133
.   Both apelin and APJ are widely distributed in the endothelium 
of a number of organs including the heart 
136, 137
.  Apelin causes peripheral vasodilatation by an 
endothelial nitric oxide (NO) dependent pathway 
143, 290
.  The effects mediated by the apelin are 
opposite to the effects of angiotensin II acting on AT1 and there is some evidence from animal 
models that the apelin-APJ axis may modulate the detrimental effects of angiotensin II-AT1 
176, 
177
.  Therefore there is much interest in the role of apelin in the pathogenesis of heart failure.   In 
humans with heart failure peripheral plasma apelin is reduced compared to patients without 
structural heart disease 
183
.  In advanced heart failure patients apelin mRNA increased in the 
myocardium with favourable left ventricular remodelling following LVAD insertion 
184
.  The 
aim of this study was to study the effect of cardiac resynchronisation therapy (CRT) on plasma 
apelin.  Large studies have shown that CRT improves survival and symptoms in patients with 
severe left ventricular dysfunction, left bundle branch block and symptoms refractory to 
optimally tolerated medical therapy. After successful CRT, up to 50% of patients may show 
favourable left ventricular remodelling.  We hypothesized that patients who remodelled 
favourably following CRT would show an increase in apelin.   
Methods 
 
Consecutive patients who were eligible under current guidelines for CRT with or without the 
requirement for an internal cardiac defibrillator (ICD) were recruited.  All patients were referred 
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to our heart failure service for consideration of device therapy.  They underwent baseline 
evaluation which included a full clinical history and examination, ECG, transthoracic 
echocardiography (TTE), 6 minute walk test (6MWT) and Minnesota living with heart failure 
questionnaires (MLWHF).  Laboratory investigations included: full blood count, serum 
biochemistry and plasma B-type natriuretic peptide (BNP).  Patients who had New York heart 
classification class III symptoms, LVEF < 35% and a prolonged QRS width (>150ms) were 
considered eligible for inclusion.  Individuals with QRS width 120-149 ms required additional 
TTE evidence of dyssynchrony as defined in the CARE-HF study.  Patients with atrial 
fibrillation (AF) and chronic right ventricular pacing were also included.   Those who fulfilled 
the current NICE guidance for an ICD received a defibrillator as well.  Exclusion criteria 
included:  Age < 18 years, uncorrected congenital heart disease, significant renal dysfunction 
(creatinine > 300umol/l) and significantly elevated liver enzymes (> 3 x normal range).  All 
patients gave informed consent and the study was approved by the local ethics committee.   
Assessment of left ventricular function 
 
Left ventricular function was evaluated by radionuclide ventriculography (RNV) performed by 
operators blinded to the clinical characteristics of the patients at baseline, 6 months and 12 
months following successful CRT.   Planar acquisition was performed with best septal separation 
view (32 frames, 20% window for R-R interval). SPECT was performed from RAO 45
0
 to LPO 
45
0 
(16 frames, 20% window). The planar data was processed with Hermes (FUGA) and SPECT 
was processed with Cedars Sinai QBS software.  Favourable reverse left ventricular remodelling 
was pre-specified as an increase of > 5 percentage points in left ventricular ejection fraction from 
baseline.  SPECT volumes were available for 19 patients at baseline and 6 months and 17 
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patients 12 months.  Therefore the results were analysed using a reduction in left ventricular end 
systolic volume (LVESV) of >10% as a second definition of favourable remodelling.    
Blood sampling 
 
All patients were fasted for at least four hours and were supine at rest for at least 15 minutes 
prior to venepuncture.  Twenty millilitres of blood was collected into chilled E.D.T.A tubes.  The 
samples were centrifuged immediately at 3000 r.p.m for 15 minutes and the supernatant plasma 
was stored in aliquots at -80
0
C until analysis.   
Apelin and BNP assays 
 
Plasma apelin-12 was measured using a commercially available enzyme immunoassay without 
extraction (Phoenix Pharmaceuticals, Belmont, CA, USA) according to the manufactures 
instructions; inter-assay and intra-assay coefficient of variation at 500 pg/ml was 12.5% and 
<5.0% respectively.   The antibody used in this assay is an immunoaffinity purified rabbit 
antibody specific for apelin 1-12 with a 100% cross-reactivity to apelin 1-12, 1-13 and 1-36 but 
no cross-reactivity to ADM-52, BNP-32, CNP-22, ANP (25-56), ghrelin, ET-1 or bradykinin.  
Plasma BNP was measured on the Beckman Access 2 immunoassay analyser using Triage BNP 
Access reagents (Biosite Ltd, Belfast UK).   The apelin and BNP assays were performed by 
individuals blinded to the patients’ characteristics and RNV results. 
Details of implantation 
 
All implants were left sided.  Endocardial right atrial and right ventricular leads were implanted 
using standard techniques.  Patients requiring an ICD received a dual coil active defibrillator 
lead.  The coronary sinus (CS) was intubated using standard catheters allowing placement of the 
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left ventricular lead in an epicardial vein overlying the lateral LV wall.  The choice of lead and 
device was left to the operator’s discretion and not specified in the protocol. 
Follow up 
 
All patients were followed up at one month and there pacemaker settings were optimized using 
transthoracic echocardiography.  With sinus rhythm the optimal AV interval was set to achieve 
maximal separation of the E and A wave without truncation of the A wave.  Then the delay 
between right and left ventricular pacing (VV interval) was altered to achieve maximum aortic 
VTI.  In patients with AF only the VV optimization was carried out.  Patients were then 
reviewed at 6 months and 12 months following CRT where the full baseline evaluation was 
repeated.  Every effort was made to optimize their medical therapy further as tolerated.   
Statistical analysis 
 
Normally distributed values are displayed as means with standard errors and variables which 
were not normally distributed are displayed as a median with interquartile range.  Categorical 
variables were compared using 2 or Fisher’s exact test.  Comparison between baseline and 
follow up was using paired t-tests and repeated measures ANOVA with Bonferroni correction.  
Plasma BNP and apelin concentrations were highly skewed therefore analysis was carried out on 
log transformed values.  The data was collated and stored using MS Excel and analysed with 
SPSS 13.0.   
Results 
 
Twenty four patients were initially recruited.  One patient declined implantation, and one patient 
was found to have a renal cell carcinoma prior to admission and so did not participate in the 
study.  In three patients it was not possible to implant an LV lead due to unsuitable venous 
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anatomy.  Two of these patients received a right ventricular outflow track (RVOT) lead in 
addition to an RV apical lead.  Therefore 21 patients were implanted and available for 6 month 
follow up.  One patient died prior to 12 month follow up and one patient failed to have a repeat 
12 month RNV leaving 19 patients available for 12 months follow up.   
Baseline characteristics 
 
The baseline characteristics are detailed in Table 16.  The median age was 74 years (52-79) and 
they were predominantly male (84%).  A third of them had persistent AF at baseline and 53% 
had chronic RV pacing.  The majority of the patients (58%) had non ischaemic dilated 
cardiomyopathy (NIDCM).  At 6 months 13/21 (62%) patients remodelled favourably and at 12 
months 10/19 (53%) of patients remodelled favourably.  Seventeen patients had SPECT data and 
using the volumetric definition of remodelling 11/17 (58%) and 12 /17 (63%) remodelled 
favourably at 6 months and 12 months respectively.  There was no significant difference in the 
baseline characteristics between the two groups.  There was a greater amount of chronic RV 
pacing at baseline among the group that remodelled favourably, but this did not reach 
significance.  Both groups were well treated with all of the patients on angiotensin converting 
enzyme inhibitors (ACE-I) or angiotensin receptor antagonists (ARB).  The majority of the 
patients were on a beta-blocker and aldosterone antagonist; however there was significantly less 
beta-blocker use at baseline in the group that remodelled favourably.   
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Table 16 Baseline demographics compared in responders vs non-responders after 12 months of  cardiac 
resynchronisation therapy 
 
 Full group  
(n=19) 
 
Remodelled 
(n=10) 
No remodelling 
(n=9) 
p-value 
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Age (years) median, (IQR) 
 
74 (52-79) 75 (47-81) 70 (56-80) 0.78 
Male, n (%) 16 (84%) 
 
8 (80%) 8 (89%) 1 
BMI mean, (SE) 28 (1.3) 
 
29 (2.2) 27 (1.7) 0.40 
Heart rate (bpm) mean, (SE) 70 (2.5) 
 
72 (2.6) 66 (4.2) 0.20 
Systolic BP (mmHg) mean, 
(SE) 
117 (5.2) 
 
117 (9.5) 113 (4.8) 0.79 
Diastolic BP (mmHg) mean, 
(SE) 
68 (3.0) 
 
69 (3.0) 66 (4.8) 0.70 
Mean BP (mmHg) mean, (SE) 88 (3.5) 
 
85 (4.8) 82 (4.6) 0.70 
Diabetes, n (%) 3 (16%) 
 
1 (22%) 2 (2%) 0.58 
Atrial Fibrillation, n (%) 7 (37%) 
 
5 (50%) 7 (77%) 0.35 
Chronic RV pacing, n (%) 10 (53%) 
 
7 (70%) 3 (30%) 0.18 
QRS width (ms), mean (SE) 182 (4.3) 
 
187 (7.6) 183 (3.8) 0.69 
6MWT (m), mean (SE 
 
245 (69) 247 (19) 251 (17) 0.86 
MLWHF score, mean (SE) 
 
48 (15) 51 (5.6) 47 (5.0) 0.53 
Aetiology of heart failure n, (%)  
 
   
Ischaemic heart disease 8 (42%) 
 
3 (30%) 5 (56%) 0.37 
Dilated cardiomyopathy (DCM) 8 (46%) 
 
6 (60%) 2 (22%)  
Valvular 3 (16%) 
 
1 (10%) 2 (22%)  
Non ischaemic DCM 11 (58%) 
 
7 (70%) 4 (44%) 0.37 
Ventricular function  
 
   
LVEF (%), mean (SE) 23 (1.7) 
 
23 (5.0) 22 (2.4) 0.70 
RVEF (%), mean (SE) 33 (3.5) 
 
28 (4.9) 34 (4.6) 0.45 
LVEDV (ml), mean (SE) 279 (27) 
 
254 (24) 293 (26) 0.23 
LVESV (ml), mean (SE) 208 (24) 
 
186 (24) 222 (25) 0.30 
SD LV Phase (
0
), mean (SE) 
 
82 (5.2) 89 (7.8) 79 (8.5) 0.42 
Medications  
 
   
ACE-I / ARB n, (%) 9 100%)    
eta-blockers n, (%) 14 69%) 5 (50% 9 (100%) p<0.04* 
Aldosterone antagonists n, (%) 14 74%) 6 (60% 8 (89% 3
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IQR =interquartile range, SE=standard error, bpm=beats per minute, RV=right ventricular, 
MLWHF=Minnesota living with heart failure, LVEF=left ventricular ejection fraction, RVEF=right 
ventricular ejection fraction, LVEDV=left ventricular end diastolic volume, LVESV=left ventricular end 
systolic volume, SD LV =standard deviation of left ventricular, APET=aortic pre-ejection time, 
IVD=interventricular mechanical delay, ACE-I =angiotensin converting enzyme inhibitor, ARB= angiotensin 
receptor blocker, BNP=B-type natriuretic peptide.  
Loop diuretics n, (%) 15 (79%) 
 
7 (70%) 8 (89%) 0.58 
Digoxin n, (%) 4 (21%) 
 
3 (30%) 1 (11%) 0.58 
Laboratory investigations  
 
   
Haemoglobin (g/dl) mean (SE) 13.4 (0.4) 
 
13.1 (0.6) 12.8 (0.4) 0.70 
Sodium (mmol/l) mean (SE) 137(0.7) 
 
137 (1.1) 136 (1.3) 0.63 
Potassium (mmol/l) mean, (SE) 4.3 (0.1) 
 
4.3 (0.2) 4.0 (0.1) 0.12 
Urea (mmol/l) mean (SE) 10.1 (0.8) 
 
9.3 (1.3) 9.9 (1.3) 0.75 
Creatinine (umol/l) mean, (SE) 127(6.0) 
 
123 (10.1) 127 (10.3) 0.79 
BNP (pg/ml), median (IQR) 308 (104-
439) 
 
265 (99-481) 308 (117-555) 0.84 
Apelin (pg/ml), median (IQR) 328 (240-
460) 
 
326 (239-398) 381 (255-497) 0.59 
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Follow up 
 
Planar LVEF increased from 23 % (+/-1.8%) at baseline to 28% (+/-2.4%) at 6 months to 32% 
(+/- 2.8%) at 12 months (ANOVA p<0.009, F=10.7) (Figure 21).  Exercise capacity also 
increased with 6MWT rising from 255 m (+/-16 m) at baseline to 322 m (+/-24 m) at 6 months to 
355 m (+/-24 m) at 12 months (ANOVA p<0.001, F=17.5).  Quality of life improved with 
MLWHF score decreasing from 49 (+/- 4) at baseline to 28 (+/-4) at 6 months to 33 (+/-5) at 12 
months (ANOVA p < 0.0001, F=15.3).   
SPECT left ventricular end diastolic volume decreased from 273 ml (+/-18) at baseline to 227 ml 
(+/-16 ml) at 6 months to 201 ml (+/-19 m) at 12 months (ANOVA p < 0.0001, F=16).  Left 
ventricular systolic volume decreased from 203 ml (+/-17 ml) at baseline to 161 ml (+/-17 ml) at 
6 months to 143 ml (+/- 18 ml) at 12 months (ANOVA p < 0.0001, F=15.5). 
The standard deviation of LV phase (SD LV Phase), a marker of intraventricular dyssynchrony 
reduced significantly form a baseline of 84
0 
(+/-5.6
0
) to 70
0
 (+/-6.5
0
) at 6 months and 58
0
 (+/-
6.0
0
) at 12 months (ANOVA p<0.003, F=7.53).  In patients that did not remodel favourably SD 
LV phase did not decrease significantly (Figure 22)  
 
BNP was unchanged throughout the whole group: baseline 331 pg/ml (+/-54pg/ml), 6 months 
258 pg/ml (+/-69pg/ml) and 12 months 291 pg/ml (+/-57pg/ml) (AVOVA p =0.210, F=2.81).   
Apelin was also unchanged throughout the whole group: baseline 357pg/ml (+/-25pg/ml), 6 
months 319pg/ml (+/-23pg/ml) and 12 months 361pg/ml (+/-21pg/ml) (ANOVA p<0.11, F 
=2.54).   
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Figure 21: Left ventricular ejection fraction at 6 and 12 months following cardiac resynchronisation therapy 
 
 
 
The planar radionuclide left ventricular ejection fraction (LVEF) at baseline, 6 months and 12 months 
following CRT.   
Figure 22: Changes in the standard deviation of left ventricular phase in responders vs non responders to 
cardiac resynchronisation therapy 
 
 
 
The change in standard deviation of left ventricular phase (SD LV) phase calculated by planar radionuclide 
ventriculography in responders and non-responders following CRT.  LVEF=Left ventricular ejection 
fraction. 
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Figure 23 B-type natriuretic peptide in responders vs non-responders after 12 months of cardiac 
resynchronisation  therapy 
 
 
The changes in plasma B-type natriuretic peptide (BNP) in patients whom planar radionuclide left 
ventricular ejection fraction increased (LVEF) > 5 percentage points at 12 months compared to those with no 
significant change. 
Figure 24 Apelin in responders vs non-responders after 12 months of cardiac resynchronisation  therapy 
 
 
The changes in plasma apelin in patients whom planar radionuclide left ventricular ejection fraction 
increased (LVEF) > 5 percentage points at 6 months compared to those with no significant change. 
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Figure 25 B-type natriuretic peptide in responders vs non-responders after 12 months of cardiac 
resynchronisation  therapy 
 
 
 
The changes in plasma B-type natriuretic peptide (BNP) in patients whom SPECT left ventricular end 
systolic volume (LVESV) < 10% at 12 months compared to those with no significant change 
Figure 26: Apelin in responders vs non-responders after 12 months of cardiac resynchronisation  therapy 
 
 
 
The changes in plasma apelin in patients whom SPECT left ventricular end systolic volume (LVESV) < 10% 
at 6 months compared to those with no significant change. 
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In patients that remodelled at 12 months BNP decreased significantly over 12 month follow up 
(Figure 23).  There was also a significant decrease in BNP in those that remodelled at 6 months.  
Apelin did not change significantly in the patients that remodelled at 12 months.  However in 
patients that did not remodel at 6 months there was a significant decrease at 6 months and a 
subsequent trend towards an increase at 12 months (Figure 24).  Similar trends were 
demonstrated using the using the volumetric definition of LV remodelling (Figures 25 & 26) 
 
Apelin increased in 6 patients at 6 months (146pg/ml (+/- 69)), a 62% increase from baseline and 
in 12 patients at 12 months (89 pg/ml (+/-47)), a 21% increase from baseline.  Those with an 
early increase in apelin had a significant greater increase in their LVEF at 6 months and 12 
months (Figure 26) compared with those that did not.  However those with a late increase in 
apelin did not show any difference in the magnitude of their change in LVEF (Figure 27).  There 
was a similar trend using the volumetric definition for LV remodelling (Figures 29 & 30) 
Discussion   
 
Despite significant improvements in LVEF, quality of life and exercise capacity following CRT 
there was no change in the concentration of plasma apelin.  However this study has shown that a 
decrease in apelin concentration is seen in patients that fail to remodel following CRT at six 
months with a subsequent increase at 12 months follow up.  Those individuals who exhibited an 
increase in apelin at 6 months had a greater increase in LVEF compared to individuals in whom 
the apelin was decreased; however those with increases in apelin at 12 months did not show any 
variation in the level of remodelling.  
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Figure 27 Changes in left ventricular ejection fraction associated with apelin increase at 6 months following 
cardiac resynchronisation therapy 
 
 
The change planar radionuclide left ventricular ejection fraction (LVEF) at 6 months and 12 months 
following CRT in patients in whom plasma apelin increased at 6 months 
Figure 28; Changes in left ventricular ejection fraction associated with apelin increase at 12 months following 
cardiac resynchronisation therapy  
 
 
The change in planar radionuclide left ventricular ejection fraction (LVEF) at 6 months and 12 months 
following CRT in patients in whom plasma apelin increased at 12 months 
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Figure 29: Changes in left ventricular end systolic volume  with apelin increase at 6 months following cardiac 
resynchronisation therapy  
 
 
The change SPECT left ventricular end systolic volume (LVESV) at 6 months and 12 months following CRT 
in patients in whom plasma apelin increased at 6 months 
Figure 30: Changes in left ventricular end systolic volume with apelin increase at 12 months following cardiac 
resynchronisation therapy  
 
 
 
The change SPECT left ventricular end systolic volume (LVESV) at 6 months and 12 months following CRT 
in patients in whom plasma apelin increased at 12 months 
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An earlier study of apelin following CRT by Francia et al showed that in 14 patients plasma 
apelin concentrations were unchanged immediately after CRT, but significantly increased over a 
mean follow up of 9 months to concentrations found in normal individuals 
186
.  There are some 
important differences which may explain the variation in the results between this study and that 
of Francia et al.  This study included patients with AF and there were a large number of patients 
with chronic RV pacing.  The effect of chronic RV pacing on the apelin and APJ is unknown.   
In patients with lone AF and no structural heart disease plasma apelin was reduced compared to 
normal individuals 
196
.  Apelin has not been studied in persistent AF, however it would be 
expected to be lower than in patients in sinus rhythm.  In this study there were no differences in 
apelin or the changes in apelin between patients in AF and those with chronic RV pacing.   
 
Although APJ and apelin mRNA are highly expressed in the myocardium, they are also found in 
the vascular endothelium of a number of organs around the body 
144, 145
.  In vivo studies suggest, 
unlike BNP, apelin production is not exclusive to the heart and in heart failure; myocardial apelin 
production is reduced, with the abolition of the step down in apelin concentration form coronary 
sinus to aorta 
291
.  Therefore plasma apelin concentrations may not truly reflect myocardial 
changes in apelin.  Further evidence that myocardial apelin is up regulated following CRT comes 
from a study by Mullens et al who showed that CRT increased the force frequency relationship 
and increased myocardial gene expression in genes involved in contractility, including apelin 
187
.  
Animal models have demonstrated that apelin is secreted in vascular beds in response to hypoxia 
178, 179
.  Therefore peripheral venous concentrations of apelin not only reflect changes in 
myocardial production of apelin, but the response of peripheral vascular beds to a reduced 
cardiac output.  This offers a possible explanation to our finding that individuals, who remodel 
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adversely initially, may have a reduction in myocardial apelin and a subsequent increase in 
peripheral apelin as a result of a decreased cardiac output.  As apelin and APJ are very highly 
expressed in myocardial tissue it is likely that changes in myocardial apelin production will 
impact significantly on the overall concentration.  
The other major difference between this study and that of Francia et al is that in our group, 
medical therapy was up-titrated.  The effect of neurohormonal blockade on apelin is not known, 
however it is well recognized that medical therapy can be up titrated following successful CRT 
292
.  Although this makes it more difficult to interpret the full meaning of our results, we felt it 
would be unethical to fail to titrate medical therapy where possible following CRT.  Despite this 
there was no difference in the level of up-titration between those that remodelled and those that 
did not at 6 and 12 months.  Also there was no difference in the level of medical up-titration 
between those in whom apelin increased or decreased at 6 or 12 months.  
The sample size of this study makes it difficult to perform further analysis into the relationship of 
apelin and the improvement in LV performance following CRT.   
 
The apelin-APJ axis is only one of a possible number of counter-regulatory mechanisms 
involved in the pathogenesis of heart failure.  In the hypertensive animal model, apelin and APJ 
are down regulated only when there is a transition to heart failure.  Following treatment with 
Ang II blockade apelin and APJ mRNA expression was restored.  However other treatment arms 
resulted in an improvement in cardiac function without affecting apelin or APJ expression 
176
.  
This observation would fit with our finding that although individuals that had an early increase in 
apelin showed a significantly greater increase in LVEF, a number of patients still exhibited 
significant LV remodelling without an increase in apelin.    
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Conclusion  
 
This studyhas shown that plasma apelin is not increased at 12 months following CRT despite 
significant favourable LV remodelling. However individuals with an early increase in apelin 
exhibit greater LV remodelling at 6 months and 12 months and patients who fail improve left 
ventricular function following CRT show a significant reduction in plasma apelin at 6 months.  
The apelin-APJ pathway is an endogenous counter regulatory pathway which may be down 
regulated with adverse remodelling making it a potential therapeutic target in advanced HF 
patients.  Targeting the apelin pathway may prevent deterioration or even improve left 
ventricular function in humans with heart failure.  The results of this study suggest that early 
changes in apelin are more important with regards to LV remodelling, however it remains to be 
seen whether apelin is integral to the pathogenesis of heart failure or just an innocent bystander.   
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Chapter 6: A reduction in soluble ST2 is associated with 
greater left Ventricular remodelling following cardiac 
resynchronisation therapy 
 
Abstract 
 
Aims: Soluble interleukin-1 receptor family member ST2 (sST2) has recently been shown to be a 
novel biomarker in heart failure (HF). It antagonises the actions of IL-33, a cardioprotective 
cytokine. It has been shown to be a predictor of mortality in HF and associated with left 
ventricular (LV) remodelling post myocardial infarction.  We sought to investigate the effect of 
cardiac resynchronisation therapy (CRT) on plasma sST2 and the relationship to LV 
remodelling. Methods: 18 patients with an LV ejection fraction (EF) < 35% on radionuclide 
ventriculography (RNV), QRS > 150ms and NYHA class III on maximally tolerated 
pharmacological therapy underwent CRT implantation. Evaluation at baseline, 6 months and 12 
after CRT included a 6 minute walk distance (6MWD), Minnesota living with heart failure 
questionnaires (MLWHF), RNV, plasma B-type natriuretic peptide (BNP) and sST2.  Results: 
6MWD increased 257m (+/-17) to 340m (+/-24) to 364m (+/-23), p<0.0001. MLWHF score 
decreased 49 (+/-4) to 27 (+/-4) to 33 (+/-5), p<0001. LVEF increased from 22 % (+/-1.9) to 
27% (+/-2.6) to 30% (+/-2.9), p<0.009.  Overall sST2 was unchanged.  However the change in 
ST2 correlated with the change in BNP (R=0.62, P<0.006) and negatively with a change in 
LVEF (-0.613, p<0.008). There was a decrease in sST2 in 9 patients at 12 months (-8.8 ng/ml (-
18.2 to -2.5)) and in these individuals there was a greater increase in LVEF and a significant 
reduction in BNP.  Conclusion: For the first time it has been shown that a reduction in sST2 
following CRT is associated with more favourable LV remodelling and a reduction in BNP. This 
suggests a role for sST2 in monitoring response to CRT. 
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Introduction 
 
Soluble ST2 (sST2) is a member of the interleukin-1 family of cytokines.  It acts as a decoy 
receptor for interleukin-33 (IL-33), antagonising its actions on its membrane bound receptor 
ST2.  Interleukin -33 and sST2 are expressed in endothelial cells of the heart and vasculature of 
animals and humans 
267
.  Animal studies have suggested a pathogenic role for IL-33 in left 
ventricular remodelling and atherosclerosis 
267
.  In human myocardial infarction sST2 is 
increased in serum early and high concentrations are an independent predictor of mortality and 
HF 
268
 
269
.  Soluble ST2 is increased in serum of humans with HF and is an independent 
prognostic marker in patients presenting with decompensated HF with preserved and reduced 
LVEF 
270
.  In acute heart failure sST2 correlates with NYHA class, natriuretic peptides, 
creatinine clearance, CRP and with decreasing LVEF 
270
.  In patients with acute decompensated 
HF a decrease in serial sST2 concentrations predicted 90 day mortality independent of natriuretic 
peptides 
271
.  In patients presenting with dyspnoea, serum sST2 correlated with 
echocardiographic abnormalities of right and left ventricular dysfunction and, high serum sST2 
was an independent predictor of mortality in patients with and without HF 
272
.  The serum 
concentrations of sST2 are raised in patients with dilated cardiomyopathy and aortic stenosis 
compared with normal controls, correlating with BNP and left ventricular end diastolic pressure 
273
.  However the production of sST2 is thought to be primarily from the periphery rather than 
the myocardium 
273
.  In humans following myocardial infarction changes in sST2 correlated with 
favourable LV remodelling and baseline sST2 predicted the extent of myocardial scarring and 
microvascular obstruction measured by CMR 
274
.  The early data suggests that sST2 may be a 
useful marker for prognosis in patients with heart failure and monitoring changes may help 
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evaluate response to HF treatment.  The effect of cardiac resynchronisation therapy (CRT) on 
plasma sST2 has not been studied. 
 
Methods 
 
We recruited patients who were eligible under current guidelines for CRT with or without the 
requirement for an internal cardiac defibrillator (ICD).  All patients were referred to our heart 
failure service for consideration of device therapy.  They underwent baseline evaluation which 
included a full clinical history and examination, ECG, transthoracic echocardiography (TTE), 6 
minute walk test (6MWT) and Minnesota living with heart failure questionnaires (MLWHF).  
Laboratory investigations included: full blood count, serum biochemistry and plasma B-type 
natriuretic peptide (BNP).  Patients who had New York heart classification class III symptoms, 
LVEF < 35% and a prolonged QRS width (>150ms) were considered eligible for inclusion.   
Individuals with QRS width 120-149 ms required additional TTE evidence of dyssynchrony as 
defined in the CARE-HF study.  Patients with atrial fibrillation (AF) and chronic right 
ventricular pacing were also included.   Those who fulfilled the current NICE guidance for an 
ICD received a defibrillator as well.  Exclusion criteria included:  Age < 18 years, uncorrected 
congenital heart disease, significant renal dysfunction (creatinine > 300umol/l) and significantly 
elevated liver enzymes (> 3 x normal range).  All patients gave informed consent and the study 
was approved by the local ethics committee.   
Assessment of left ventricular function 
 
Left ventricular function was evaluated by radionuclide ventriculography (RNV) performed by 
operators blinded to the clinical characteristics of the patients at baseline, 6 months and 12 
months following successful CRT.  Planar acquisition was performed with best septal separation 
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view (32 frames, 20% window for R-R interval). SPECT was performed from RAO 45
0
 to LPO 
45
0 
(16 frames, 20% window). The planar data was processed with Hermes (FUGA) and SPECT 
was processed with Cedars Sinai QBS software.  Favourable reverse left ventricular remodelling 
was pre-specified as an increase of > 5 percentage points in left ventricular ejection fraction from 
baseline.  SPECT volumes were available for 17 patients at baseline and 6 months and 16 
patients 12 months.  Therefore the results were analysed using a reduction in left ventricular end 
systolic volume (LVESV) of >10% as a second definition of favourable remodelling.    
Blood sampling 
 
All patients were fasted for at least four hours and were supine at rest for at least 15 minutes 
prior to venepuncture.  Twenty millilitres of blood was collected into chilled E.D.T.A tubes.  The 
samples were centrifuged immediately at 3000 r.p.m for 15 minutes and the supernatant plasma 
was stored in aliquots at -80
0
C until analysis.   
BNP assay 
 
Plasma BNP was measured on the Beckman Access 2 immunoassay analyser using Triage BNP 
Access reagents (Biosite Ltd, Belfast UK).   
C-reactive protein (CRP) assay 
 
High resolution CRP was measured using a Beckman Coulter assay and Beckman DxC600 
analyser (Beckman Coulter Inc., Brea, CA, U.S.A).  The range of detection was 1mg/L-250mg/l 
and the intra and inter assay CVs were 5% and 7.5% respectively.   
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Soluble ST2 assay 
 
Soluble sST2 was measured using a commercially available enzyme linked immunosorbent 
assay (ELISA).  The Critical Diagnostics Presage™ ST2 Assay (Critical Diagnostics, 3030 
Bunker Hill, Suite 115A, San Diego, USA).is a quantitative sandwich monoclonal ELISA in a 96 
well plate format for measurement of ST2 in serum or plasma.  Diluted plasma was used 
according to the manufacturer’s instructions.  Intra-assay coefficient of variation (CV) was 3.4%-
6.5% and inter-assay CV was 5.5%-9.1% for the range of concentrations in this study.   
The measurement of BNP, CRP and sST2 was undertaken by individuals blinded to the patient 
characteristics and clinical data.   
Calculation of Glomerular filtration rate (GFR). 
 
The estimated GFR (eGFR) was calculated using the formula derived from the Modification of 
Diet in Renal Disease study 
293
.   
Details of implantation 
 
All implants were left sided.  Endocardial right atrial and right ventricular leads were implanted 
using standard techniques.  Patients requiring an ICD received a dual coil active defibrillator 
lead.  The coronary sinus (CS) was intubated using standard catheters allowing placement of the 
left ventricular lead in an epicardial vein overlying the lateral LV wall.  The choice of lead and 
device was left to the operator’s discretion and not specified in the protocol. 
Follow up 
 
All patients were followed up at one month and there pacemaker settings were optimized using 
transthoracic echocardiography.  With sinus rhythm the optimal AV interval was set to achieve 
maximal separation of the E and A wave without truncation of the A wave.  Then the delay 
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between right and left ventricular pacing (VV interval) was altered to achieve maximum aortic 
VTI.  In patients with AF only the VV optimization was carried out.  Patients were then 
reviewed at 6 months and 12 months following CRT where the full baseline evaluation was 
repeated.  Every effort was made to optimize their medical therapy further as tolerated.   
Statistical analysis 
 
Normally distributed values are displayed as means with standard errors and variables which 
were not normally distributed are displayed as a median with interquartile range.  Categorical 
variables were compared using 2 or Fisher’s exact test.  Comparison between baseline and 
follow up was using paired t-tests and repeated measures ANOVA with Bonferroni correction.  
Plasma BNP, sST2 and CRP concentrations were highly skewed therefore analysis was carried 
out on log transformed values.  The data was collated and stored using MS Excel and analysed 
with SPSS 13.0.   
Results 
 
Twenty four patients were initially recruited.  One patient declined implantation, and one patient 
was found to have a renal cell carcinoma prior to admission and so did not participate in the 
study.  In three patients it was not possible to implant an LV lead due to unsuitable venous 
anatomy.  Two of these patients received a right ventricular outflow track (RVOT) lead in 
addition to an RV apical lead.  Therefore 21 patients were implanted and available for 6 month 
follow up.  One patient died prior to 12 month follow up and one patient failed to have a repeat 
12 month RNV.  In one patient the CRP and sST2 concentrations were found to be markedly 
elevated at follow up coinciding with the onset of autoimmune thyroiditis.  Therefore he was 
excluded from further analysis making the total cohort of patients 18.   
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Baseline characteristics 
 
The baseline characteristics are detailed in table 17.  At 12 months 10/18 (56%) patients had 
remodelled favourably at 12 months.  Using the volumetric definition 11/16 (61.1%) of patients 
remodelled favourably at 12 months.  Beta-blocker usage at baseline was lower in the group that 
remodelled favourably.  There was a trend towards greater RV apical pacing and higher baseline 
sST2 concentrations in the patients who remodelled favourably.  There was a correlation 
between log sST2 and log BNP (r=0.471, P<0.05) and log CRP (r=0.864, p<0.05) at baseline.  
There was negative correlation between baseline eGFR and log sST2 (r= -0.509, p<0.04) (Figure 
31) 
Follow up 
 
The changes at 6 and 12 months are detailed in Table 18.  There are significant improvements in 
LVEF and RVEF with decreases in left ventricular volumes.  The standard deviation of LV 
phase, which is a marker of intraventricular dyssynchrony reduced significantly.  The 6MWT 
distances improved and the MLWHF score decreased indicating an improvement in the quality 
of life.  The BNP was reduced, but did not reach statistical significance.  Soluble ST2 and CRP 
remained unchanged at 6 and 12 months. 
The change in LVEF, LVESV, LVEDV and change in log BNP correlated with the change in log 
sST2 (Figure 32), however there was no correlation between the change in log CRP or eGFR and 
log sST2.  In 8 patients sST2 decreased from baseline and the median decrease in these patients 
was -8.8 ng/ml (-18.3 to -2.3) compared to a median increase of 5.6 ng/ml (0.37-10) in the 
remainder.  The baseline characteristics of the two groups are detailed in Table 19.  Patients who 
showed a decrease in sST2 had a significantly increased heart rate and a trend towards less beta-
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blocker usage at baseline.  The baseline concentrations of BNP and sST2 were also significantly 
higher in this group of patients whereas CRP, which was also higher, did not reach statistical 
significance.  There was also a trend towards a greater proportion of patients with non-ischaemic 
dilated cardiomyopathy.   
In the group that showed decrease in sST2 there was a greater increase in LVEF (Figure 33) with 
a greater decrease in LVESV (Figure 34) and BNP (Figure 35).  The right ventricular function 
also improved a greater amount in patients who decreased their sST2 concentrations although the 
change was predominantly at 6 months (Figure 36). 
Figure 31: Correlations with baseline soluble ST2  
A                                                                         B 
 
C 
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Legend for Figure 31: The correlation between log soluble ST2 (sST2) and (panel A) log B Type natriuretic 
peptide (BNP), (panel B) estimated glomerular filtration rate (eGFR) and (panel C) log C-reactive protein 
(CRP). 
 
 
Figure 32: Correlations with change in soluble ST2 at 12 months 
A                                                                          B 
 
 
C                                                                          D 
 
 
 
The correlation between the change in log soluble ST2 (sST2) at 12 months and the changes in (panel A) 
planar radionuclide left ventricular ejection fraction (LVEF), (panel B) SPECT left ventricular end diastolic 
volume (LVEDV), (panel C) SPECT left ventricular end systolic volume (LVESV) and (panel D) log type B B-
type natriuretic peptide (BNP) following cardiac resynchronisation therapy.  
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Figure 33: Left ventricular function changes related to a decrease in soluble ST2 at 12 months 
 
 
 
The changes in planar radionuclide left ventricular ejection fraction (LVEF) following cardiac 
resynchronisation therapy in 8 individuals who demonstrated a reduction in soluble ST (sST2) concentrations 
compared to 10 in whom there was no change or increase in sST2.    
Figure 34: Left ventricular end systolic volume changes related to a decrease in soluble ST2 at 12 months 
 
 
The changes in SPECT left ventricular end systolic volume (LVESV) following cardiac resynchronisation 
therapy in 7 individuals who demonstrated a reduction in soluble ST (sST2) concentrations compared to 9 in 
whom there was no change or increase in sST2.  
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Figure 35: B-type natriuretic peptide changes related to a decrease insoluble ST2 at 12 months 
 
 
 
The changes in plasma B-type natriuretic peptide (BNP) following cardiac resynchronisation therapy in 8 
individuals who demonstrated a reduction in soluble ST (sST2) concentrations compared to 10 in whom there 
was no change or increase in sST2 
Figure 36: Right ventricular ejection fraction changes related to a decrease in soluble ST2 at 12 months 
 
 
The changes in planar radionuclide right ventricular ejection fraction (RVEF) following cardiac 
resynchronisation therapy in 8 individuals who demonstrated a reduction in soluble ST (sST2) concentrations 
compared to 9 in whom there was no change or increase in sST2 
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Table 17: Baseline demographics compared in responders vs non-responders after 12 months of cardiac 
resynchronisation therapy 
 Full group  
(n=18) 
 
Remodelled 
(n=10) 
No remodelling 
(n=8) 
p-value 
Age (years) median, (IQR) 
 
74 (54-78) 75 (47-80) 67 (56-75) 0.47 
Male, n (%) 15 (83%) 
 
8 (80%) 7 (87%) 1.0 
BMI mean, (SE) 28 (1.5) 
 
29 (2.2) 27 (1.9) 0.40 
Heart rate (bpm) mean, (SE) 69 (2.6) 
 
72 (3.0) 65 (4.8) 0.20 
Systolic BP (mmHg) mean, 
(SE) 
116 (5.6) 
 
117 (9.1) 115 (6.3) 0.79 
Diastolic BP (mmHg) mean, 
(SE) 
68 (2.8) 
 
69 (3.0) 67 (5.3) 0.70 
Mean BP (mmHg) mean, (SE) 84 (3.4) 
 
85 (4.8) 83 (5.1) 0.70 
Diabetes, n (%) 2 (11%) 
 
1 (10%) 1 (13%) 1.0 
Atrial Fibrillation, n (%) 7 (39%) 
 
5 (50%) 2 (25%) 0.37 
Chronic RV pacing, n (%) 9 (50%) 
 
7 (70%) 2 (25%) 0.15 
QRS width (ms), mean (SE) 185 (4.6) 
 
187 (4.8) 183 (4.3) 0.69 
6MWT (m), mean (SE 
 
251 (13) 247 (19) 256 (18) 0.86 
MLWHF score, mean (SE) 
 
49 (4.0) 51 (5.6) 47 (5.7) 0.53 
Aetiology of heart failure n, (%)  
 
   
IHD 7 (39%) 
 
3 (30%) 4 (50%) 0.63 
DCM 8 (44%) 
 
6 (60%) 2 (25%)  
Valvular 3 (17%) 
 
1 (10%) 2 (25%)  
NIDCM 12 (61%) 
 
7 (70%) 4 (50%) 0.63 
Ventricular function  
 
   
LVEF (%), mean (SE) 22 (1.9) 
 
23 (2.7) 21 (2.5) 0.70 
RVEF (%), mean (SE) 32 (3.6) 
 
28 (4.9) 35 (5.1) 0.45 
LVEDV (ml), mean (SE) 278 (18) 
 
254 (24) 309 (24) 0.23 
LVESV (ml), mean (SE) 208 (17) 
 
186 (24) 237 (23) 0.30 
SD LV Phase (
0
), mean (SE) 
 
85 (5.8) 89 (7.6) 81 (9.3) 0.42 
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IQR =interquartile range, SE=standard error, bpm=beats per minute, RV=right ventricular, 
MLWHF=Minnesota living with heart failure, LVEF=left ventricular ejection fraction, RVEF=right 
ventricular ejection fraction, LVEDV=left ventricular end diastolic volume, LVESV=left ventricular end 
systolic volume, SD LV =standard deviation of left ventricular, , ACE-I =angiotensin converting enzyme 
inhibitor, ARB= angiotensin receptor blocker, CRP =C-reactive protein, C-reactive protein, BNP=B-type 
natriuretic peptide. sST2 =soluble ST2.   
Medications  
 
   
ACE-I / ARB n, (%) 18 (100%) 
 
   
Beta-blockers n, (%) 13 (72%) 
 
5 (50%) 8 (100%) <0.04* 
Aldosterone antagonists n, (%) 14 (78%) 
 
6 (60%) 7 (88%) 0.31 
Loop diuretics n, (%) 14 (78%) 
 
7 (70%) 7 (88%) 0.59 
Digoxin n, (%) 4 (22%) 
 
3 (30%) 1 (13%) 0.58 
Statins n,(%) 
 
8 (44%) 4 (40%) 4 (50%) 1.0 
 
Laboratory investigations  
 
   
Haemoglobin (g/dl) mean (SE) 13.4 (0.4) 
 
13.1 (0.6) 12.9 (0.4) 0.70 
Sodium (mmol/l) mean (SE) 136 (0.9) 
 
137 (1.1) 136 (1.4) 0.63 
Potassium (mmol/l) mean, (SE) 4.2 (0.1) 
 
4.3 (0.2) 4.0 (0.1) 0.12 
Urea (mmol/l) mean (SE) 9.7 (0.9) 
 
9.3 (1.3) 10.2 (1.5) 0.75 
Creatinine (umol/l) mean, (SE) 125 (7.4) 
 
123 (10.1) 127 (10.3) 0.79 
Glomerular filtration rate 
(ml/min/1.73
2
) mean, (SE) 
57 (4.8) 58 (7.5) 55 (5.7) 0.75 
CRP (mg/l) median (IQR) 2.6 (1.9-
12.9) 
 
2.9 (2.1-12.9) 2.3 (1.6-13.2) 0.42 
BNP (pg/ml), median (IQR) 265 (99-
377) 
 
265 (99-481) 251 (93-343) 0.84 
sST2 (ng/ml), median (IQR) 26.5(21-
41.6) 
32 (22.2-42.6) 23.5 (20.8-26.6) 0.19 
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Table 18 Changes at 6 month and 12 months of cardiac resynchronisation therapy 
 
 N Baseline 6 Months 12 months p-value 
 
LVEF (%) 
 
18 22 (1.9) 27 (2.6) 30 (3.0) <0.01 
RVEF (%) 
 
17 31 (3.8) 46 (3.4) 45 (2.8) <0.002 
LVEDV (ml) 
 
16 278 (18) 230 (17) 205 (20) <0.001 
LVESV (ml) 
 
16 208 (17) 164 (17) 146 (9.0) <0.001 
SD LV Phase 
 
18 85 (5.8) 72 (6.5) 60 (6.1) <0.005 
6MWT (m) 
 
15 250 (16) 334 (25) 355 (24) <0.001 
MLWHF 
 
16 50 (3.9) 28 (3.8) 34 (5.4) <0.001 
NYHA class >II 
 
18 18 (100%) 3 (17%) 3 (17%) <0.001 
CRP (mg/l) 
 
18 2.65 (1.9-12.9) 2.35 (1.4-5.9) 3.25 (1.78-6.6) 0.29 
BNP (pg/ml) 
 
18 265 (99-377) 170 (86-269) 187 (69-388) <0.12 
sST2 (ng/ml) 
 
18 26.5 (21.0-41.6) 28.5(23.0-33.8) 26.8 (21.6-35.2) 0.97 
 
Normally distributed values are shown with mean and (standard error) and skewed values shown with 
median and (interquartile range).  The p values are for the trend.  LVEF=left ventricular ejection fraction, 
RVEF=right ventricular ejection fraction, LVEDV=left ventricular end diastolic volume, LVESV=left 
ventricular end systolic volume, SD LV =standard deviation MLWHF=Minnesota living with heart failure, 
CRP =C-reactive protein, BNP=B-typenatriuretic peptide, sST2= soluble ST2. P-values are for the trend. 
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Table 19: Demographics of patients and the relationship to 12 month changes in soluble ST2 
 
 
 No decrease in Decrease in sST2 p-value 
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sST2 (n=10) (n=8) 
Age (years) median, (IQR) 
 
73 (54-82) 64 (45-75) 0.36 
Male, n (%) 
 
9 (90%) 6 (75%) 0.56 
BMI mean, (SE) 
 
28 (1.6) 29 (2.7) 0.68 
Heart rate (bpm) mean, (SE) 
 
64 (3.0) 76 (3.5) <0.03* 
Systolic BP (mmHg) mean, (SE) 
 
122 (4.9) 108 (10.9) 0.25 
Diastolic BP (mmHg) mean, (SE) 
 
68 (4.1) 69 (4.0) 0.85 
Mean BP (mmHg) mean, (SE) 
 
86 (4.2) 82 (5.9) 0.61 
Diabetes, n (%) 
 
2 (20%) 0  0.48 
Atrial Fibrillation, n (%) 
 
3 (30%) 4 (50%) 0.63 
Chronic RV pacing, n (%) 
 
5 (50%) 4 (50%) 0.1 
QRS width (ms), mean (SE) 
 
186 (4.5) 184 (9.1) 0.86 
6MWT (m), mean (SE 
 
234 (13) 272 (23) 0.16 
MLWHF score, mean (SE) 
 
44 (4.8) 56 (6.0) 0.18 
Aetiology of heart failure n, (%)  
 
  
Ischaemic heart disease 
 
6 (60%) 1 (13%) 0.08 
Dilated cardiomyopathy (DCM) 
 
3 (30%) 5 (63%)  
Valvular 
 
1 (10%) 2 (25%)  
Non ischaemic DCM 
 
4 (40%) 7 (87%) 0.08 
Ventricular function  
 
  
LVEF (%), mean (SE) 
 
24 (2.4) 20 (2.9) 0.32 
RVEF (%), mean (SE) 
 
33 (4.4) 29 (6.0) 0.54 
LVEDV (ml), mean (SE) 
 
277 (20) 280 (34) 0.92 
LVESV (ml), mean (SE) 
 
203 (18) 216 (34) 0.73 
SD LV Phase (
0
), mean (SE) 
 
81 (7.9) 91 (6.8) 0.44 
Medications    
ACE-I / ARB n, (%) 
 
   
Beta-blockers n, (%) 
 
9 (90%) 4 (50%) 0.12 
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IQR =interquartile range, SE=standard error, bpm=beats per minute, RV=right ventricular, 
MLWHF=Minnesota living with heart failure, LVEF=left ventricular ejection fraction, RVEF=right 
ventricular ejection fraction, LVEDV=left ventricular end diastolic volume, LVESV=left ventricular end 
systolic volume, SD LV =standard deviation of left ventricular, , ACE-I =angiotensin converting enzyme 
inhibitor, ARB= angiotensin receptor blocker, CRP =C-reactive protein, CRP=C-reactive protein, BNP=B-
type natriuretic peptide. sST2 =soluble ST2.   
Aldosterone antagonists n, (%) 
 
7 (70%) 7 (75%) 1.0 
Loop diuretics n, (%) 
 
8 (80%) 6 (75%) 0.07 
Digoxin n, (%) 
 
1 (10%) 3 (38%) 0.78 
Statins n,(%) 
 
6 (60%) 2 (25%) 0.19 
 
Laboratory investigations    
Haemoglobin (g/dl) mean (SE) 
 
12.8 (0.4) 13.3 (0.6) 0.45 
Sodium (mmol/l) mean (SE) 
 
137 (1.3) 135 (1.0) 0.25 
Potassium (mmol/l) mean, (SE) 
 
4.1 (0.1) 4.2 (0.2) 0.49 
Urea (mmol/l) mean (SE) 
 
10.1 (1.4) 9.2 (1.2) 0.63 
Creatinine (umol/l) mean, (SE) 
 
128 (10.7) 122 (10.5) 0.69 
Glomerular filtration rate 
(ml/min/1.732) mean, (SE) 
 
57 (7.6) 57 (5.6 0.99 
CRP (mg/l) median (IQR) 
 
2.3 (1.8-3.5) 8.4 (2.0-24.7) 0.13 
BNP (pg/ml), median (IQR) 
 
181 (66-209) 354 (257-788) <0.02* 
sST2 (ng/ml), median (IQR) 23.4 (18.8-27.4) 38.7 (25.6-45.0) <0.02* 
 155 
 
There was no significant change in CRP in those individuals where the sST2 was reduced.  
Logistical regression analysis did not reveal any strong predictors of those patients who 
increased their LVEF > 5 percentage points (Table 20).  This was also similar with the 
volumetric definition of favourable LV remodelling.  In particular beta-blocker usage at baseline 
did not predict remodelling despite the differences at baseline.  All efforts were made to up 
titrate medical therapy and there were no significant difference in the up titration of medical 
therapy between those that remodelled and those that did not (Table 21).  Furthermore there was 
also no significant difference in the medical therapy changes in the patients who showed a 
reduction in sST2 (Table 22).   
Table 20: Univariate predictors of favourable left ventricular remodelling (LVEF >5%) at 12 months 
 
Variable 
 
Exp (B) 95%CI Exp (B) P value 
Upgrade of right ventricular pacing 
 
0.143 0.02-1.11 0.07 
Reduction in sST2 at 12 months 
 
4.5 0.6-34.6 0.148 
Reduction in BNP at 12months 
 
3.9 0.5-27.9 0.176 
 
sST2 = Soluble ST2, BNP=B-type natriuretic peptide 
 
Table 22 Medication changes and the relationship to left ventricular remodelling (LVEF >5%) at 12 months 
 
 Whole group 
N=18 
 
Remodelled 
N=10 
No remodelling 
N=8 
P-value 
Increase in ACE-I/ARB 
 
9 (50%) 5 (50%) 4 (50%) 1.00 
Increase or addition of beta-blocker 
 
13 (72%) 7 (70%) 6 (75%) 1.00 
Increase or addition of AA 
 
1 (6%) 1 (10%) 0 1.00 
Decrease in loop diuretic 
 
5 (28%) 2 (20%) 3 (38%) 0.61 
 
ACE-I=Angiotensin-converting enzyme inhibitor, ARB=Angiotensin-Receptor blocker, AA=Aldosterone 
antagonist. 
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Table 22: Medication changes and relation to changes in soluble ST2 at 12 months 
 
 Whole group 
N=18 
 
No change or 
increase in 
sST2 
(N=10) 
Reduction in 
sST2 
(N=8) 
P-value 
Increase in ACE-I/ARB 
 
9 (50%) 4 (40%) 5 (63%) 0.64 
Increase or addition of beta-blocker 
 
13 (72%) 7 (70%) 6 (75%) 1.00 
Increase or addition of AA 
 
1 (6%) 0  1 (12%) 0.44 
Decrease in loop diuretic 
 
5 (28%) 3 (30%) 2 (25%) 1.00 
 
ACE-I=Angiotensin-converting enzyme inhibitor, ARB=Angiotensin-Receptor blocker, AA=Aldosterone 
antagonist 
Discussion 
 
This is the first study to investigate the changes in sST2 following CRT.  This study has shown 
in a group of patients undergoing CRT, despite a significant improvement in biventricular 
function, symptoms and exercise capacity, sST2 was did not change in the overall group.  
However in individuals in whom there was a reduction in sST2 at 12 months there was a greater 
positive effect of CRT on left ventricular performance and a greater reduction in left ventricular 
volumes and BNP.   
As with previous studies this study has shown that baseline sST2 correlates with BNP, CRP and 
lower creatinine clearance 
270, 294
.  Plasma sST2 also correlated negatively with resting LVEF 
and post MI the change in sST2 negatively correlates with left ventricular diastolic volume index 
274, 295
. These associations are consistent with our findings that changes in sST2 also correlate 
negatively with LVEF and positively with a reduction in left ventricular volumes at 12 months 
following CRT.  This study has also shown that the 12 month changes in BNP correlate with 
change in sST2 as seen in acute decompensated HF patients over a shorter follow up period 
271
.   
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The sST2 concentrations in normal population has been characterised using the same assay and 
the references ranges for males and females are 8.6-49.3 ng/ml and 7.2-33.5 ng.ml respectively 
288
.  This compares to our group who had a median concentration of 26.6 ng/ml (21.1-42.0) in 
men and 22.9 ng/ml (19.3-32.2) in women.  In acute heart failure sST2 is markedly raised and in 
a subset of patients a reduction in serial sST2 of > 15.5% confirmed a favourable 90 day 
prognosis; with a mortality of 7% compared to 33% in the remainder 
271
.  In our cohort the 
subset who experienced a reduction in sST2 had a mean decrease of 22% (+/-8) compared to a 
mean increase of 32% (+/-13) in the remainder.  This is most probably as a reflection of the 
greater improvement in left ventricular function in the first group.  In chronic heart failure 
plasma sST >0.15 ng/ml was an independent predictor of sudden cardiac death (OR: 4.56, 95% 
CI: 1.31 to 15.9, p < 0.01) 
275
 and a change in sST2 was an independent predictor of transplant 
free survival, but baseline concentrations were not 
294
.  The assays used in these studies were 
older and a recent evaluation with the high sensitivity assay also used in our study showed that in 
a heart failure population there was a markedly increased hazard ratio of death in the highest 
tertile (>36.3 ng/ml) compared with the lowest tertile (<22.3ng/ml) 
295
.  They also showed that 
independent predictors of raised sST2 were severity of HF symptoms, increasing age, use of 
ACE-I or ARB, use of beta blockers, lower systolic blood pressure, raised creatinine and NT-Pro 
BNP.  In this study the predictive power of sST2 was greater when the aetiology was non-
ischaemic cardiomyopathy.  In our study the group with a reduction in sST2 did show a trend 
towards more patients with NIDCM.   
Interleukin-33 is a cytokine which predominantly exerts its actions on the TH2 subset of T-cells, 
releasing cytokines which promote a humoral immune response and lead to fibrosis and healing.  
Soluble ST2 is a decoy receptor which prevents binding of IL-33 to the membrane bound ST2 
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receptor; however it may also act independently to inhibit the release of proinflammatory 
cytokines from macrophages.  Therefore the IL-33-ST2 pathway may be involved in the 
pathogenesis of left ventricular remodelling.  Following myocardial infarction serum 
concentrations of sST2 are increased and decrease by 24 weeks.  The change in sST2 correlated 
with the change in LVEDV index measured on CMR and the baseline and 24 week 
concentrations of sST2 correlated with the extent of myocardial scar following infarction and 
microvascular obstruction 
274
.  This is consistent with the hypothesis that the IL-33-ST2 pathway 
is activated following myocardial injury and may be involved with interstitial remodelling.  It 
follows that interventions which cause favourable remodelling may reduce factors promoting 
fibrosis.  In an elegant invasive study by Bartunek et al it was shown that the production of sST2 
was mainly from the peripheral vascular endothelium rather than the myocardium and correlated 
with BNP, CRP and left ventricular end diastolic pressure 
273
.  It may well be that sST2 is 
released from endothelium as a result of low cardiac output and tissue hypoxia.  It follows that 
improvement in left ventricular haemodynamics and improvement in cardiac output following 
CRT should lead to a reduction in sST2.  High concentrations of sST2 are independent predictors 
of adverse prognosis, even in patients with preserved systolic function suggesting that it may be 
a part of an early adaptive response in HF.  However although sST2 is a marker for prognosis in 
cardiovascular disease and HF, it is still not known whether it is involved in the pathogenesis or 
a mere bystander 
 
With the small number of patients in this study it is difficult to perform more detailed analysis 
and investigate whether a reduction in sST2 is an independent prognostic marker in patients 
following CRT.  This was predominantly a male group and was also a more elderly population 
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then most of the larger CRT studies.  There were a greater number of patients with AF and 
chronic RV apical pacing.  Medical therapy was up-titrated in a large number of patients and 
although this makes interpretation of the results more difficult it would have been unethical not 
to do so.  Every effort was made to maximise medical therapy prior to CRT and there is evidence 
that one of the benefits of CRT is to facilitate up-titration of evidence based HF therapy 
296
.  The 
effects of targeted HF therapy on sST2 has not been investigated, but it is likely that HF 
pharmacotherapy may also contribute to reducing sST2 levels by reducing afterload and 
improving cardiac performance.  However in our study the level of up-titration of medical 
therapy did not differ significantly in the group that remodelled or those that had a reduction in 
sST2. 
Conclusions 
 
For the first time it has been shown that a reduction of sST2 is associated with a greater 
improvement in LV remodelling and reduction in BNP following CRT.  This study adds to the 
growing evidence that sST2 may be a useful biomarker in patients with HF and may help 
monitor response to CRT.  However larger studies are needed to fully investigate these 
observations and examine whether sST2 can independently predict favourable outcomes in 
patients undergoing CRT. 
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Chapter 7: Cytokine networks following Cardiac 
Resynchronisation therapy 
 
Abstract 
 
Aim:  Heart failure secondary to severe left ventricular dysfunction is known to be associated 
with immune activation.  The effect cardiac resynchronisation therapy on left ventricular 
remodelling and a panel of cytokines and their soluble cytokines was studied.  Methods 18 
patients with an LV ejection fraction (EF) < 35% on radionuclide ventriculography (RNV), QRS 
> 150ms and NYHA class III on maximally tolerated pharmacological therapy underwent CRT 
implantation. Evaluation at baseline, 6 months and 12 after CRT included clinical parameters 
and the cytokines: Interferon (IFN)-γ, Interleukin (IL) -1b, IL-1ra, IL-6, Tumour necrosis factor 
(TNF)-α, soluble TNF receptor (sTNFR)1, sTNFR2, IL-4 and IL-10.  Results: LVEF increased 
from 22 % (+/-1.9) to 27% (+/-2.6) to 30% (+/-2.9), p<0.009.  IFN-γ was reduced 32.7 pg/ml 
(+/-19.8) to 17.3 pg/ml (+/- 8.7) to 19.8 pg/ml (+/-10.6), p<0.03.  IL-10 was reduced 12.8 pg/ml 
(+/-3.2) to 8.8 pg/ml (+/-2.4) to 8.5 pg.ml (+/-2,5), p<0.02.  IL-6 was reduced 50.3 pg/ml (+/-
17.8) to 13.5 pg/ml (+/-13.5) to 16.8 pg/ml (+/-6.4), p<0.034.  In the 10 patients who increased 
their LVEF by > 5 percentage points IL-10 was reduced whereas IFN-γ was reduced 
significantly only in the 8 patients who failed to respond to CRT.  The other cytokines were 
unchanged.  Conclusion:  CRT reduces serum concentrations of IFN-γ, IL-6 and IL-10 and 
favourable left ventricular remodelling may be associated with a reduction in humoral immune 
activation and acute phase response.  This study adds to the growing evidence that modulating 
the immune activation may provide a target for HF therapy 
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Introduction 
 
Immune activation is a well described phenomenon in Heart Failure (HF) secondary to left 
ventricular systolic dysfunction 
213
.  There are numerous studies which have demonstrated that 
serum concentrations of cytokines are elevated in HF and are associated with a worse prognosis 
however, to date immunomodulatory treatments have been largely unsuccessful 
215
 .  Cytokines 
are secreted by a variety of cells including endothelium and immune cells.  They have pleiotropic 
actions and act in networks to orchestrate the recruitment of immune cells to remove injured 
tissue and bring about healing and fibrosis.  T-cells are the required for persistence of an immune 
response and are activated in HF 
247
.  Subsets of T-helper cells can direct the immune response 
towards a cellular (TH1) or more humoral (TH2) response by the array of cytokines they secrete 
249
.  Changes in the balance of TH1 and TH2 cytokines may be involved in the process of 
adverse left ventricular remodelling opening up the role that more targeted immunomodulation 
may have a role in the treatment of HF 
249
. 
Cardiac resynchronisation therapy (CRT) has emerged as a treatment for patients with left 
ventricular systolic dysfunction and dyssynchrony.  It improves morbidity and mortality and 
results in reverse left ventricular remodelling 
44
.  This makes CRT a good in vivo model to study 
immune activation in human left ventricular remodelling.  There have been a number of studies 
which have looked at serum cytokines following CRT; however they have yielded conflicting 
results 
278-281, 283-285
.  Therefore the effect of CRT on cytokines networks is still unclear and 
whether there is a shift in the balance between TH1 and TH2 cytokines is unknown.  We sought 
to investigate the effect CRT on immune activation by measuring a panel of cytokines and their 
soluble receptors.   
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Methods  
 
Consecutive patients who were eligible under current guidelines for CRT with or without the 
requirement for an internal cardiac defibrillator (ICD) were recruited.  All patients were referred 
to our heart failure service for consideration of device therapy.  They underwent baseline 
evaluation which included a full clinical history and examination, ECG, transthoracic 
echocardiography (TTE), 6 minute walk test (6MWT) and Minnesota living with heart failure 
questionnaires (MLWHF).  Laboratory investigations included: full blood count, serum 
biochemistry and plasma B-type natriuretic peptide (BNP).  Patients who had New York heart 
classification class III symptoms, LVEF < 35% and a prolonged QRS width (>150ms) were 
considered eligible for inclusion.   Individuals with QRS width 120-149 ms required additional 
TTE evidence of dyssynchrony as defined in the CARE-HF study.  Patients with atrial 
fibrillation (AF) and chronic right ventricular pacing were also included.  Those who fulfilled the 
current NICE guidance for an ICD received a defibrillator as well.  Exclusion criteria included:  
Age < 18 years, uncorrected congenital heart disease, significant renal dysfunction (creatinine > 
300umol/l) and significantly elevated liver enzymes (> 3 x normal range).  All patients gave 
informed consent and the study was approved by the local ethics committee.   
Assessment of left ventricular function 
 
Left ventricular function was evaluated by radionuclide ventriculography (RNV) performed by 
operators blinded to the clinical characteristics of the patients at baseline, 6 months and 12 
months following successful CRT.  Planar acquisition was performed with best septal separation 
view (32 frames, 20% window for R-R interval). SPECT was performed from RAO 45
0
 to LPO 
45
0 
(16 frames, 20% window). The planar data was processed with Hermes (FUGA) and SPECT 
was processed with Cedars Sinai QBS software.  Favourable reverse left ventricular remodelling 
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was pre-specified as an increase of > 5 percentage points in left ventricular ejection fraction from 
baseline.  
Blood sampling 
 
All patients were fasted for at least four hours and were supine at rest for at least 15 minutes 
prior to venepuncture.  Twenty millilitres of blood was collected into chilled E.D.T.A tubes.  The 
samples were centrifuged immediately at 3000 r.p.m for 15 minutes and the supernatant plasma 
was stored in aliquots at -80
0
C until analysis.   
BNP assay 
 
Plasma BNP was measured on the Beckman Access 2 immunoassay analyser using Triage BNP 
Access reagents (Biosite Ltd, Belfast UK).  
Cytokine assay 
 
The panel of cytokines was measured using a commercially available enzyme linked 
Multiplex
TM
 MAP panel immunoassay (Millipore Corporation, Billercia, M.A, U.S.A) and read 
using a Luminex 100 reader (Luminex Corp, Austin, Texas, U.S.A).  The intra assay and inter 
assay coefficients of variation are typically <7.2% and <10.7 % respectively.  We chose to look 
at IFN-γ, IL-1b, IL-1ra, IL-6, TNF-α, sTNFR1, sTNFR2, IL-4 and IL-10.   
C-reactive protein (CRP) assay 
 
High resolution CRP was measured using a Beckman Coulter assay and Beckman DxC600 
analyser (Beckman Coulter Inc., Brea, CA, U.S.A).  The range of detection was 1 mg/L-250 mg/l 
and the intra and inter assay CVs were 5% and 7.5% respectively 
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Details of implantation 
 
All implants were left sided.  Endocardial right atrial and right ventricular leads were implanted 
using standard techniques.  Patients requiring an ICD received a dual coil active defibrillator 
lead.  The coronary sinus (CS) was intubated using standard catheters allowing placement of the 
left ventricular lead in an epicardial vein overlying the lateral LV wall.  The choice of lead and 
device was left to the operator’s discretion and not specified in the protocol. 
Follow up 
 
All patients were followed up at one month and their pacemaker settings were optimized using 
transthoracic echocardiography.  With sinus rhythm the optimal AV interval was set to achieve 
maximal separation of the E and A wave without truncation of the A wave.  Then the delay 
between right and left ventricular pacing (VV interval) was altered to achieve maximum aortic 
VTI.  In patients with AF only the VV optimization was carried out.  Patients were then 
reviewed at 6 months and 12 months following CRT where the full baseline evaluation was 
repeated.  Every effort was made to optimize their medical therapy further as tolerated.   
Statistical analysis 
 
Normally distributed values are displayed as means with standard errors and variables which 
were not normally distributed are displayed as a median with interquartile range.  Categorical 
variables were compared using 2 or Fisher’s exact test.  Comparison between baseline and 
follow up was using paired t-tests and repeated measures ANOVA with Bonferroni correction.  
Plasma BNP, Cytokines and CRP concentrations were highly skewed therefore analysis was 
carried out using the Freidman’s test and Wilcoxon Sign ranked test.  For correlations the data 
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was log transformed.  The data was collated and stored using MS Excel and analysed with SPSS 
13.0.   
Results  
 
Baseline characteristics 
 
The baseline characteristics are detailed in table 17 (Chapter 6).  At 12 months 10/18 (56%) 
patients had remodelled favourably.  Beta-blocker usage at baseline was lower in the group that 
remodelled favourably.  There was a trend towards greater RV apical pacing in the patients who 
remodelled favourably as well as a trend towards lower IL-1ra and a higher IL-1b / IL-1ra ratio 
(Table 23 and Table 24).  There was no significant difference in the concentrations of other 
cytokines.  As would be expected the baseline concentration of a number of cytokines and their 
soluble receptors correlated with each other (Table 25)  However there was no correlation 
between cytokines and any baseline clinical parameters including BNP and left ventricular 
function. 
Follow up 
 
The changes in clinical parameters at 6 and 12 months are detailed in Table 18 (Chapter 6).  
There are significant improvements in LVEF and RVEF with decreases in left ventricular 
volumes.  The standard deviation of LV phase, which is a marker of intraventricular 
dyssynchrony reduced significantly.  The 6MWT distances improved and the MLWHF score 
decreased indicating an improvement in the quality of life.  The BNP was reduced, but did not 
reach statistical significance.  The changes in a number of cytokines correlated with each other 
(Table 26).  However only the change in IL-1b and TNF-α showed a moderate negative 
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correlation with LVEF. In the overall group IFN-γ, IL-10 and IL-6 were reduced significantly at 
12 months following CRT.  Interleukin-6 and IL-10 were also reduced at 6 months (Figure 37).  
Tumour necrosis factor-alpha showed a trend towards a reduction, but was not significant 
(Figure 38).  The rest of the cytokines remained unchanged (Figure 38).  C-reactive protein 
remained unchanged throughout the whole group and also in responders.  When comparing non-
responders to responders there were significant reductions in the concentrations of IFN-γ in non-
responders, and in responders there was a significant reduction in IL-10 (Figure 39).  With IL-6 
there was a trend towards a reduction in responders only (Figure 39). 
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Figure 37: Reduction in cytokines following Cardiac resynchronisation therapy. 
 
       A       B 
 
      C 
 
 
The changes in serum concentrations of Interferon-gamma (panel A), Interleukin-10 (Panel B) and 
Interleukin-6 (Panel C), following 12 months of cardiac resynchronisation therapy.  Points represent mean +/- 
SE 
 
Legend for Figure 38:  The changes in serum cytokines following 12 months of cardiac synchronisation 
therapy are shown: Interleukin-1b (Panel A), Interleukin-1ra (Panel B), Tumour necrosis factor –alpha 
(Panel C), soluble Tumour necrosis factor receptor 1(Panel D) and 2 (Panel E), Interleukin-4 (Panel F). Points 
represent mean +/- SE  
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Figure 38: Changes in cytokines following Cardiac resynchronisation therapy 
 
 
 
 
A B 
C D 
E F 
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Figure 39: Differences in the changes in cytokines between responders vs non-responders following 12 months 
of cardiac resynchronisation therapy  
 
A      B 
 
C 
 
 
Interferon –Gamma, (Panel A), Interleukin-10 (Panel B) and Interleukin-6 (Panel C) in responders and non-
responders to Cardiac resynchronisation therapy at 12 months.  Points represent mean +/- SE 
 
 
 
 
 170 
 
Table 23: Baseline concentrations of serum cytokines 
 
Table 24: Baseline ratios of cytokines and soluble receptors 
 
 
Cytokine concentration 
(pg/ml) 
Full group 
(n=18) 
 
Remodelled 
(n=10) 
No remodelling 
(n=8) 
p-
value 
Interferon-γ  
 
32.6(19.5) 51.4 (34.4) 9.25 (4.9) 0.53 
Interleukin-1b 
 
32.2 (22.3) 46.8 (40.0) 14.0 (6.8) 0.91 
Interleukin-1ra 
 
63.9 (26.9) 29.9 (9.2) 111.5 (56.8) 0.06 
Interleukin-6 
 
50.3 (17.8) 66.8 (29.8) 37.2 (16.1) 0.97 
Tumour necrosis factor (TNF)–α 
 
30.9 (13.5) 42.4 (24.0) 16.6 (2.6) 0.65 
Soluble TNF receptor 1 
 
2295 (367) 7760 (1680) 2159 (352) 0.94 
Soluble TNF receptor 2 
 
8837 (1205) 2404 (613) 10182 (1713) 0.28 
Interleukin-4 
 
123.9 (94.7) 46.1 (31.2) 221.1 (212) 0.94 
Interleukin-10 
 
12.8 (3.1) 10.2 (2.9) 16.0 (6.2) 0.52 
Cytokine ratios Full group  
(n=18) 
 
Remodelled  
(n=10) 
No remodelling 
(n=8) 
p-
value 
IFN-γ / IL-4 
 
7.0 (5.8) 11.7 (10.5) 1.0 (0.25) 0.83 
IFN-γ / IL-10 
 
2.2 (1.0) 3.3 (1.7) 0.86 (0.23) 0.52 
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Interferon-gamma =IFN-γ, Interleukin=IL, Receptor antagonist =ra, Tumour necrosis factor –α=TNF, 
Soluble TNF receptor =sTNFR 
 
 
 
IL-1b / IL-1ra 
 
1.6 (1.4) 2.7 (2.5) 0.15 (0.03) 0.051 
TNF-α / IL-4 
 
4.0 (1.3) 4.7 (2.3) 3.2 (0.75) 0.72 
TNF-α / IL-10 
 
2.6 (0.45) 3.1 (0.70) 2.1 (0.51) 0.36 
TNF-α / sTNFR1 
 
0.080 (0.006) 0.02 (0.01) 0.008 (0.0009) 1.0 
TNF-α / sTNFR2 
 
0.0039 (0.014) 0.0082 (0.0008) 0.0018 (0.0003) 0.32 
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Table 25: Baseline correlations 
 
 
 
* P<0.05, **p<0.01 
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Table 26: Correlations of changes in cytokines 
 
 
* P<0.05, **p<0.01 
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Discussion: 
 
This study has shown that following CRT, serum IFN-γ, IL-10 and IL-6 are reduced while there 
is a trend towards a reduction in TNF-α.  In responders at 12 months the reduction in IL-10 is 
significant, whereas there is a trend towards reduction with IL-6.  Interferon -γ, was only 
significantly reduced in non-responders.  The ratios of cytokines to their receptors was not 
changed in the whole group or in responders compared with non-responders.  Nor was there any 
significant difference between the ratios of TH1 vs. TH2 type cytokines. 
 
Previous studies looking at peripheral cytokines following CRT have shown conflicting results.  
Six studies have looked at serum TNF-α in 8-120 patients, following CRT.  In 28 patients TNF-α 
was reduced after 48 hours of biventricular pacing compared to chronic RV pacing.  This was the 
case in patients who increased their cardiac output (calculated by TTE) by > 10% and in 
individuals who failed to do so 
280
.  In 20 patients TNF-α, sTNFR1 and sTNFR2 were reduced 
after 3 months of CRT and remained reduced even after subsequent 3 months of RVA pacing.  
These results would suggest that some the anti-inflammatory effects of CRT are maintained even 
after the cessation of biventricular pacing for at least 3 months.  However in a study of 100 
patients receiving CRT there was no change in TNF-α after 12 months compared to 20 eligible 
patients who refused treatment.  There was also no difference between responders and non-
responders to CRT 
284
.  In three smaller studies there was no change in TNF-α or sTNFR1 and 
sTNFR2 after 3-12 months of CRT 
278, 283, 285
. 
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Six studies which have looked at IL-6 following CRT and show similar conflicting results.  In 4 
studies IL-6 was reduced, especially in the group that had a favourable clinical outcome 
278-281
 
whereas in the other two IL-6 was unchanged 
283, 285
.   
 
In one study IL- β and IL-10 was not changed in 8 patients receiving CRT after 6 months 278.  To 
our knowledge there have been no studies looking at IFN-γ, IL-4 or IL-1ra in patients following 
CRT.  Therefore this study represents an interesting addition to the evolving data on the changes 
immune activation following CRT.  The actions of cytokines are pleiotropic and counteracted by 
their soluble receptors.  Therefore this study is novel in choosing to look at a larger array of 
cytokines in conjunction with their soluble receptors.  In this study there was trend towards a 
reduction in TNF-α over 12 months, but there was no change in TNF receptors.  There was a 
reduction in IL-6 as shown before, but this study has shown for the first time that IL-10 and IFN-
γ are reduced following CRT.   
 
Interleukin-1, TNF-α and IL-6 are important activators of the acute phase response in humans 
and as such are part of the initial reaction to tissue injury.  Increased serum concentrations of 
TNF-α and IL-6 are associated with a poor prognosis in heart failure 297.  Interleukin-6 is one of 
the most important mediators of the acute phase response and stimulates complement production, 
hepatic CRP release as well as cellular and humoral T-cell responses.  The reduction of this 
cytokine following CRT is suggestive that there is an anti-inflammatory effect of CRT.  In 
responders this trend persisted, but did not reach statistical significance.   
Interleukin-10 is an important cytokine secreted by TH2 and is involved in stimulating healing 
and fibrosis.  It also counteracts the production of TNF-α and enhances the actions of TNFR1 
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and TNFR2.  In HF patients, plasma IL-10 and IL-6 were elevated compared to normal controls 
and correlated with higher filling pressures 
256
.  In patients with a dilated cardiomyopathy 
(DCM), IL-10 was lower than in those with ischaemic aetiology 
256
.  In our study there was no 
difference in the concentrations of cytokines between IHD and those with non-ischaemic DCM 
and an improvement in filling pressures as a result of CRT would explain the reductions in IL-10 
and IL-6.  However IL-10 has also been shown to be protective in viral myocarditis in rats and 
ameliorate post infarct left ventricular remodelling 
298, 299
.  In humans with HF, high TNF-α and 
low IL-10 were associated with depressive symptoms and serum IL-10 is reduced with 
increasing NHYA class 
257, 259
.  After one year follow up high BNP (>280 pg/ml) and low IL-10 
(<5mg/ml) was associated with worse survival at 1 year 
260
.  Interleukin-10 is activated in HF 
initially to counteract the harmful effects of pro-inflammatory cytokines and although it may 
protect the myocardium initially, prolonged TH2 activation may be detrimental in the long term.  
In humans IL-10 reduces the production of TNF-α from stimulated peripheral monocytes 254.  
There is evidence in animal models that reduced IL-10 in relation to TNF-α correlates to 
depressed cardiac function post MI 
300
.  It has also been shown that IL-10 counteracts the 
increase in oxidative stress caused by TNF-α on cardiac myocytes in rats 255.  However this 
effect is only demonstrated when the ratio is 1 and higher or lower concentrations of IL-10 may 
be detrimental in left ventricular remodelling 
300
.  The current study did not demonstrate any 
changes in the ratio of TNF-α/IL-10, even in responders.  One explanation of this finding is that 
favourable left ventricular remodelling reduces shear stress leading to decreased local IL-10 
production and improves cardiac output leading to decreased tissue hypoxia and subsequent 
peripheral IL-10 production; thereby resetting the balance of pro-inflammatory and anti-
inflammatory cytokines. 
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Interferon-γ is the main cytokine secreted by TH1 cells and has not been investigated following 
CRT.  This study shows that overall IFN-γ is reduced, but this is mainly in the non-responders to 
CRT suggesting that there is a relative persistence of a TH1 response in patients that remodel 
favourably.  It has been suggested that in animal models of left ventricular remodelling and 
cardiac fibrosis that there is an early TH1 response followed by a TH2 response in the later 
stages 
249
.  This study suggests that CRT restores the balance of T-cell immune responses 
towards favourable left ventricular remodelling.  Although peripheral cytokine concentrations 
may not accurately reflect immune activation at tissue level, it has been shown that CRT reduces 
myocardial TNF-α, markers of cellular apoptosis and collagen volume fraction 118. 
 
There are a number of limitations in this study.  Small numbers of patients and wide variations in 
the cytokine concentrations make it difficult interpret the data in a wider context.  This study 
lacked a control group and a large number of patients with chronic RVA pacing and AF were 
recruited.  However the sample size was similar and in some cases larger than many of the 
published cohort studies looking at cytokines following CRT.  The current study also looked at a 
larger number of cytokines and their receptors but small sample size precluded meaningful 
regression analysis to look for predictors of response.   
 
Medical therapy was up-titrated and as previously shown there was greater remodelling in 
patients that were intolerant of a beta-blocker prior to CRT.  However it is well recognised that 
CRT enables further up-titration of medical treatment following CRT and it would have been 
unethical not to do so 
296
.  It has also been shown that beta-blockers can modulate cytokines 
concentrations.  In one study beta-blockers reduced TNFR1, TNFR2 and IL-10 in patients with 
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HF 
301
, however a more recent study showed that carvedilol increased IL-10 and decreased IL-18 
concentrations in all patients regardless of whether they remodelled favourably 
302
.  
Conclusions 
 
This study has shown that CRT reduces serum concentrations of IFN-γ, IL-6 and IL-10 and that 
favourable left ventricular remodelling may be associated with a reduction in humoral immune 
activation and acute phase response.  This study adds to the growing evidence that modulating 
the immune activation may provide a target for HF therapy.   
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Chapter 8: Discussion 
 
Summary of findings 
 
This study has shown that in a population of advanced heart failure patients, many of whom were 
in atrial fibrillation and had upgrades of chronic right ventricular apical (RVA) pacing, CRT 
results in significant left ventricular remodelling over a period of 12 months in over 50% of 
individuals.  This small cohort represents an unselected population of HF patients who differ 
from the randomised controlled trials which recruited younger patients who were in sinus rhythm 
and mostly did not include upgrades of chronic RVA pacing.   
 
The original intention was to recruit a much larger sample size so that regression analyses could 
be performed to investigate independent predictors of favourable LV remodelling.  The small 
sample size that was eventually recruited did not allow this.  I also chose to include two patients 
who had a right ventricular outflow tract (RVOT) lead when it was not possible to place an 
epicardial LV lead.  Lead placement was left to the operator’s discretion and multisite pacing 
from RVA and RVOT can be haemodynamically beneficial 
303
, therefore in an intention to treat 
analysis I felt that it was justified to include these patients, both of whom remodelled favourably 
with multisite pacing. 
 
In this study medical therapy was uptitrated in order to maximise the benefits of evidence based 
therapy in all patients.  This would certainly have a bearing on the LV remodelling observed.  In 
particular the low use of beta-blockers at baseline in the group that remodelled favourably would 
support this fact.  It is well known that beta blockers can lead to favourable LV remodelling 
304
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and in our clinic every effort was made to optimise beta-blocker usage prior to device insertion 
or upgrade.  It has already been demonstrated that beta blockers can be increased or initiated 
after CRT 
296
 and data from a larger cohort of patients from our heart failure pacing clinic also 
showed that before CRT implantation, beta blockers were used not at all or at suboptimal doses 
in 85% and at optimal doses only in 15% of patients.  Following CRT, beta blocker usage was 
increased to 66% and 34% in the respective groups (p<0.003) (Guha et al, personal 
correspondence).  
 
This study has shown that for the first time that apelin is produced in the heart and that in HF 
myocardial production of apelin is reduced compared to controls without HF 
291
.  Unlike BNP 
which is exclusively produced in the heart apelin is also produced in the peripheral circulation.  
This data would add to the current hypothesis that apelin acts to counter the harmful effects of 
angiotensin-II at a local and systemic level.  A down regulation of apelin secretion may lead to a 
deterioration of left ventricular function and be a harbinger of symptomatic decline and 
decompensation in HF patients.  Since this study others have also demonstrated that differences 
in myocardial concentration gradients of apelin may be a more accurate method of evaluating the 
role of the apelin –APJ system in normal and disease states.  In patients with aortic stenosis and 
HF myocardial apelin secretion was increased compared to patients with aortic stenosis and no 
heart failure in whom there was no difference between aorta and coronary sinus (CS) 
305
.  This 
suggests that in chronic pressure overload myocardial apelin production is increased initially 
with the onset of HF.  The patient group in this study is different to our own; although they had 
an increased wedge pressure their ventricular function measured by echocardiography was 
preserved.  Our HF cohort patients had systolic dysfunction so represent a later stage in the 
 181 
 
pathogenesis of adverse left ventricular remodelling and include patients with ischaemic heart 
disease and dilated cardiomyopathy.  However in similar group of controls, aortic apelin was 
higher than CS, which is the opposite finding to our study 
305
.  Both groups of controls were 
patients with normal LV function undergoing elective electrophysiological procedures, but in our 
group only one patient was on any vasoactive medication.  In the study by Helske et al 50% were 
either on beta-blockers or angiotensin converting enzyme inhibitors/angiotensin receptor 
blockers 
305
.  It is still unclear what the effects of neurohormonal blockade are on the apelin-APJ 
pathway in humans and medication use could explain the difference in the results between the 
two studies.  In a Dahl salt sensitive hypertensive rats with end stage HF, treatment with 
Olmesartan prevented the down regulation of apelin and APJ mediated by the Akt/ endothelial 
nitric acid synthase pathway, suggesting that some of the beneficial effects of angiotensin 
receptor blockers in HF may be mediated by the apelin-APJ system 
306
.    
 
This study has shown that following CRT early changes in apelin are related to left ventricular 
remodelling.  In those who failed to remodel following CRT apelin was significantly reduced at 
6 months and rose again at 12 months.  In patients who increased their apelin at 6 months left 
ventricular function improved considerably, but in those with an apelin rise at 12 months there 
was no significant difference in the change in LVEF.  The changes in apelin were opposite to 
BNP.  Our study is only the second to look at plasma apelin following CRT.  Unlike the smaller 
study by Francia et al. our study failed to show an increase in apelin in the whole group or in the 
individuals that remodelled favourably 
186
.  The main difference between the two studies is that, 
in our study medical therapy was uptitrated.  Although there were no significant changes in the 
level of uptitration therapy between the two groups, beta-blocker usage was lower at baseline in 
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the group that remodelled favourably.  It is known that medical therapy can be up titrated 
following CRT and adds to the overall benefit 
296
; therefore it was felt to be unethical not to do 
so.  This current study also lacked a control group and included patients in AF and a high 
proportion of patients who were upgraded from chronic RV pacing; differences which may also 
explain the variance in results between the our study and that of Francia et al.  As demonstrated 
in a previous study peripheral apelin may not reflect local production of apelin at a myocardial 
level.  Following CRT myocardial apelin genes are upregulated along with other genes which are 
involved in the contractile apparatus 
187
.  Also in patients with successful remodelling following 
left ventricular assist devices myocardial apelin and APJ are upregulated 
184
.  However a recent 
study in humans with atherosclerosis and dilated cardiomyopathy found that myocardial apelin 
mRNA was unchanged compared to controls in the LV, whereas APJ mRNA was reduced 
307
.  
Apelin was however upregulated in coronary arteries of patients with atherosclerosis localising 
to plaques and associated with markers of macrophage and smooth muscle infiltration 
307
.  In 
humans without HF exogenous apelin increases cardiac output, causes peripheral and coronary 
vasodilatation and reduces preload along with afterload 
308
.  These positive haemodynamics 
effects of apelin are still present in patients with chronic HF, suggesting a possible role for apelin 
in HF therapy 
308
.   
 
There is a wide variability in the concentrations of apelin measured in the plasma of normal 
humans (20-4000pg/ml) and current immunoassays cannot quantify the individual apelin 
isoforms as they rely on the use of antibodies directed against the common C-terminal of each 
peptide fragment.  A new method using a combination of liquid chromatography and mass 
spectrometry failed to detect the expected apelin-12, apelin-13, pyroglutamyl apelin-13, apelin -
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17 or apelin -36 in ten healthy individuals where standard assays measured apelin concentrations 
of 208 -466 pg/ml 
309
.  This may explain some of the variation in the studies of apelin in humans, 
although further work is needed to investigate which isoforms of apelin are physiologically 
important in vivo in healthy individuals and in disease states.   
 
Apelin and APJ are widely distributed in the human body and in this study the central action of 
apelin have not been investigated.  Apelin is expressed in the hypothalamus and animal studies 
have suggested initially that apelin is involved in fluid homeostasis 
141, 165
.  However more recent 
data has shown that in spontaneously hypertensive rats (SHR), apelin expression is increased in 
the rostral ventrolateral medulla (RVLM) compared with normotensive rats 
310
.  Gene transfer of 
apelin genes, using a viral vector into the RVLM of normotensive rats resulted in apelin 
overexpression and consequent chronic hypertension and cardiac hypertrophy.   
 
This is the first study looking at the effect of CRT on sST2 and has shown that there is a negative 
correlation between changes in soluble ST2 correlates and changes in LVEF following CRT.  
Although sST2 was unchanged throughout the whole group; individuals in whom sST2 was 
reduced exhibited a greater rise LVEF following CRT.  Changes in CRT correlated with changes 
in BNP and a reduction in ST2 has been shown to be associated with a favourable prognosis in 
patients with decompensated HF 
271
.  This patient group were predominantly NYHA class III and 
not acutely decompensated and as such their ST2 concentration were not much higher the normal 
reference ranges.  Despite this there is a significant increase in LVEF in those patients whose 
sST2 concentration was reduced at 12 months.  A larger study is needed to show whether sST2 
can predict a favourable response to CRT.   
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This study has shown that IFN-γ, IL-10 and IL-6 are reduced 12 months following CRT.  In 
those that remodelled favourably IL-10 was significantly reduced, whereas there was trend 
towards a reduction in IL-6.  IFN-γ was reduced significantly only in those that failed to improve 
their LVEF at 12 months.  There was no change in a wide array of other cytokines including IL-
1b, IL-1ra, TNF-α, TNFR1, TNFR2 and IL-4.  This study was the first to look at this particular 
combination of cytokines and soluble receptors.  The findings of this study suggest that there is a 
reduction in both humoral immune activation and acute phase response following CRT.  The 
changes in IL-10 and IFN-γ, may represent a shift in the balance between a TH1 and TH2 
activation in heart failure, however further studies are needed to confirm this finding.  Our 
results would suggest that favourable left ventricular remodelling is associated with a relative 
decrease in TH2 activation.  Other studies have suggested that TH2 activation is protective in 
heart failure by directing the immune response towards healing and fibrosis.  In contrast a TH1 
pattern of activation results in a cellular response and is thought to be detrimental in HF 
246
.  
However this simple dichotomy of T-cell responses has to be re-evaluated with the advent of 
new data which demonstrates a variety of different T-helper cell subsets with evidence of 
plasticity between them dependent on the cytokine milieu 
249
.  Animal models of LV remodelling 
and fibrosis have suggested that there is an early TH1 response with a shift to a TH2 response 
later to allow fibrosis and healing 
249
.  Our results would suggest that at the later stages of 
adverse LV remodelling that prolonged TH2 activation may be detrimental and a positive effect 
of CRT is to shift the balance back towards a TH1 pattern.   
The small cohort of patients precludes any meaningful regression analysis and so our results are 
mainly useful in generating hypotheses for future, larger studies.  The effect of medical therapy 
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on cytokine activation is also not fully known.  Peripheral cytokines concentrations may not 
accurately reflect T-Cell responses at a myocardial level and so our results may also be due to 
changes in cytokines produced in the periphery, secondary to changes in cardiac output and a 
relief of systemic congestion.   
Future work 
 
The effect of medical therapy on apelin-APJ system in healthy individuals and in heart failure 
needs to be investigated further. It is likely that inhibition of the renin-angiotensin-aldosterone or 
the sympathetic nervous system will have some effect on apelin concentrations.  Ideally the 
concentration gradients between coronary sinus, aorta and renal vein should be investigated, but 
it would prove challenging to obtain ethics for such invasive investigation, especially in healthy 
volunteers.  A larger study of apelin concentrations following CRT would also help to determine 
whether it is a useful biomarker in LV remodelling.  These studies would only prove useful if 
there is a consensus on which apelin peptides are biologically active in humans and which 
technique is the best to measure them.  Synthetic analogues of apelin-13 and apelin-36 are 
available and studies using them in the treatment of acute HF are required to show whether they 
can provide benefit where other inotropic agents have failed to do so.   
 
A larger study looking at a number of cytokines including sST2 in CRT may help show whether 
any are useful biomarkers in patients who respond favourably to CRT.  A larger study would 
allow multivariate regression analyses to determine independent predictors of response compared 
known clinical and biochemical variables.  Even with a smaller cohort, analysis of peripheral 
blood mononuclear cells using flow cytometery may help determine whether CRT leads to a 
change in the subsets of circulating T-cells more accurately than measuring serum cytokines. 
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Appendix 
 
Appendix 1:  Cytokine Coefficients of Variation 
 
Cytokine Normal serum 
concentration (pg/ml) in 
humans (Median n=40) 
Mean intra-assay 
CV% (4 labs) 
Mean inter-assay 
CV% (6 labs) 
Interferon-gamma 1.73 6.05 5.72 
Interleukin-1b 2.35 6.39 7.87 
Interleukin-1ra 11.25 6.30 13.28 
Interleukin-4 7.56 6.85 10.64 
Interleukin-6 1.14 6.87 8.47 
Interleukin-10 1.71 5.14 17.39 
Tumour necrosis 
factor-alpha 
3.10 11.08 15.53 
 
Milliplex 
TM
 MAP panel immunoassay (Millipore, corporation, Billercia, MA, U.S.A).  Table 
showing normal (median value) and intra and inter assay coefficients of variation (CV).   
 
Appendix 2:  CRT optimisation protocol 
 
Set pacemaker to pace at 70 beats per minute 
 
1.Baseline 
Parameter Done (Tick) Measurement 
LVOT (cm)   
 
PW Doppler 
Mitral inflow   
LVOT   
RVOT   
CW Doppler MR duration   
 
Pulse wave TDI  
LV septum   
LV lateral wall   
LV post wall   
RV free wall   
 
2.AV optimisation 
 
AV delay (ms) 60 80 100 120 140 160 180 200 
Mitral VTI cm2         
 
Select AV delay that results in the maximum E/A separation and record for subsequent analysis. 
 
3.VV optimisation 
VV delay  (ms) 0 LV+ 20 LV+40 LV+60 LV+80 RV+20 RV +40 RV+60 
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Select optimal VV delay (greater than 10% difference from sequential pacing) 
 
4.Post optimisation 
 
Repeat baseline measurements 
 
Parameter Done (Tick) Measurement 
 
PW Doppler 
Mitral inflow   
LVOT   
RVOT   
CW Doppler MR duration   
 
Pulse wave TDI  
LV septum   
LV lateral wall   
LV post wall   
RV free wall   
 
 
Breakdown of contributions to this project 
 
I was involved with the planning of the project with the help of my supervisor.  I designed the 
project protocol and submitted the ethics application and amendments.  I helped to run the heart 
failure –pacing clinic and designed the protocol for device optimisation.  I recruited the patients 
from this clinic and organised their investigations and obtained their blood samples.  I 
coordinated their follow up and booked all their investigations.  I also inserted a number of the 
devices under the supervision of Dr Rakesh Sharma.  I stored all the blood samples and collected 
the results in a database which I designed.  I also did the majority of the echo optimisation in the 
clinic.  I analysed the results with the helpful advice of the trust statistician.   
 
Apelin, BNP, CRP and cytokines quantification was carried out by Jackie Donovan and Dr 
James Hooper from the biochemistry department. 
 
LVOT VTI cm2         
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The planar and SPECT RNV measurement of left and right ventricular function were carried out 
by Dr Jim Stirrup, Dr K Wechalekar.  
 
Soluble ST2 was measured by Dr James Snider from Critical Diagnostics in San Francisco, 
U.S.A. 
 
The invasive measurements in coronary sinus, aorta and renal vein were carried out by Dr 
Jonathon Clague and Dr Paul Kalra as part of a previous project and the stored samples were 
kindly donated to me for my project.  I was responsible for sorting these samples, collating the 
clinical data and the subsequent analysis.   
Sources of funding 
 
I was funded by the Robert Luff Fellowship from Imperial College London. 
 
Paul Kalra was funded by the British Heart Foundation 
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